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ABSTRACT
CHOLESTEROL METABOLISM AND STATIN EFFECTS
ON AN FH CLASS II LDL-RECEPTOR MUTATION
Linda Omer
November 9, 2018
Familial hypercholesterolemia (FH) is a common genetic disease and has been
studied with the aim of finding a curative measure for decades. FH is caused by
mutations in the low-density lipoprotein receptor (LDLR) resulting in defects in LDLcholesterol (LDL-C)-receptor mediated endocytosis and development of premature
cardiovascular disease (CVD). Here I describe the use of a corrected and non-corrected
LDLR FH cell model to investigate receptor-mediated endocytosis and statin effects.
For these studies, we reprogrammed FH fibroblast cells to induced pluripotent stem cells
(iPSC) and confirmed their pluripotency and ability to differentiate to hepatocyte-like
cells (HLC). A clustered regularly interspaced short palindromic repeats
(CRISPR)/CRISPR-associated 9 (Cas9) design was created and used to successfully
correct a 3 base pair deletion in the class II LDLR FH iPSC. Western blot and
immunocytochemistry analysis showed maturation and proper localization of the LDLR
after correction in iPSC and HLC. We used internalization analyses to detect LDL-C
receptor mediated endocytosis in non-corrected and corrected HLC. Real time PCR for
ER stress markers showed that statin-induced accumulation of an immature LDLR in
non-corrected FH cells did not activate the unfolded protein response. Together, this
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work demonstrates the capacity to utilize the resources of CRISPR, iPSC, and HLC to
study misfolded class II LDLR providing a physiologically relevant in vitro model for
investigating the differential effects of mutant versus corrected LDLR-mediated
metabolism and current treatments like statins.
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CHAPTER I
BACKGROUND/LITERATURE REVIEW
PART I: FAMILIAL HYPERCHOLESTEROLEMIA AND THE LDLR

Familial Hypercholesterolemia (FH)
High serum cholesterol levels are correlated with an increased risk in the
development of cardiovascular disease. A subset of the population cannot maintain
cholesterol levels without medical interventions due to genetics.
Familial hypercholesterolemia (FH) is the most common genetic disease in our
population, affecting 1:250 people (heterozygous FH, HetFH) [1-3]. As early as 1938, Dr.
Carl Muller observed “an inborn error of metabolism” or genetic mutation he used to
describe young patients with both high cholesterol and myocardial infarctions [4]. He
labeled FH as a single gene-determined autosomal dominant trait. Two decades later,
researchers studying populations with high incidence of FH believed to be due to a
founder’s affect confirmed clinically both the HetFH and homozygous FH (HoFH) disease.
Still then, it was unknown what mutation was causing this hypercholesterolemia.
Cholesterol is obtained by diet and liver synthesis [5]. Intestinal mucosal cells
convert dietary cholesterol into lipoproteins. A lipoprotein is a micelle-like structure
comprised of a nonpolar core containing triacyclglycerols and cholesterol esters
surrounded by a amphiphilic proteins and cholesterol. There are five classes of lipoproteins
categorized by density and function: chylomicrons, very low density lipoprotein (VLDL),
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intermediate density lipoprotein (IDL), low density lipoprotein (LDL), and high density
lipoprotein (HDL) [5]. The protein component of the lipoprotein is the apoprotein. Our
lipoprotein of interest, LDL, contains a single apolipoprotein B-100 (apoB-100) molecule
that covers half the particle surface [5]. Because LDL is the major carrier of cholesterol, it
is commonly referred to as LDL-cholesterol (LDL-C).
The levels of cholesterol are tightly regulated to maintain balance between
biosynthesis, utilization, and transport of cholesterol to prevent its accumulation and
deposition in arteries [6]. Briefly, cholesterol biosynthesis begins when acetate (from
acetyl-CoA) is converted to isoprene units containing a 5-carbon skeleton. These isoprene
units will eventually condense to form a linear molecular with 30 carbons that cyclizes to
form the cholesterol molecule [6]. The process begins in the liver where acetyl-CoA is
converted to 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) by HMG-CoA synthase and
thiolase. The next step is the rate-limiting step of cholesterol biosynthesis. HMG-CoA
reductase will catalyze the reaction of HMG-CoA to mevalonic acid which will proceed
through an additional 8-12 steps for the production of cholesterol [6]. HMG-CoAreductase is the enzyme involved in the rate-limiting step in cholesterol synthesis, and is
regulated through feedback control where the amount of enzyme present in the cell can
increase or decrease based on the amount of cholesterol in the cell [7]. HMG-CoA is also
controlled by competitive inhibition, allosteric effects, and covalent modifications that will
change it from active and less active states [4]. Statins competitively inhibit HMG-CoA
reductase activity with a greater Km than its HMG-CoA substrate [8, 9].
In the early 1970s studies on human livers were nearly impossible making it
difficult to study cholesterol metabolism [10]. To overcome this limitation, investigation
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using skin fibroblast cells from patients with FH because they were known to express the
inherited mutation. Normal and FH affected skin fibroblasts were treated with lipoprotein
deficient serum (LPDS) with or without additional LDL-C [4, 11]. They HMG-CoAreductase activity to determine activity in FH patient fibroblasts [11, 12]. In the presence
of serum, normal fibroblasts had low HMG-CoA-reductase activity while LPDS media
resulted in a 50-fold increase in HMG-CoA-reductase activity. In addition, they noticed
the addition of as low a concentration as 5 g/mL LDL would decrease HMG-CoAreductase activity [11]. These results allowed them to hypothesize that a receptor might be
regulating cholesterol uptake since LDL and its concentration were necessary to see
changes in enzymatic activity of HMG-CoA-reductase.
In fibroblasts from HoFH patients, there was a 50-100-fold increase in HMG-CoAreductase activity even in the presence of lipoproteins [11], and the addition of LPDS with
or without LDL had no effect on HMG-CoA-reductase activity. This led to their hypothesis
that HMG-CoA-reductase may be the site of a mutation, causing a break in the feedback
loop of LDL-C metabolism and hence FH. However, upon the addition of ethanoldissolved cholesterol to either normal or affected FH skin cells, enzymatic activity was
suppressed uniformly [7, 11]. This indicated that HMG-CoA-reductase was not responsible
for the phenotype of FH.
To try to solve this mystery, Brown and Goldstein turned to the use of radioiodine
labeled LDL-C (125I-LDL) and hypothesized that a cell surface receptor must be present
and responsible for the uptake of LDL-C. Normal and FH fibroblasts were incubated in
125

I-LDL to measure binding [7, 13]. Normal human fibroblasts bound and degraded 125I-

LDL and at a high rate when 125I-LDL was present at a low concentration [7, 13]. This is
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correlated with a high rate of degradation. However, upon incubation with high levels of
125

I-LDL, the binding decreased and the rate of bound/degraded was similar in both normal

and FH fibroblasts. It was hypothesized this was due to receptor independent endocytosis.
In the presence of low or high concentrations of

125

I-LDL, HoFH fibroblasts had low

binding and degradation [7, 13]. Further studies were done to differentiate between
internalized or surface bound 125I-LDL. Techniques involved experiments at 4 C and 37
C and the sequential use of buffers that would allow the measurement of bound versus
internalized

125

I-LDL. It was discovered that

125

I-LDL-bound to a receptor and remained

so for no more than 10 minutes [7, 13]. This followed with complete catabolism of

125

I-

LDL into its components of amino acids and free fatty acids within an hour. With the
chloroquine inhibitor and lysosomal defective patient fibroblasts, it was confirmed this
rapid degradation occurred within the lysosomal vesicle [7, 13]. The free fatty acids
released by the lysosome then went on to act as an inhibitor of HMG-Co-A reductase,
inhibiting its activity and therefore cholesterol production [7, 13]. This data clearly
demonstrated the definite presence of a cell surface receptor that was responsible for the
binding and endocytosis of LDL-C [7, 13].
Although most FH is caused by mutations of the low-density lipoprotein receptor
(LDLR), defects in the apolipoprotein B (ApoB), proprotein convertase kinase 9 (PCSK9),
and the low-density lipoprotein receptor adaptor protein 1 (ARH) genes are also
responsible for this disease [14]. This inherited disease can be transmitted through due to
a single (HetFH) or two defective alleles (HoFH) leading to a range in the development of
cardiovascular disease. Normal cholesterol levels should be less than 100 mg/dL. As levels
increase, a person can be considered hypercholesterolemic if levels reach between 150-200
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mg/dL. HetFH patients are common (1:250) can have LDL-C levels from 200-500 mg/dL.
The rarer HoFH is present in 1:250,000 people and leads to cholesterol levels as high as
1000 mg/dL [1-3]. Because of the extremely elevated cholesterol levels, apparent
symptoms can arise that include cutaneous xanthomas and corneal arcus [14]. HoFH
patients especially present with murmurs of aortic stenosis and symptoms of ischemic heart
disease in early childhood [15] which can result in death due to myocardial infraction
before the age of 25 if left untreated [15-18].
HetFH is treatable through strict lifestyle requirements such as exercising regularly,
consuming a low saturated and trans-fat diet, taking medications, and using lipid apheresis
[15, 19-21]. Several non-curative pharmacologic treatments are available, while new ones
have been recently approved for FH patients [22-24]. The well-known and most prescribed
drug is statin [25]. Statins are competitive inhibitors of HMG-CoA reductase and therefore
(1) inhibit endogenous cholesterol production and (2) upregulate LDLR expression [25].
This process forces the cell to scavenge LDL-C that is present in circulation through the
increased LDLR in a process called LDLR-mediated endocytosis resulting in decreased
circulating LDL-C levels [9, 25].
Although statin treatment has a significant therapeutic benefit in HetFH patients,
most HoFH patients receive minimal benefit [2, 15, 26]. A non-functional/receptordefective/negative patient will be required to supplement their diet with high dose statins
along with other drugs and alternative treatments such as Mipomersin [2, 15, 26].
Mipomersin acts similarly to microRNAs [24]. It is an antisense oligonucleotide that binds
to the mRNA sequence of ApoB-100, promoting ApoB’s mRNA degradation by
ribonuclease H [24]. By reducing ApoB-100 production, very low-density lipoprotein
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(VLDL) generation by the liver is also reduced, consequently decreasing circulating LDLC levels. An emerging therapy for FH is the use of monoclonal antibody to PCSK9. PCSK9
binds to LDLR, accelerating its degradation [27-29]. Within the human population exist
mutations for PCSK9 loss-of-function that leads to an 88% reduction in coronary artery
disease (CAD) [27]. PCSK9 binds in the epidermal growth factor (EGF)-A domain of
LDLR, and mutation of an aspartate residue (Asp310) in LDLR inhibits binding and
subsequent degradation of LDLR by PCSK9 [28]. Monoclonal antibodies like Evolocumab
target PCSK9 and are 70% more effective in lowering LDL-C than statins [30]. However,
receptor negative HoFH patients did not respond to Evolocumab since there is no plasma
membrane LDLR to target [23]. There was a large variation in response to Evolocumab in
2 genetically identical homozygous receptor-defective patients. Both began with similar
baseline LDL-C levels; one patient showed the largest decrease in LDL-C levels while the
other had the smallest decrease in LDL-C post-clinical trial [22]. Furthermore, statins have
been shown to upregulate PCSK9, reducing LDLR levels and decreasing statins’ efficacy
in the more prevalent HetFH [31].
An alternative treatment for HoFH patients that do not respond to medicinal
treatments is the dialysis-like lipid apheresis [15, 19]. The aim of lipid apheresis is to
reduce plasma LDL-C levels to prevent the progression of premature CAD. The technique
involves “plasma exchange” in which plasma LDL-C is selectively removed without
affecting other proteins present in the serum [19, 32]. Lipid apheresis is beneficial in having
shown over a 60% decrease in LDL-C levels. However, upon removal from apheresis, the
cholesterol levels rebound rapidly [19]. Although this can be the only standard of treatment
for some patients with HoFH, it is limited in availability, requires frequent trips for dialysis
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that can cost upwards of $250,000/year, and presents patient complication, such as venous
access [19].
A liver transplant is the only currently definitive cure for FH, but also requires
lifelong immunosuppressive drugs [3, 33, 34]. It is not the first treatment option, but rather
a secondary prevention for patients with severe HoFH [34-36]. One study reported that
after treating 36 FH patients with liver transplants the key to successful liver transplantation
is timing of transplant [33]. In the study, the majority of patients had LDL-C levels greater
than 500 mg/dL, and 11 of these patients were under 8 years old [33]. When treatment with
high dose statins had failed to decrease LDL-C levels, a liver transplant was considered for
treatment. After liver transplantation, the patients were followed up from six months to six
years. Three patients under the age of four years died due to cardiac arrest or septicemia
[33]. Most of the patients showed a regression of xanthomas and normalization of LDL-C
levels. A seven-year-old boy with severe HoFH presented a drastic reduction in LDL-C
from 946 mg/dL to 71 mg/dL post-liver transplant; however, he still required an aortic root
replacement [37]. The current practice is to treat patients with the maximal dose of statins
and monitor until the necessity for a liver transplant occurs because of the onset of CVD.
This case helps argue that the timing of transplantation is key to a successful liver
transplantation, rather than following the current practice [33, 37].
An experimental treatment approach for FH involves gene therapy that uses a
vector to deliver a functional LDLR to the liver [3]. Gene delivery can be performed ex
vivo, in vitro, and in vivo. Ex vivo gene therapy [38] was one of the first processes used for
gene therapy [3] and included harvesting the liver resection tissue from an FH patient,
isolating the autologous hepatocytes, growing the cells in vitro, introducing the LDLR into
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the cells using a recombinant retrovirus, and delivering the now genetically modified cells
back into the FH patient [39, 40]. Studies using the Watanabe heritable hyperlipidemic
rabbit (WHHL), which is considered an authentic model of FH [41], demonstrated that
transplantation of both normal or genetically altered allogenic hepatocytes could lower
serum LDL-C in WHHL rabbits. However, the decrease was temporary with the high
number of rejected allogenic cells likely due to an immune response [42-44]. Instead,
Wilson and colleagues focused on using autologous retroviral-LDLR expressing
hepatocytes transplanted back into the WHHL rabbit. The results were a prolonged
improvement in serum cholesterol levels with liver tissue showing a high level of
recombinant derived LDLR RNA expression throughout the duration of the six and a halfmonth experiment [45].
The success of liver-based gene therapy is largely dependent on the method of gene
delivery. The most efficient method used thus far has been through viral vectors [46-49].
Wilson’s group found that the delivery of 0.1 to 1 proviral copy of the LDLR-expressing
retrovirus into isolated human hepatocytes resulted in LDLR protein levels exceeding the
normal endogenous levels of the human hepatocytes [40]. In addition, the infection
efficiency was highest when the cells were exposed to the virus 48 hours post plating,
allowing gene transduction to be achieved within 72 hours after initial seeding, minimizing
the time the hepatocytes were in culture prior to transplantation [40].
When the technique appeared to be successful in the animal models, Wilson moved
onto clinical trials with FH patients. The trial involved a receptor-defective HoFH patient
who underwent liver resection followed by transplantation of the genetically modified
autologous hepatocytes [50]. The patient had a 17% decrease in plasma LDL-C levels after
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a 25% hepatectomy and re-infusion. She also did not show any immunogenic response to
the viral vector. This study demonstrated the feasibility, safety, and potential efficacy for
ex vivo gene therapy in humans [50]. After 2.5 years, the patient still maintained a 20%
decrease in serum LDL-C levels. However, because the patient was receptor defective but
had a partially functional LDLR to begin with, there were questions in regard to whether
patients with different genotypes, including receptor negative LDLR, would respond to this
treatment. The first pilot study for liver-directed gene therapy to be done in HoFH patients
included patients ranging in age from 7 to 41 years old and with mutations that resulted in
receptor defective and receptor negative phenotypes [51]. From the studies, a 12-year-old
receptor negative HoFH patient showed a significant reduction in serum LDL-C levels post
gene transfer. Another two patients also showed prolonged reduction in LDL-C levels 4
months after therapy. However, two patients failed to show any significant changes in
LDL-C levels. The variability in results led to a halt in the clinical trials [51]. Of
importance, the isolation and survival of primary hepatocytes for this process was essential
for the successes seen in the trials. Primary hepatocytes cannot be passaged; therefore,
transduced cells cannot be selected and expanded [49, 52, 53]. The cells also remain
differentiated and viable for only a short period of time; Wilson’s experiment showed that
infecting cells within 48 hours of isolation showed an open window in which the cells were
most susceptible to infection [54].
There are still barriers preventing successful gene therapy including 1) vector
genome persistence in which the expression can vary depending on if the DNA exists as
an episomal molecule or integrative in the host, 2) loss of gene expression due to
immunogenicity to the transduced cells or gene product, and 3) their uptake and transport

9

requires tissue specificity but this can be influenced by the organ’s vascular supply and
endothelial barriers [53, 55, 56]. In addition, their delivery usually requires the stimulation
of hepatocyte proliferation through either hepatectomy or cytotoxic agents [57-60]. Gene
correction through gene targeting could provide an alternative approach to correcting the
mutation in vivo without affecting the rest of the genome.
Statins
With the link finally made between risk of heart disease and cholesterol levels,
many researchers began their focus on finding a molecule inhibitor of any of the 30 steps
involved in the synthesis of cholesterol [61, 62]. Of the many inhibitors synthesized and
tested, only one made it to the market, Triparanol (MER/29). MER/29 inhibited 24dehydrocholesterol reductase preventing the conversion of desmosterol to cholesterol [63,
64].
Since MER/29 inhibited the enzyme that catalyzed the final step to cholesterol, it
caused an accumulation of cholesterol intermediates resulting in severe side effects
including vision loss due to irreversible cataracts, accelerated atherosclerosis, and even
alopecia [65, 66]. At this time, other groups studying enzymes discovered the ability of
antibiotics to inhibit enzymatic activity . An antibiotic that inhibits HMG-CoA-reductase
in microbes could be lethal to them and successful in mammals. This led Akira Endo’s
group to hypothesize that fungi like molds and mushrooms could potentially produce
antibiotics that inhibit the rate-limiting step in cholesterol synthesis thru HMG-Co-A
reductase and thus, be lethal to these microbes [67]. His group utilized radiolabeled 14Cacetate active microbial culture broths. The concept was that broths that inhibited the
incorporation of

14

C-acetate into nonsaponifiable (or non-ester bonded) lipids could be
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tested for their ability to inhibit lipid synthesis from 3H-mevalonate. If a culture broth was
inactive, it was suspected to contain inhibitory compounds that prevented the early stages
of cholesterol synthesis from acetate to mevalonate. The isolated compounds were tested
on rat liver enzymes [67-69].
Over one year and 3800 fungal strains later, Endo found a mold culture broth
containing citrinin [70]. Citrinin inhibited HMG-CoA-reductase and even lowered serum
cholesterol levels in rats [71]. However, the molecule also caused kidney toxicity [71].
Eventually, his group found an active culture of blue-green mold, Penicillium citrinum
Pen51, isolated from a rice sample. They isolated 3 active metabolites through solvent
extraction, silica gel chromatography, and crystallization [72]. Compactin (ML-236B) was
the most active and structurally similar to HMG-CoA. Because of this, compactin was an
extremely effective competitive inhibitor for HMG-CoA-reductase [8]. Unless cells were
homogenized to dilute compactin in vitro, no HMG-CoA-reductase activity could be
detected. However, when rats were fed compactin 7 days in a row, there was no reduction
in serum cholesterol [73]. The caveat of compactin is its ability to lower cholesterol but
only for 3 to 8 hours after a single dose. After 8 hours, an almost 10-fold induction of
hepatic HMG-CoA-reductase activity would occur [67, 73]. Endo’s findings suggested
compactin would still be beneficial but in experimental animals with elevated blood
cholesterol levels. They showed that in chickens, dogs, and monkeys compactin treatment
decreased plasma cholesterol levels after a month [67]. With the collaboration of Dr. Akira
Yamamoto at Osaka University Hospital, compactin was used to treat an 18-year-old
female FH patient who had serum cholesterol levels of 1000 mg/dL. Within two weeks of
a daily dose of 500 mg compactin, her serum cholesterol levels dropped to 700 mg/dL.
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However, she developed muscular dystrophy like symptoms and elevated trans-aminase
that were reversed upon discontinuation of the high dose of compactin [67, 74]. Reducing
her dose to 200 mg still resulted in reduced tuberous and Achilles tendon xanthomatosis,
but no reduction in serum cholesterol levels. Nevertheless, clinical trials continued with 5
HetFH patients who showed an on average 30% reduction in serum cholesterol levels with
no adverse side effects [67, 74].
Many pharmaceutical industries set out to find molecular inhibitors similar to
compactin. Merck, upon signing a confidentiality agreement with Sankyo, obtained both
samples of compactin and the experimental data of Endo [67]. With this resource, Merck’s
scientists developed a structurally similar drug to compactin called mevinolin from the
fungus Aspergillus terreus [75]. The two compounds differed by only one methyl group
and displayed similar biological properties [75, 76]. Endo continued his work at Tokyo
Noko University and isolated another statin named monacolin K from Monascus ruber.
Surprisingly, monacolin K and mevinolin were the same compound and would be renamed
Lovastatin [77].
Clinicians began treating patients with severe hypercholesterolemia with
Lovastatin and saw their LDL cholesterol levels decrease dramatically with minor side
effects [78]. In 1986, the Food and Drug Administration approved Lovastatin as the first
commercially available statin [78]. Since then, another 6 statins have been developed.
Simvastatin and Pravastatin are semi-synthetic statins that are Lovastatin with either an
extra methyl group or hydroxyl group, respectively [25]. Four synthetic statins have
subsequently been developed including Fluvastatin, Rosuvastatin, Pitavastatin, and the
currently popular Atorvastatin [67]. Many large scale clinical trials, including a five-year
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study, have all shown the ability of statins to lower LDL-cholesterol and decrease the
incidence of CVD and stroke by 30% [67]. It is estimated that over 30 million people
globally take statins generating over $25 billion in revenue [67]. Ideal for modern day
medicine, a difficulty of statins is the ability to predict an individual’s response and genetic
predispositions that cause adverse side effects. For example, a study has shown a 45-fold
variability in plasma Atorvastatin and Rosuvastatin concentration, in patients receiving the
same dose [9, 79]. Major genetic variants have been linked to both the variability in
concentration as well as serious side effects seen in certain populations, requiring further
research to determine statin efficacy and safety on a person-to-person level [9].
Interestingly, besides statins primary role in lowering lipids levels, it has also become an
imperative treatment for the intervention in coronary artery and vascular disease [80, 81],
rheumatoid arthritis, polycystic ovary syndrome, sepsis, and cancer [81-86].

Low Density Lipoprotein-Receptor (LDLR)
The LDLR is a cell-surface endocytic receptor responsible for the internalization
and regulation of LDL-C [4, 87]. The mature LDLR is an 839-amono acid type I
transmembrane glycoprotein encoded by 18 exons [88, 89]. These 18 exons code for 5
functional domains (Figure 1).
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Figure 1. Schematic Representation of the Human LDLR Promoter, Gene, Domain, and
Protein Structure. The mature LDLR is made up of 18 exons that code for 5 functional
domains to make up a cell surface endocytic receptor. Mutations have been found in the
promoter region and the 18 exons leading to dysfunction LDLR structure and/or function.
Adapted and modified from Faisal A. Al-Allaf et al. Int Arch Med. 2010; 3: 36. [90]

The promoter region for LDLR is made up of three cis-acting DNA sequences,
which have been found to allow for the ubiquitous and regulated expression of the LDLR
gene [91, 92]. Repeats 1 and 3 interact with a general factor, Sp1, to promote transcription
[91, 92]. Repeat 2 contains a conditional-positive sterol regulatory element (SRE-1) that is
14

necessary for sufficient high-level expression of LDLR. If sterols are absent, SRE-1
synergizes with the two Sp1 sites to promote LDLR transcription. The presence of sterols
inactivates SRE-1, suppressing LDLR transcription and hence surface LDLR expression
[4, 93, 94].
Exon 1 encodes a short 21 amino acid signal sequence for the LDLR that is cleaved
upon translocation to the ER [92, 95]. The ligand-binding domain is encoded by exons 26. This domain is made up of 7 repeats termed the LDLR type A repeat (LR). LR’s 1, 2, 6,
and 7 are each coded by a single exon while LR’s 3-5 are encoded by a single exon. The
LR’s are 40 amino acids long and contain 6 cysteine residues that form three intra-repeat
disulfide bonds [92, 95]. The C-terminus of the LR’s also contain a negatively charged
repeat of Ser-Asp-Glu that is important for Apo B-100, Apo-E, and calcium binding to the
LDLR. Of interest, these LR’s have homology to the C9 protein of the complement
cascade involved in the immune response. The EGF precursor domain is encoded by exons
7-14 and is made up of 400 amino acids. This region contains 3-40 amino acid cysteine
rich repeats or 33% sequence identity to the human EGF precursor gene. These cysteine
rich repeats are different than those found in the LR of the ligand binding domain. The first
two repeats, EGFP-A and EGFP-B, are contiguous and are separated from the third repeat
(EGFP-C) by 280 amino acids. This separation sequence contains 5 copies of a conserved
YWTD (tyrosine, tryptophan, threonine, and aspartate) repeat every 40-60 amino acids.
EGFP-A’s role is special in that it interacts in a sequence-specific manner with PCSK9 [28,
96] leading to the early degradation of the LDLR. Otherwise, these EGFP-domains are
required for the acid-dependent disassociation of the lipoproteins from the receptor in the
endosome [92]. Exon 15 encodes for an enriched serine and threonine 58-count amino
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acid sequence. These act as sites for the attachment of O-linked carbohydrates. Deletion of
exon 15 has not been shown to have any functional consequences in cultured hamster
fibroblasts [97]. The 22 hydrophobic amino acids of the transmembrane or anchor domain
of the LDLR is encoded by exon 16 and the 5’ end of exon 17. The last 50 amino acids
make up the cytoplasmic domain and are encoded by the rest of exon 17 and exon 18. This
region contains an NPxY motif necessary for the localization of the receptor into clathrincoated pits as well as the sorting of the receptor to the basolateral membrane in polarized
cells [87].
In normal cells, the LDLR is transcribed and the mRNA is translated in the ER
where the newly synthesized protein is properly folded into its immature 120-kDa form.
The manner in which the domains fold into a functional LDLR is still unclear. Interestingly,
the LDLR has a structure that is vectorially organized—each domain is sequential to the
next. Even so, it has been shown that the N-terminal repeats will not attain their native
conformation until 30 minutes after chain termination [98]. Studies using electrophoretic
mobility assays in combination with metabolic radiolabeling revealed that instead the
newly synthesized LDLR polypeptide chains folded rapidly into a compact structure with
creating random disulfide bond interactions connecting distant regions of the LDLR [99,
100]. Through isomerization, the random disulfide bonds rearranged themselves, allowing
extension of the LDLR until the native conformation is formed and the only disulfide bonds
present are between the cysteine residues within each individual LDLR type A repeat [99,
100]. Interestingly, even when undergoing the extensive formation of non-native disulfide
bonds during its folding, the LDLR seldom aggregates [98], which has led to the
assumption that non-native disulfide bonds isomerization process is originally part of the
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folding of the LDLR. Calcium also plays a significant role in the proper folding and
function of the LDLR. The cysteine repeats in both the ligand binding domain and the
EGFP-A and EGFP-B regions have high affinity for calcium ions. Once the native disulfide
bonds have formed, calcium binds between distal disulfide bonds. This is especially critical
in the EGFP regions since the calcium ion stabilizes the linker region between the repeats
and maintains their fixed orientation to each other [101, 102].
Of course, the proper folding of the LDLR could not be as efficient as it is without
the assistance of chaperones. Chaperones are important in maintaining newly synthesized
proteins in a protected environment until its disulfide bonds are formed. Disulfide bonds
are usually formed in a vectorial manner unless the N and C-termini are in close proximity
in their tertiary structure. The most well-known and described is Grp78 for glucoseregulated protein-78-kDa. This ER-localized Hsp70 family member binds transiently to the
LDLR to assist in its folding after which LDLR is released for transport to the Golgi [98,
103, 104]. There is some evidence to suggest that Grp78 may prolong its interaction with
LDLR mutants to aid in folding unless it is misfolded permanently, causing the mutant
LDLR to be targeted to the cytosolic 26S proteasome for degradation [98, 105]. Another
chaperone, the 39-kDa-receptor-associated protein (RAP), has also been shown to facilitate
folding of the LDLR [98, 106, 107]. RAP interacts specifically with nascent LDLR-like
family members in the ER, blocking the binding sites of the receptors by binding the LDLA repeat of the ligand binding domain, allowing for its folding [98, 106, 107]. Willnow
and colleagues demonstrated that RAP promotes the receptor folding and maturation by
preventing formation of intermolecular disulfide bonds and aggregation of LDLR [107].
However, this was done in overexpression studies in human glioblastoma U87 cells. Others
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have shown that RAP-deficient mice had normal LDLR levels in the liver but lower LDLR
levels in brain indicating that RAP may play a role in folding, but only in particular
pathophysiological conditions [108, 109]. Even less known is the mesoderm development
(MesD)’s role in the folding of the LDLR. MesD acts as a chaperone to promote plasma
membrane localization of LDLR-like family members, LRP5 and LRP6 [98, 110]. In S2
insect cells expressing human LDLR, the insect homologue of MesD, Boca, facilitated the
folding of LDLR and other LDLR-like proteins [111]. MesD and Boca appear to act on
proteins containing EGF-like repeats and B-propeller structures indicating a wide range of
specificity in their substrates of choice [98, 112].
After it is properly folded, the LDLR is transported to the Golgi complex where it
matures to a 160-kDa protein through O-glycosylation. The LDLR is then transferred to
the cell surface where it will bind LDL-C via Apo-B. Here, the LDLR-LDL-C complex is
internalized through clathrin-coated pits, which fuse with early endosomes. The acidic
environment of the endosomes triggers a release of the complex as the LDL-C molecule is
processed for degradation by the lysosome into its basic components for cell
regulation/structure, and the LDLR is recycled back to the plasma membrane to wait
another cycle of internalization until its degradation [4, 113].
Mutations in exons correspond to mutations in its correlative domain and hence the
physiological function of the LDLR at any step in its life cycle [92, 98, 113, 114]. Over
1200 mutations in the LDLR have been identified, and they range from small missense
mutations

like

SNPs

and

indels

(58%),

nonsense

mutations

(10.4%),

and

deletions/insertions (22%) to larger rearrangements of splicing defects (9.4%) [95]. About
half of all mutant LDLR genes produce receptors with partial function due to a point
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mutation that causes a partial defect in the folding of the LDLR, its transfer to the cell
surface, or its ability to bind LDL-C [95]. A patient with this kind of mutation has reduced,
but not null, LDLR activity and is called receptor-defective. The other 50% mutant of
LDLR genes are true null alleles that fail to produce any detectable LDLR activity [91, 95].
The latter is called receptor-negative. Some HoFH patients are genetic compounds with
two different mutant alleles, referred to as compound heterozygotes. Receptor-deficient
patients are more likely to respond to drugs like statins since there is some LDLR activity
to stimulate. HoFH receptor-negative patients usually die prior to age 20 without
aggressive therapy and can pass as early as 4 years [2, 15, 18]. LDLR mutations have been
classified into 6 classes.
Class I mutations are described as null alleles due to the absence of protein caused
by lack of processed mRNA into the secretory pathway [87, 92, 98]. Some of these null
alleles produce no LDLR mRNA due to deletions in exons 1 or the promoter. However,
most Class I null alleles do produce LDLR mRNA but with either rapid mRNA turnover
due to non-sense mutations in exons 2 and 8 or premature termination codons due to
deletions in parts of exons 13, 14, or 15 [92]. Class II or transport defective alleles affect
the transport of the LDLR from the ER to Golgi and will be discussed in further detail
below (Figure 2). Class III mutant receptors do reach the cell surface but are unable to
bind LDL-C [92, 98] because of mutations in the LR repeat of the ligand binding domain
results in the same dysfunction as deleting the entire repeat [92]. Class IV mutations are
internalization defective alleles in which LDLR will bind LDL-C but the LDLR-LDL-C
complex cannot be endocytosed [92, 98]. These rare mutations in the cytoplasmic domain
called 4A or in the transmembrane domain called 4B [95], affect the ability of clathrin-
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coated pits to internalize the complex [92, 98]. Recycling deficient alleles cannot release
the LDL-C ligand from LDLR and are targeted to the endosome for early degradation
instead of recycling back to the plasma membrane [92, 98]. The Class V mutations are
usually the result of mutations in the EGFP domain that is responsible for acid-dependent
dissociation of the receptor and ligand (Figure 2). The most recently described group of
LDLR mutants, termed Class VI, contain LDLR’s that mislocalize to the apical instead of
the basolateral membrane in polarized cells [98, 115]. Over 50% of mutations have been
described as class II mutations, specifically class IIB, and will be focused on hereafter [92,
98].
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Figure 2. Schematic Representation of Human LDL-Receptor Mediated Endocytosis.
LDLR is synthesized on the endoplasmic reticulum (ER) and processed into an immature
120-kDa protein. It is then shuttled to the Golgi for further processing into a mature 160kDa LDLR. The mature LDLR is transported and inserted into the plasma membrane where
it will bind an LDL-C molecule through apoB-100 interaction. This complex will be
internalized through clathrin-coated pits and fuse with an endosome where a lower pH
causes the release of the LDL-C from LDLR. The LDLR is recycled back to the plasma
membrane to repeat this cycle approximately 100 times before it is degraded by the
lysosome. There are 5 classes of mutations that affect the LDLR life cycle; 1) Lack of
processed mRNA, 2) transport-defective, 3) LDL-C binding defect, 4) Clustering defect,
and 5) early degradation defect. Class 2 mutations make up 50% of FH LDLR mutations.
Promoter adapted and modified from Faisal A. Al-Allaf et al. Int Arch Med. 2010; 3: 36.
[90]

Class II LDLR Mutation
The normal LDLR is synthesized in the ER as a partially glycosylated precursor
of 120-kDa. Upon reaching the Golgi, N-and O-linked sugars are added yielding a
molecular weight of 160-kDa. Pulse chase experiments have shown this process to occur
within an hour after synthesis [116, 117]. This process is delayed or completely abolished
when LDLR contains class II mutations [92]. Instead, the LDLR doesn’t leave the ER [118]
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and remains at 120-kDa until it is degraded [92, 98, 119]. Over 50% of FH mutations
identified have been classified as class II transport defective mutations. Because this
mutation results in a misfolded LDLR unable to leave the ER, it is commonly referred to
as a “folding or conformational disease” [98, 120, 121].
Class II defects have been clustered in the exons that encode for the ligand binding
and EGFP homology domains [92, 114, 117]. Mutations affecting the cysteine-rich repeats
present in both domains appear to be casually linked to the slowing or halting of the LDLR
from the ER. Russell’s group was the first to isolate the cDNA sequence of the 12-base
pair deletion found in the 3rd cysteine-rich repeat of the ligand-binding domain in the FH
Watanabe rabbit [122]. This in-frame deletion eliminates 4 amino acids and hence disrupts
the LDLR’s movement from the ER to the Golgi. Although the deletion did not actually
remove any of the cysteine residues, the change in amino acids present likely altered the
folding pattern of the protein and prevented proper disulfide bond formation [122].
Class IIA vs IIB
Class II mutations can be further divided into two categories depending on the
percent activity of the LDLR. Mutations that completely block receptor transport out of the
ER are designated as class IIA mutations [91, 92, 114]. Class IIA mutations have been
linked to mutations in the EGFP homology domain, sometimes within one of the 3
cysteine-rich repeats or within the YWTD region between repeats B and C [92]. A
particular class IIA mutation, p.G565V, is completely retained in the ER as shown through
co-localization western blot [123, 124] and has no surface LDLR or LDL internalization
demonstrated by flow cytometry [123]. Jorgensen et al demonstrated two-class IIA mutant
LDLRs, C646Y and W556S, were totally retained in the ER and bound to Grp78 [125]. A
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pulse-chase experiment followed by SDS-PAGE

of Class IIA FH429 and FH261

fibroblasts showed zero mature LDLR compared to normal fibroblasts nearly all-mature
LDLR [118].
Class IIB mutations produce LDLRs that are transported at a measurable but
reduced rate [91, 92, 114]. These mutations appear to change the spacing between the
highly conserved cysteine residues thereby interfering with disulfide bond formation and
proper protein folding [92, 114, 122]. Studies in fibroblasts carrying Class IIB mutations
showed less than 5% conversion of immature to mature LDLR [118]. This extreme case in
Class IIB is due to the fact that the cell line used was from a HoFH patient. Cases of Class
IIB mutations that are heterozygous do not have such a significant presence of immature
LDLR.
FH Piscataway
FH Piscataway is named from a young American HoFH patient from Piscataway,
New Jersey [92]. The mutation, FH563, is localized to the 5th repeat of the ligand-binding
domain causing a 3-base pair deletion of TGG in exon 4 of the LDLR [117, 122, 126]. This
removes glycine-197 and results in an in-frame mutation. When Russell’s group was
identifying if deletions in the cysteine-rich repeats of the LDLR would affect transport,
they used both the Watanabe rabbit (12 base pair deletion) and human FH563 fibroblast
cells [122].
Pulse-chase experiments with FH563 and normal fibroblasts followed by
immunoprecipitation with a monoclonal LDLR antibody [122], unsurprisingly
demonstrated that the normal fibroblasts’ LDLR had been transported to the Golgi for
processing to the mature 160-kDa proteins within 30 minutes. 95% of the FH563 LDLR
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remained as 120-kDa after 2 hours. The heterozygous parents’ fibroblasts were also pulsechased and showed that after 2 hours, half of their LDLR’s were mature and the other half
still in precursor form. This indicated FH563 inherited the same mutant allele from each
parent and was homozygous for a transport-deficient receptor similar to the Watanabe
rabbit [122].
FH563 fibroblasts were also carefully studied through electron microscopy to
identify the distribution of the intracellular LDLR [118]. Less than 5% of LDLR was
detectable on the cell surface and in coated pits or vesicles in the endocytic pathway unlike
normal fibroblast LDLR with almost all LDLR found in coated pits. Instead, most of the
FH563 LDLR was present in membrane extensions of the rough ER [118]. It’s
hypothesized that the extensions the mutant LDLR is localized is the site where the ER is
blocking exit of the LDLR and appeared to be morphologically similar to the transitional
zone of the ER implicated in transport of secretory proteins to the Golgi [118, 127]. My
work is focused on the FH563 mutation and its correction using CRISPR/Cas9.
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PART II: GENOME EDITING AND CRISPR/Cas9

Genetic Mutations and Disease
Genetic mapping is a process that has and is used to link transmittance of a disease
from parent to child through at least one gene. DNA markers isolated from both the affected
and normal family members are used to pinpoint the disease-causing gene [128]. Genetic
mapping has come a long way since the first mapping of a genetic disease marker (found
in Huntington’s disease on chromosome four) and the first comprehensive genetic map
produced based on DNA sequencing with restriction enzymes. The first draft of the human
genome was completed in 2003 and revealed over 20,000 genes [129]. Of those genes,
3500 have been linked to genetic diseases [130]. Monogenic diseases are usually inherited
via the classical Mendelian inheritance pattern. These genetic mutations occur in less than
1% of the population. The most common contributor of genetic variation is due to singlenucleotide polymorphisms (SNPs). One nucleotide change in the 3.2-billion nucleotide
pairs can lead to an amino acid conversion altering a protein’s structure or function.
Understanding the causal link of a disease is necessary to create a treatment plan
for the patients. Therapies vary across diseases from surgical treatment to dietary
restrictions, pharmaceuticals, and gene/cell therapy. Some disorders currently have no
form of treatment and require further studies to understand the disease and identify
potential treatments. The development of animal models to mimic a mutant phenotype
has proved beneficial in the research and clinical field in allowing translation of animal
models in clinical development for patient treatments.
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History of Genome Editing
Homologous recombination (HR) is the genome’s natural system to create both
genetic diversity and repair DNA damage [131-133]. Capecchi and Smithies were the first
investigators to demonstrate homologous recombination induction in mammalian cells
between transfected plasmids [134]. Smithies’ lab continued advancing HR in vitro in a
substantial way: they showed that co-transfection of two non-overlapping exogenous DNA
mutants into a somatic mammalian cell line would yield neomycin-resistant cells through
HR [135]. Of importance, this study showed that HR increased 10-fold when a double
stranded break (DSB) was introduced into one of the input plasmids. This provided the
foundation for others to work at optimizing HR-DSB repair by modifying cell cycle
introduction, gene homology length, introduction of double-stranded gaps, and the use of
linear or circular plasmids [136-140]. This was followed with the correction of a deletion
in the hypoxanthine-guanine phosphoribosyl transferase (Hprt) gene in a Hprt-/- mouse
embryonic stem cell (ES) line using the “pre-treated” or cut exogenous DNA [141].
A major step was taken when two labs that introduced Hprt-/- mouse ES into mouse
blastocysts through microinjection produced chimeric mice [142, 143]. Further enhancing
this field, Bradely’s lab observed that HR using an insertion vector targeting Hprt in murine
ES occurred nine times more frequently than with a replacement vector containing the same
homologous sequences [144]. Site-directed mutagenesis through the combination of HDR
and ES cells provided the platform for future development of mouse models to study
human disease.
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Gene Targeting
Specific gene modification is referred to as gene targeting [145]. Initially, the
tedious method of genetic manipulation resulted in a low number of cells containing the
modification. Evidence suggested that adding DSB with an endonuclease occurred during
metabolic processes such as the production of antibodies [146-150]. In 1995, Jasin et al
was the first group to introduce DSBs in the genome of mouse cells. They used the yeast
S. cerevisiae endonuclease, I-SceI [151, 152]. The repair of the DSBs also required the use
of donor DNA template that contained homology-flanking arms and the mutation of
interest. This increased targeting efficiency 100-fold compared to no homology-flanking
arms, providing further evidence that a template containing a certain length of homology
on either side was necessary for successful gene targeting [153]. Although beneficial, this
also limited the number of sites for modification. In addition, the DNA recognition site
and cleavage function are intertwined into a domain, making it more challenging to modify
the sites of recognition creating a highly inefficient system.
By contrast, zinc-finger nucleases (ZFNs) contain distinct domains for DNA
recognition and nuclease activity. ZFNs were developed by combining the cleavage
domain of bacterial FokI-endonuclease and two different zinc finger proteins [154-156].
Zinc fingers domains are one of the most abundant DNA binding molecules in mammals,
containing 4000 binding regions within the genome [145]. A finger is made up of 30 amino
acids with histidine and cysteine residues coordinating a single zinc atom within a betabeta-alpha helix structure. This finger contacts primarily 3 nucleotides and this 3-bp target
is specific to each finger. In addition, each nucleotide contacts a single amino acid side
chain projecting from one end of the zinc finger alpha helical structure. This means that
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multiple zinc fingers could be combined to target multiple sites and amino-acid changes in
the alpha helix altering specificity of the zinc finger. Flavobacterium okeanokoites or Fok
bacteria contain an endonuclease with a nonspecific DNA-cleavage activity in its Cterminal domain. Its N-terminal domain contains a DNA binding domain. Combining the
endonuclease domain of Fok with a zinc-finger protein, a chimeric restriction enzyme was
created called the ZFN that will only generate a DSB when dimerized to its target site
[145]. The zinc finger binds to the DNA by inserting an alpha-helix into the major groove
of the DNA double helix. Each finger makes its own unique contact with the DNA due to
variations in the amino acid side chains that make up the ZF. The full structure of the ZFN
is N-terminal ZF DNA binding domain, a variable peptide linker, and the C-terminal FokI
domain. After much optimization, it was demonstrated that inverse orientation, a six base
pair space between binding sites, and no linker between the ZF and nuclease domain
produced the most efficient cleavage and recombination. To promote genome editing, a
pair of ZFNs must bind to a target site, one recognizing the forward strand of a target site
and the other the reverse strand of the target [131]. Upon binding to their sites, the pair of
Fok1 domains dimerize and cleave the DNA target, creating a DSB with a 5’ overhang.
This break is repaired either through non-homologous end joining (NHEJ) or homologydirected repair (HDR) [131] (Figure 3). The first mammalian cells targeted with ZFNs by
Porteus and Baltimore integrated a GFP reporter into human embryonic kidney cells
(HEK293) [157]. Fast forward to more recent work in modifying the human genome in
CD4+ T-cells with ZFNs. Holmes group shows that ZFNs targeting X-linked severe
combined immune deficiency (SCID) mutation in IL2RG gene had the ability to modify
the genetic disease mutation on both chromosomes at a high frequency in human T cells
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[158]. Despite ZFNs availability, it has proven difficult to engineer ZFNs to bind extended
stretches of nucleotides with high affinity. An academic consortium developed an opensource library of ZFNs and protocols to help alleviate this challenge so that others may
identify ZFNs that bind to desired sequences with high affinity [131, 159].
Transcription activator-like effector nucleases (TALENs) use an even simpler
method for identifying DNA than ZFNs (Figure 3). The TAL effector domain was
discovered in a plant pathogen, Xanthomonas, and consists of 10-30 tandem repeats. A
single repeat domain can identify a single nucleotide by using 2 amino acid residues also
called the repeat variable di-residues (RVDs) [160, 161]. Because of the simplicity in its
recognition of DNA, TALEN is easily customized for its target DNA and only requires to
be conjugated to the FokI nuclease domain used with ZFNs. The RVD code can be
modified resulting in an increased binding affinity to target DNA sequences [131].
TALENs are designed similar to ZFNs. The TALE central DNA-binding repeat is fused to
the FokI catalytic domain through a linker. It’s been shown that TALENs are most
functional when the spacer length is between 12-30 bp. In addition, TALENs have been
shown to have fewer context-dependent effects [162]. Another plus of TALENs is the
ability of the TALE repeat to be designed to target 18-bp of DNA or even longer [163].
Because of their ability to be created in a short amount of time and at a high volume, a
library of TALENs targeting all of the genes in the genome has been created [131]. A
disadvantage of TALENs is their cumbersome size, at least in comparison to ZFNs [131].
The cDNA encoding ZFNs is about 1 kb while the TALEN cDNA is 3 kb making the
delivery more difficult.
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The main limitation of both ZFNs and TALENs are their inability to be used in
high-throughput applications. Because they function through protein-DNA interactions,
each target site requires engineering and cloning of a new protein [145]. In contrast,
CRISPR/Cas9 is a RNA-guided nuclease whose sequence specificity is through WatsonCrick base pairing between its guide RNA and target DNA site [164].

Figure 3. Representation of Tools and their Mechanisms for Genome Editing and DSB
Repair. Zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases
(TALENs), and clustered regularly interspaced short palindromic repeats (CRISPR) and
CRISPR-associated proteins (Cas) are genome modifying tools that have been utilized to
induce double stranded breaks (DSBs) in DNA. ZFN and TALEN require the use of 2
DNA-recognizing proteins conjugated to a nuclease to create a DSB. CRISPR/Cas is an
RNA-guided system that uses a single nuclease and guide RNA for a DSB. DSBs are
repaired either through non-homologous end joining (NHEJ) or homology-directed repair
(HDR). Adapted from Hao Yin et al. Nat Rev Drug Discov. 2017; 16 (6): 387-99. [165]
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CRISPR
Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPRassociated proteins (Cas) are an RNA-mediated immune response mechanism used by
bacteria to prevent the invasion of foreign DNA like viruses and other bacteria [131, 145,
166]. The Cas protein can be programmed to target any site by changing its guide RNA
sequence, providing a platform for high-throughput applications [164]. Before proceeding
to its mechanism of action, its historical discovery deserves acknowledgement.
In the early 1990s, Dr. Francisco Mojica characterized the CRISPR locus in an
archaeal microbe, Haloferax mediterranei, that grew in the extremely salty marshes off the
coast of Santa Pola near the laboratory where he worked [131, 167]. Prior to this, Japanese
researchers had described the presence of short direct repeats interspaced with short
sequences within the genome of E. coli [168]. Through bioinformatics studies, the CRISPR
loci would be found in 20 different microbes [169]. However, the function of these repeats
was still unknown as were the “spacer sequences” between them. He used BLAST to
analyze the unknown sequences. Eventually, a spacer matched the sequence of a P1 phage
in an E. coli strain that was also resistant to this infectant [170]. Continuing his BLAST
work on thousands of bacterial strains, of 88 with similar sequences, he found 2/3 of the
spacers coding for viruses or conjugative plasmids. It was concluded that the CRISPR loci
encoded the instructions for an adaptive immune response that protected microbes against
specific infections [167, 170]. Another group in the French Ministry of Defense had come
to a similar conclusion after finding identical tandem-repeat loci in closely related isolates
from a Y. pestis bacterial strain from Vietnam [167, 171]. Instead of an immune response,
they claimed, “CRISPR may represent a memory of past genetic aggressions” [172].
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The search went on to investigate if CRISPR was truly an adaptive immune
mechanism in bacteria. A group of Dutch scientists working in a food laboratory at Danisco
were interested in the correlation between phage resistance and the spacers in CRISPR
[167]. They focused on using S. thermophilus, since it’s mainly used in the dairy industry
to produce yogurt and cheese. It is also phage sensitive and prone to phage attacks during
yogurt making [173]. They infected the sensitive S. thermophilus until they were able to
genetically isolate now phage-resistant bacteria [167, 173]. The resistant strains acquired
phage-derived sequences in their CRISPR loci and the more inserted spacers acquired, the
increased resistance the bacteria demonstrated giving them immunity against subsequent
bacteriophage infections [173]. In addition, they discovered that a cas7 gene coding for
Cas7 protein helped generate new spacer and repeats but not resistance. The cas9
(originally called cas5) gene coding for Cas9 protein with two catalytic nuclease domains
was needed for phage resistance [174, 175]; hence, it was actively involved in the now
confirmed CRISPR adaptive immune response.
Van der Oost’s group at Wageningen University in Amsterdam took on the task of
characterizing Cas proteins [167, 176]. His group took a CRISPR deficient E. coli strain
and transferred into it the CRISPR of another E. coli strain. They knocked out single genes
and discovered that the whole system was essential to produce a 61-nucletoide long
CRISPR RNA (crRNA) from a long precursor RNA transcribed from the CRISPR locus
[176]. They performed a co-immunoprecipitation study of the Cas proteins followed by
cloning and sequencing of the associated crRNA. This demonstrated that all the Cas
proteins began with the 8 final bases of the repeat sequences followed by the spacer
sequence and the start of the next repeat region [176]. It was necessary to verify that crRNA
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is what confers CRISPR-based resistance. For this, they created a CRISPR array to target
4 genes in the lambda phage using either anti-sense or sense sequences. The bacteria
carrying this artificially designed CRISPR conferred resistance to the lambda phage, and
even more so efficiently in the group carrying the sense strand [176]. This provided
evidence that CRISPR could be directly programmed and led to a hypothesis of CRISPR
targeting DNA [176].
Marraffini and Sontheimer at Northwestern University studied Staphylococcus’s
CRISPR system and noticed that the nickase gene (nes) on plasmids from the antibiotic
resistant S. aureus was also present in the spacer sequence of S. epidermidis. Transfection
of the S. aureus plasmid into the S. epidermidis bacteria was blocked and unable to be
transferred. If the nes sequence was disrupted by the plasmid or spacer sequence, the
plasmid was not blocked from interfering into the S. epidermidis [177]. Utilizing the nes
gene in the plasmid, they inserted a self-splicing intron in the middle of the sequence. The
idea was that if mRNA was targeted by CRISPR, the intronic sequence would be spliced
out, and therefore, the plasmid would not affect interference. If DNA was targeted by
CRISPR, the intron would prevent the spacer from matching with the plasmid DNA. It
turned out that the spacer would not match the plasmid DNA and interfered with the
CRISPR activity, clearly showing that DNA was targeted by CRISPR [177]. It’s important
to note that there is another CRISPR system that specifically targets RNA [178]. Through
this discovery, they were the first to state that Cas was a programmable restriction enzyme
and could potentially be used outside of bacterial systems [167].
The group at Danisco’s food laboratory continued on working with CRISPR after
confirming it was a bacterial adaptive immune response [173]. Their next step was to
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dissect the mechanism by which CRISPR/Cas cleaved DNA. To do this, they transfected
plasmid free S. thermophilus with vector pNT1, derived from a native S. thermophilus and
carries a chloramphenicol-resistance gene as its selection marker. These strains were also
either cas5 or cas7 gene negative. Cas5 (now known as cas9) is involved in interference
while cas7 plays a role in spacer acquisition [173]. Newly sensitive colonies were screened
and from the 54, 30 were found to have acquired a new spacer-repeat in their CRISPR loci
and had also lost the pNT1 vector. Interestingly, 14 different variations of spacers were
found in these bacteria, all homologous to pNT1 sequences [179]. In addition, consistent
with previous evidence, no chloramphenicol-sensitive colonies were isolated from the cas5
deficient bacteria that also retained their pNT1 plasmid. The cas7 deficient bacteria did
produce chloramphenicol-sensitive colonies; however, none of the colonies had acquired a
new spacer in their CRISPR loci, indicating pNT1 loss was due to other circumstances.
Within these two groups, they found strains with CRISPR conferred partial protection
against pNT1 transformation [179]. One strain even contained a linearized pNT1 plasmid.
They used this linearized plasmid to study the cutting process of CRISPR and found that it
was specifically Cas5’s endonuclease protospacer specific and orientation dependent
activity that cleaved both bacteriophage and plasmid DNA in vitro [179]. In the presence
of Cas5, the linearized plasmid contained a single blunt end cut event 3 nucleotides
upstream of the protospacer adjacent motif sequence or PAM site [179]. The PAM site is
a homologous spacer region in the phage genome that also must be present in the target
DNA to provide immunity. The PAM site is unique to each CRISPR system in providing
a sequence recognition pattern for the Cas enzymes to function [173, 180, 181]. Garneau
also showed that the cuts made were in the same position relative to the PAM site regardless
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if the positive or negative DNA strand was present or if it was in early or late transcription.
Altogether, this work showed that Cas9 was the nuclease cutting DNA and at specific
positions encoded by the crRNAs [167].
In another collaborative effort to dissect S. pyogenes and its RNAs that could be
involved in virulence control, another required component of the CRISPR system was
discovered [182]. Charpentier’s group used differential RNA sequencing of a class II
CRISPR system. They retrieved data that small crRNAs originally from a 511-nucleotide
pre-crRNA was the most abundantly expressed. These crRNAs were between 39-42
nucleotides long and low in primary transcript number indicating they likely were
processed RNA. The third most expressed transcript present was small trans-activating
CRISPR RNA (tracrRNA). These were different lengths of 171, 89, 75, and 65 nucleotides.
The 171 and 89 nucleotide tracrRNA both contained a 25-nucleotide stretch of almost
identical complementarity to the CRISPR repeats [182]. They hypothesized these
differences in sizes were likely due to potential base-pairing between tracrRNA and precrRNA that lead to their co-processing and eventual generation of mature crRNA for
CRISPR function. To test this, they created in frame deletions within either tracrRNA or
pre-crRNA. Mature crRNA was absent in the mutant tracrRNA and the 75-nucleotide form
of tracrRNA was not present in the pre-crRNA mutant. The addition of long tracrRNA
restored pre-crRNA, processing in the mutant tracrRNA bacteria while an 89-nucleotide
tracrRNA appeared once pre-crRNA function was restored. This indicated that non-coding
RNAs, tracrRNA and pre-crRNA are required for the function of CRISPR; specifically, it
is the tracrRNA that directs the maturation of pre-crRNA so that it may target DNA for
cleavage by Cas enzymes [182]. Of interest, Charpentier’s group also found that it was an
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RNase III-Csn1 complex that processed the tracrRNA-pre-crRNA to mature crRNA and
the tracrRNA has the ability to form a stem-loop/inter-molecular RNA structure for precrRNA processing [182].
At this point, Sapranauskas in Virginijus Siksnys’ lab was working on cloning the
now well-known CRISPR system of S. thermophilus into a different bacterial genus, E.
coli. Transfer of the system into E. coli provided protection against bacteriophage infection
and plasmid transformation [183]. In addition, they found that the Cas9 protein was the
sole endonuclease necessary for both crRNA maturation and DNA cleavage [183].
Gasiunas in Siksnys’ lab continued on to study Cas9-crRNA interaction [184]. Cas9 is a
large multi-domain protein with 2 catalytic domains, HNH and RuvC [183, 184]. These
two domains have been shown necessary for interference in vivo [183]. Although Cas9 was
known to be necessary for the steps of crRNA maturation and DNA cleavage [174, 175],
it was still unclear which motifs served which purpose. Gasiunas and his colleagues worked
to isolate the Cas9-crRNA complex, using streptavidin-labeled Cas9 in S. thermophilus
[184], and confirmed the presence of a 42-nucleotide crRNA that co-purified with the Cas9.
Using a 55-nucleotide oligoduplex containing a PAM site with flanking identical sequences
and a protospacer between them, they demonstrated that the Cas9-crRNA complex cleaved
dsDNA 3-nucleotides away from the terminal end of the protospacer-adjacent to the PAM,
leaving blunt ends and only in the presence of magnesium ions. This cleavage did not occur
in the absence of the crRNA and a PAM site. They then went on and mutated each catalytic
motif to identify each one’s role in the nuclease. The RuvC mutant domain generated
nicked DNA cutting the positive DNA strand (non-complementary) and the HNH mutant
cleaved the negative strand only (complementary DNA), indicating each domain is active
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on opposite strands to produce a DSB. These results clearly demonstrated a mechanism for
CRISPR’s action [184].
Charpentier, in collaboration with Jennifer Doudna, also worked on the mechanism
of CRISPR [167]. After purifying Cas9 from S. pyogenes, they tested its DNA, cleaving
ability in the presence of mature crRNA, complementary to the target DNA and the absence
of tracrRNA. No DNA cleavage was present until they added magnesium and tracrRNA,
which pairs with the repeat sequence of crRNA and allows its maturation. They also found
that the DNA cleavage occurred 3 base pairs upstream of the PAM sequence, producing a
blunt cut [185]. After creating point mutations in the catalytic domains of Cas9, they
demonstrated that each catalytic domain cleaves the opposite DNA strand. Using an
electromobility shift assay, they also demonstrated that tracrRNA is required for target
DNA recognition. Then, using different length tracrRNA lacking 5’ or 3’ ends and either
a full-length mature crRNA or ones lacking the 5’ or 3’ end as well, their group found that
truncated tracrRNA was still capable of supporting DNA cleavage. Truncation of the 5’
end of the crRNA abolished DNA cleavage while truncation of the 3’ end of crRNA still
allowed DNA cleavage. This indicated to them that there must be a critical structure formed
between the RNAs to allow this process to occur. Charpentier and Doudna’s group
describes the PAM sequence as a short sequence motif that allows the recognition of selfversus non-self in the foreign genome [185]. The PAM sequence of Type II CRISPR
systems is a NGG consensus sequence. Jinek mutated the PAM site of an oligonucleotide
and found that the GG was necessary for efficient DNA cleavage and either one’s mutation
reduced affinity of Cas9-tracrRNA-crRNA to the DNA. At this point, it had been observed
that crRNA and tracrRNA functioned as individual components; however, whether they
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combined into a single unit to complete the mechanism of CRISPR was unknown. Jinek et
al designed a chimeric RNA containing a target recognition sequence at the 5’ end followed
by a hairpin structure to maintain the base-pairing interaction between the tracrRNA and
crRNA. Using GFP as the target gene, chimeric guide RNAs targeting GFP were able to
cleave the DNA efficiently. This was a logical design of chimeric RNA that realistically
could be programmed for a DNA target-binding sequence similar or more easily than ZFNs
and TALENs [185].
Altering the mammalian genome using CRISPR was the next feat at task. Feng
Zhang’s lab at MIT proved to be the first group to engineer CRISPR/Cas systems to cleave
genomic DNA in human and mouse cells [186]. Bacteria cells do not contain a nucleus so
they began by combining the type II CRISPR locus from S. pyogenes Cas9 (SpCas9) with
a GFP reporter and different number of nuclear localization signals to guarantee it would
compartmentalize to the mammalian cell’s nucleus. They transfected 293FT cells and
observed that an SpCas9 attached to 2 nuclear localization signals had the highest GFP
expression and hence efficiency of nucleus targeting [186]. After transfecting in the
different components of CRISPR, they verified that the spCas9, in combination with a
tracrRNA and pre-crRNA, were enough to facilitate efficient cleavage of the Emx1 locus.
Then they tested the ability to use a chimeric RNA fusion of a partial tracrRNA to a mature
crRNA using a synthetic stem loop. They targeted the human PVALB and mouse Th loci
and found efficient cleavage in both loci with the chimeric RNA [186]. They continued
their study to explore the specificity of the chimeric RNA for genome editing. To do this,
they created guide RNAs with single-nucleotide mismatches between the spacer and its
mammalian protospacer target. A single-base pair mismatch from the 5’ site of PAM up to
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11 base pairs away fully abrogated SpCas9 cleavage activity. On the other hand, mutations
upstream in the spacer maintained cleavage of the genomic DNA against the protospacer
target [186]. To further enhance the mechanism of CRISPR, Zhang’s group went on to
mutate the RuvC I domain within SpCas9 to convert it to a nickase (Figure 4). As a
nickase, the SpCas9 should only nick the genomic DNA, which is mediated to repair
through HDR rather than non-homologous end joining (NHEJ). They also introduced a
homology repair template to promote the changes desired in the EMX1 locus. After
transfection and sequencing of the loci, a pair of inserted restriction enzyme sites found in
the donor repair template were discovered and integrated in the genome demonstrating the
ability of CRISPR to facilitate targeting genomic insertions [186]. This also showed that
the Cas9 enzyme, as a nickase, could enable genomic editing with a decrease for off-targets
[186].
After this publication, CRISPR research modifying and editing the genome
skyrocketed [187-191]. It helped tremendously that publications included protocols and
detailed methodology and results [166, 172, 186, 192]. In addition, many labs deposited
their vectors for the various CRISPR components into Addgene repository, making it even
more available for researchers. This collaboration has allowed the reproducibility of
genome editing both in vitro and in vivo [187, 189-191] and the optimizing of CRISPR to
work effectively and efficiently, including the use of ribosomal CRISPR and the deadCas9
[193-197].
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Figure 4. CRISPR/Cas9 and its Modification for Altering the Genome. The gRNA binds
through complementarity to the target sequence. Because of the 2 active catalytic domains
(RuvC and HNH), Cas9 enzyme creates a DSB at the 5’ end of the gRNA that usually
results in NHEJ for DNA repair. By inactivating one of the catalytic domains a nickase is
generated that cleaves only the DNA strand that is complementary to it. Pairing 2 nickases
will increase Cas9 specificity and produce two nicks each with a 5’ overhang that can be
repaired through HDR when a repair template is provided. Paired nickases also decrease
the potential for off-target mutations. Adapted and modified from Jeffry D. Sanders et al.
Nat Biotechnol. 2014; 32 (4): 347-55. [198]

There are two classes of CRISPR systems that exist across a range of bacteria and
archaebacterial [164, 199]. The components involved, and the mechanism of action
determines the class. The class I system requires a large complex of multiple effector
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protein for RNA-guided target cleavage while the class II system only needs a single RNAguided endonuclease for DNA cleavage [199]. Each system is comprised of a distinctive
array of direct repetitive repeats, non-coding RNAs, and a Cas gene to complete
recognition and cleavage of DNA [164, 199]. The repeats are interspaced by short variable
sequences derived from the exogenous DNA targets known as protospacers. The host
acquires its protospacer through recognition of fragments of invading phages or plasmids
[164, 199]. The direct repeats and protospacer is known as the CRISPR RNA (crRNA)
array [164]. The crRNA is the 20-nucleotide guide sequence that will bind via WatsonCrick base-pairing to the DNA target. Adjacent to the crRNA-target must be a protospacer
adjacent motif (PAM). The PAM is essential for crRNA targeting and changes for each
type of CRISPR system [164]. The target sequence must be preceded by the PAM
sequence, which will recognize this sequence and allow the target to try and base pair. The
PAM sequence is absent in the host’s genome to prevent self-cleavage [164].
The mechanism of action is uniform throughout, though the CRISPR action will be
dependent on the presence and sequence of PAM [164]. The bacteria’s first step is the
acquisition phase in which protospacers are acquired and incorporated into the host’s
CRISPR locus as spacers. In the transcription phase, the CRISPR array is transcribed into
pre-crRNA, which is cleaved and processed to mature crRNA by the now expressed Cas
protein. Finally, in the interference stage, the Cas protein recognizes the target sequence
through the guidance of the crRNA and cleaves the phage/plasmid DNA, defending itself
from an infection [164, 199].
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Current Advancements
There have been many successes and improvements with CRISPR. The most well
characterized system is the type II CRISPR system. Streptococcus pyogenes (S. Pyogenes)
contain the type II CRISPR that works by incorporating sequences from the invading DNA
into its own genome, specifically within the CRISPR repeat sequence set up as an array
within the bacterial genome [164]. Its PAM conforms to the 3’NGG consensus sequence,
containing two G:C base pairs that occur one base pair downstream of the crRNA binding
sequence, within the target DNA [182]. When it cleaves DNA, it creates a blunt ended cut
3 base pairs away from the PAM site [182]. It is also the most commonly used Cas (Cas9)
protein for genome editing. The Cas9 has been modified to act as a nickase by mutating a
nuclease domain, thereby allowing a DSB that has a higher likelihood for HDR with the
addition of an oligonucleotide while decreasing off-target effects [166, 186]. In addition,
both of Cas9’s catalytic domains can be mutated to act as a “dead” protein. The protein can
still be guided and bind DNA, but it will not cut [197]. This allows the protein to be used
to act as a transporter to deliver other factors to activate or repress the genome and study
epigenetic modifications [200].
There are other type II Cas enzymes that have been discovered to mediate DNA
cleavage and found to be useful in mammalian cells. Cpf1 is a class II type V CRISPR that
only requires the guidance of a crRNA without a tracrRNA [201]. Although it is very
similar to Cas9, its PAM sequence is 5’TNN and must be located on the 5’ end of the target
DNA. Its 2 catalytic residues are found in its singular RuvC domain. Unlike Cas9, if any
of the catalytic residues in the RuvC domain are mutated, no cleavage activity can occur.
It creates a 5-base pair- 5’ overhang 18 base pairs away from the PAM site. Some
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advantages that Cpf1 may provide over Cas9 include sticky ends after cleavage, which
could allow gene transfer in non-dividing cells that usually cannot be modified through
HDR. Since its PAM site is 5’TNN rather than the G-rich Cas9, AT-rich regions or
genomes without 3’NGG could be targeted with Cpf1 [201]. In addition, the single crRNA
needed would be smaller and easier to deliver in somevectors than Cas9’s about 100nucleotide tracrRNA/crRNA hybrid [201, 202]. Finally, the number of off-target effects
created by Cpf1 is not much smaller than that of Cas9; however, computationally, the
number of off-target sites predicted for Cpf1 is usually in the 1-12 range while Cas9 is as
high as 90 sites [202, 203].
The delivery of CRISPR systems is an essential component in the success or failure
of a modified genome. After identifying how many components need to be delivered (Cas,
sgRNA, repair template), the delivery method can be selected. Delivery via transfection,
viral infection, or even injection as protein, RNA, or DNA is suitable [204]. The expression
system for efficient cleavage of the genome will be dependent on the end goal. An
expression vector is appropriate for transient or stable transfection for high efficiency in a
mammalian cell [204, 205]. Lentiviral transduction is the most commonly used for
CRISPR genome wide screening and difficult to transfect cell lines and even in vivo [9,
204]. Adeno-associated viral (AAV) transduction is useful for transient and stable
expression of only the Staphylococcus aureus Cas9 (SaCas9). An AAV is common for in
vivo delivery due to its low immunogenicity and ability to preferentially infect specific
tissues [33, 204]. However, it can only package up to 4.5 kb [33, 204].
Feng Zhang’s group continues to pave the way in optimizing the use of CRISPR
by developing a Cas9 that would fit into an AAV. The Cas9 enzyme is large ranging in
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size from 1000-1300 amino acids [206] and in combination with the chimeric sgRNA (4.2
kb) cannot be shrunk to fit into the 4.5 kb package. To find a Cas9 enzyme, six different
sized Cas9 enzymes were transfected into 293FT cells with sgRNAs for specific genes. Of
the six Cas9 orthologs tested, the Cas9 from the Staphylococcus aureus (SaCas9) had the
highest cleavage activity [206]. Since another species of Cas9 was being used, various
sized sgRNA also had to be tested to see if the length of the sgRNA would vary with each
Cas as well. The highest editing efficiency with SaCas9 turned out to be 21-23 nucleotides
long. In addition, using deep sequencing, their group identified a strong linear correlation
between DSB scores and indel levels for each Cas9 and sgRNA pair in 293FT cells
transfected with the different Cas9s and sgRNAs targeting EMX1 [206]. However, they
also noticed other genes that were cleaved besides EMX1 due to homology of their
sequences. These off-target sites were generated both through Watson-Crick base pairing
and through guide: target heteroduplex formation [206]. The group still proceeded to target
the Apob gene in vivo in the mouse genome using SaCas9, driven by a CMV promoter, and
a sgRNA, driven by the U6 promoter, all packaged into an AAV vector. The virus was
injected intravenously into C57BL/6 mice and after one week, they noticed a 5% indel
formation in the liver tissue. They extended the wait time to 4 weeks after which dissection
of the liver tissue demonstrated characteristics of hepatic lipid accumulation in the Apob
knockout mice with higher oil red staining [206]. They saw the opposite results when using
the CRISPR system to target the Pcsk9 gene; they observed a 95% decrease in serum
PCSK9 levels and a 40% decrease in total cholesterol after just the first week of
administering CRISPR [206]. Of course, it’s necessary to determine if any off-target effects
occurred within the genome after injection with the Pcsk9 targeting CRISPR. Deep
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sequencing of DNA extracted from the liver tissue did not reveal significant levels of indel
formations; the mice did not show any signs of toxicity or any acute immune response to
the virus or CRISPR [206].
Other methods of delivery of CRISPR include plasmids containing the gRNA and
Cas9 mRNA, which can be delivered through electroporation or microinjection [204]. This
is usually only used when generating transgenic embryos or transient expression [204]. An
improvement in the delivery of CRISPR has been through the use of Cas9-gRNA
ribonucleoprotein complexes (RNPs) [204, 207]. The Cas9-RNP, delivered via gold
nanoparticles in mice with muscular dystrophy, had a high efficiency of gene editing in
muscle tissue with low toxicity [195]. All in all, the use of CRISPR has only just begun
and advancements in technology will ensure that CRISPR is utilized far beyond what we
think imaginable.
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PART III: THE ENDOPLASMIC RETICULUM and
UNFOLDED PROTEIN RESPONSE

Endoplasmic Reticulum, Protein Folding and Chaperones
The ER is a large and crucial component of the cell made up of a closed, yet
interconnected network of tubules and flattened sacs extending from cell membrane to
form a contiguous connection with the nuclear envelope. Its extensive structure is required
for all the processes the ER maintains: synthesis and folding of proteins trafficking through
the secretory pathway, biosynthesis of lipids and proteins, and maintaining a quality control
process to prevent cell stress [208, 209]. The ER is made up of both the smooth and rough
ER. Most cell types contain a small volume of smooth ER; however, hepatocytes are rich
in smooth ER [210]. It is in the smooth ER that enzymes chemically convert toxic
hydrophobic compounds like pesticides to water-soluble molecules for secretion from the
body [210].
The quality control system of the ER ensures that newly synthesized proteins only
leave the compartment when their folding criteria have been met [208, 209, 211]. Newly
synthesized unfolded proteins enter the ER. At the N-terminus of the protein is a signal
sequence that is recognized by a signal recognition particle (SRP). The protein sequenceSRP complex binds to an SRP receptor in the ER membrane. This chain is then guided to
the Sec61 translocon, an integral membrane protein, which acts as a tunnel to allow the
translocation of the growing amino acid chain across the ER membrane and into the ER.
Once fully in the ER lumen, the protein completes its folding assembly into its native
structure with the assistance of ER chaperones such as Grp78 [208, 212, 213]. The protein
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can undergo further post-translational modifications in the ER though these modifications
also occur in the Golgi as it does for the LDLR [98]. The properly folded protein is then
released by the ER chaperone to proceed to its proper cellular compartment via vesicles
[208, 213].
The specific factors and molecular mechanisms responsible for LDLR folding and
maturation is still unclear. Chaperones are expressed in the ER and play a major role in the
protein folding process [105, 214]. The general chaperone, Grp78, is known to transiently
bind LDLR and assist in its proper folding under normal conditions [124, 125, 215]. This
correlates with studies of Grp78 acting selectively in retaining proteins in the ER [215].
Another chaperone that has been implicated in binding and facilitating the proper folding
and maturation of the LDLR is the receptor-associated protein (RAP) [216]. The rate at
which the ER folds proteins is dependent on the physiological and pathological reactions
occurring within the biological system. The ER folding process can become susceptible to
aggregation in times of inflammation, diabetes, and cancer [208].
Because the ER is responsible for processing of proteins, it requires a strict and
modulated signaling mechanism to maintain homeostasis and prevent aggregation of
unfolded or misfolded proteins and even correct misfolded proteins. This quality control
ensures that only properly folded protein exit the ER for the Golgi, while misfolded
proteins are retained in the ER. If unable to be corrected, misfolded proteins in the ER
eventually undergo a process called ER-associated degradation, or ERAD. ERAD is a
retrograde transport process where the misfolded protein is translocated back through the
Sec61 tunnel to the cytosol. The protein is ubiquitinated and finally degraded by the 26S
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proteasome [208, 217]. Otherwise, misfolded proteins can and do lead to cell death by
apoptosis [213, 217, 218].

Unfolded Protein Response in FH Class II Mutations
Before some misfolded proteins can undergo the process of ERAD, the
accumulation of these proteins leads to condition called “ER Stress” [213, 217, 218]. ER
stress elicits a coping mechanism of “unfolded protein response (UPR)” [213, 217, 218].
The UPR’s major role is to maintain protein homeostasis in the presence of accumulated
un/misfolded proteins [213]. There are three known signaling pathways in mammals that
are activated to adapt to the ER stress environment and “fix” the misfolded proteins [213].
The 3 major stress sensors of these pathways are IRE1, PERK, and ATF6 [213] and work
to restore folding capacity in the ER by controlling the expression of transcription factors
and other downstream factors (Figure 5).
Inositol-requiring transmembrane kinase/endonuclease (IRE1) is the bestcharacterized sensor of the ER stress response pathway. It’s signaling is conserved across
bacteria, plant, and animal [219, 220]. This serine/threonine protein kinase and
endoribonuclease catalyzes the processing of transcription factor X-Box binding protein-1
(XBP1) [213, 221, 222] (Figure 5). The splicing of a 26-nucletoide intron from xbp1
generates the transcription factor, spliced XBP1 (XBP1s) [213, 221, 223]. XBP1s regulates
UPR genes for folding, ERAD, autophagy, and organelle biogenesis [213, 224-226]. Of
interest, XBP1s targets different genes in different tissues and under specific conditions for
each indicating that this ER stress responder is as unique and in need of dissecting as most
of the players involved in the UPR [213, 227].
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PKR-like ER kinase (PERK) is an ER transmembrane protein whose activation
through phosphorylation mediates UPR by phosphorylating initiation factor EIF2 [213,
217, 228]. EIF2 phosphorylation renders it inactive; this leads to an inhibition of protein
translation and a decrease of misfolded proteins. Through its inactivation, EIF2 also
increases the translation of a transcription factor, activating transcription factor 4 (ATF4)
[213, 217, 228]. It does this by recognizing an inhibitory upstream open reading frame in
ATF4’s 5’ untranslated region [218]. ATF4 modulates another subset of UPR genes
involved in antioxidant response, glutathione biosynthesis, amino acid metabolism,
autophagy, and apoptosis [229-231] (Figure 5).
Activating transcription factor 6 (ATF6) is another ER transmembrane protein that
mediates UPR [213]. Within the ATF6 protein structure is a cytosolic domain that renders
it inactive in the ER [221, 232]. During ER stress, ATF6 translocates to the Golgi where
the cytosolic domain is released by two proteases. This segment termed ATF6f (a fragment
of ATF6) then goes on to act as a transcription factor to upregulate the expression of UPR
genes involved in protein folding like ER chaperones and degradation like ERAD [221,
232] (Figure 5).
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Figure 5. Schematic of the Unfolded Protein Response (UPR). When misfolded or
unfolded proteins begin to aggregate in the endoplasmic reticulum (ER), Grp78
disassociates from the three ER stress receptors leading to a sequential activation of the
receptors and their downstream effectors. Pancreatic ER kinase (PKR)‐like ER kinase
(PERK) is activated by autophosphorylation and leads to phosphorylation of eukaryotic
initiation factor 2α (eIF2α) inhibiting translation of proteins except activating transcription
4 (ATF4). ATF4 acts on genes for amino acid synthesis and antioxidant production.
Activating transcription factor 6 (ATF6) activation generates a fragmented ATF6 that acts
as a transcription factor for expression of degradation and apoptotic protein CHOP.
Inositol‐requiring enzyme 1 (IRE1) regulates the expression of X box‐binding protein 1
(XBP1), another transcription factor, that is spliced into its active form by IRE1. Spliced
XBP1 protein (SXBP1) translocates to the nucleus regulates transcription of genes for
chaperones and protein degradation. Adapted from Eva Szegezdi et al. EMBO Rep. 2006;
7: 880-85. [233]

To be brief, under stressful conditions the ER utilizes the UPR to regain
homeostasis. If UPR is prolonged, severe consequences including oxidative stress,
inflammation, and eventually apoptosis can occur [213, 217, 218, 229]. How does ER
stress and the UPR relate to class II LDLR mutants in FH?
Evidence in the literature claims that ER stress does occur due to a class II
misfolded LDLR [124, 125]. A few studies first confirmed that class II LDLR mutants are
retained in the ER [118, 124, 125]. For example, Chang cells overexpressing wild type
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LDLR or mutant W556S or C646Y LDLR were subjected to pulse chase experiments and
showed wild type LDLR was processed to mature LDLR while the mutants remained in
the immature form [125].
Using mass spectrometry and western blot others have demonstrated that Grp78
binds and retains class II LDLR in the ER [125]. Grp78 is an ER chaperone that binds
unfolded proteins and also regulates activation of ER stress response [103, 104]. Lysates
from Chang cells overexpressing class II LDLR mutants co-immunoprecipitated with
Grp78 and blotted for LDLR showed binding between the two proteins. In fact, Grp78
transiently interacts with the wild type LDLR as it is processed to its mature form and its
interaction is prolonged with the mutant LDLRs [125]. Another study by Sorensen and
colleagues overexpressed other class IIA and class IIB mutant LDLR into Chinese hamster
ovary cells (CHO) and confirmed prolonged interaction between mutant LDLR and Grp78
[124]. To test for ER stress, they looked at UPR gene and protein expression markers
XBP1s and phosphorylated-PERK. Mutant G544V LDLR expressed XBP1s mRNA and
had a fold induction of phosphorylated-PERK [124]. These two studies indicated that the
accumulation of misfolded LDLR in the ER increased Grp78 and activated the UPR.
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CHAPTER II
CRISPR CORRECTION OF A HOMOZYGOUS LDLR MUTATION IN FAMILIAL
HYPERCHOLESTEROLEMIA INDUCED PLURIPOTENT STEM CELLS

INTRODUCTION
Cardiovascular disease (CVD) is the leading cause of death worldwide. While risks
include lifestyle choices and environmental factors, a subgroup of the population develop
early CVD due to inheritable genetic mutations. Familial hypercholesterolemia (FH) is an
autosomal dominant disease primarily caused by mutations in the low-density lipoprotein
receptor (LDLR) gene, resulting in supra-elevated low-density lipoprotein-cholesterol
(LDL-C) that leads to premature CVD [17, 234-236]. Defective LDLR in FH presents in
two forms; the more common single allele mutation, heterozygous FH (HetFH), 1:250 [1,
237] and the rare two allele mutation form, which can be a true homozygous or compound
heterozygous mutations (both referred to as homozygous (HoFH), 1:250,000) [237, 238].
Over 1200 LDLR mutations have been identified leading to a wide spectrum of disease
severity depending on the mutation’s effect on LDLR activity [236, 239]. While HetFH
patients can generally be treated with standard hypercholesterol therapeutic approaches
(i.e. lifestyle changes, statins), receptor-defective HoFH patients with <2% LDLR activity
are generally non-responsive and must rely on more extreme, costly approaches such as
weekly/bi-weekly lipid apheresis [15]. Transplantation of a normal liver in HoFH patients
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has been shown to restore normal LDL-C levels, however, the lack of organ donors creates
a deficit in availability
[129, 240]. In addition, the most severely affected patients can present as adolescents in
their first decade of life [17, 236]. By the time these patients are considered for liver
transplant, they often have already developed severe CVD requiring a heart transplant.
Therefore, mitigating the effects of genetically induced hypercholesterolemia at the earliest
time possible is critical for these patients.
Because of the common donor organ shortage and challenges related to liver
transplantation, alternative approaches for providing LDL-C regulation have been
investigated. Hepatocyte cell therapy demonstrates efficacy in animals [41, 42, 45] and
humans [51]. However, as with solid liver organs, there is a shortage of high quality
hepatocytes. Since FH is a monogenic disease, it has long been the target of gene therapy
which has shown promise in animal models [41, 42, 45, 241] but mixed results in humans
[51]. The discovery of cellular reprogramming to generate patient specific iPSC presents
the potential for generating unlimited autologous therapeutic cells [242]. The iPSC have
been generated from FH patients [243-245], but the LDLR mutations are retained and
require modifications for receptor-mediated LDL-C internalization [244, 245]. The
genome editing system, clustered-regularly-interspaced-short-palindromic-repeats/Casassociated 9 (CRISPR/Cas9) is a relatively simple technology capable of permanent
genetic modifications and has been used to repair endogenous disease-causing genetic
mutations in several diseases [187, 192, 246]. Although many cell types are used for
correction with CRISPR/Cas9, an advantage of correcting at the iPSC level is their
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theoretical unlimited expansion post-correction without concern for cell senescence. They
also have the capability of differentiating to the cell source of choice.
As a proof-of-concept, we reprogrammed FH fibroblasts carrying a homozygous 3
bp deletion in exon 4 of the LDLR gene (GM03040). This mutation causes a Class II
mutation and has <5% normal receptor activity. This mutation is referred to as FHPiscataway [92]. To introduce a permanent correction, we utilized Cas9 nickase (Cas9n)
with paired single-guide RNAs (sgRNA) to generate adjacent off-set nicks in the selected
genomic target. This strategy is reported to reduce off-target mutations [186, 198]. For the
repair template, we used a single-stranded oligodeoxynucleotide (ssODN) [186, 247].
After double positive transfection and magnetic sorting of the final isolated clones, we
estimate an efficiency of homozygous correction of 0.2% with this approach. The HLC
derived from the corrected FH-iPSC confirmed restoration of the mature LDLR protein
and normalization of receptor-mediated LDL internalization compared to non-corrected
FH-HLC. This demonstrates the feasibility to generate permanently restored endogenous
LDLR activity in FH-HLC by CRISPR technology.

MATERIALS AND METHODS
Cell Culture. Human fetal fibroblasts (IMR90; [248]) were cultured in DMEMHG (Invitrogen, Carlsbad, CA), 2mM L-glutamine (Invitrogen, Carlsbad, CA), and 10%
fetal bovine serum (Invitrogen). Cells were maintained at 37 C and 5% CO2. Cells were
passaged by rinsing the cell monolayer with Dulbecco’s PBS without calcium and
magnesium (Invitrogen). 0.05% trypsin-EDTA (Invitrogen) was added to the cells and
incubated at 37 C for 3 minutes. Once detached, complete media was added to cell
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suspension to inactivate trypsin. A 1:10 split ratio was dispensed into a new culture vessel.
Skin fibroblasts from an FH patient (GM03040; Coriell Cell Repositories) were cultured
in FH growth medium comprised of MEM (Invitrogen), 15% FBS, 2mM L-glutamine, and
0.1 mM Non-Essential Amino Acids (MNEAA) (Invitrogen). Cells were maintained at 37
C and 5% CO2. Cells were passaged as above. Reprogrammed GM3040 (3040-iPSC) were
cultured on hESC-Qualified Matrigel coated plates (BD Biosciences, San Jose, CA) in
mTeSR1 with media changed daily (STEMCELL Technologies, Vancouver, Canada)
[245]. Cells were passaged using Gentle Cell Dissociation Buffer (GCDB; STEMCELL
Technologies) with 10 M Rock inhibitor (Selleck Chemical, Houston, TX) and
maintained at 37 C and 5% CO2 [245]. H1 stem cells (WiCell, Madison, WI) were cultured
in the same way as iPSC.
Genotype Analysis by Sequencing, Karyotype Analysis, and DNA
Fingerprinting. The GM03040 LDLR was genotyped by Ambry Genetics (Aliso Viejo,
CA) and Sanger sequencing (Genomics Core, Louisville, KY) was used to confirm the
mutation using a 20 M forward primer for LDLR exon 4 (Integrated DNA Technologies
(IDT); (5’-CGGCTATAGAATGGGCTGG-3’)). IMR90 fibroblasts were also sequenced
as a normal LDLR gene control. Corrected clones were sequenced in the Genomics Core
using the same forward LDLR exon 4 primer, and the results were analyzed in Seqman Pro
(DNASTAR) to determine homozygous or heterozygous correction. DNA karyotyping and
fingerprinting on GM03040 fibroblasts and derived 3040-iPSC were performed by Cell
Line Genetics (Madison, WI) to confirm both were karyotypically normal and preserved
matching DNA fingerprints.
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Cellular Reprogramming. GM03040 fibroblasts were reprogrammed using
Stemgent’s MicroRNA enhanced feeder free synthetic modified mRNA reprogramming
according to the manufacturer’s instructions (STEMGENT, Cambridge, MA) [245].
Immunocytochemistry. 3040-iPSC were fixed with 2% PFA/PBS (10 minutes,
24° C; Electron Microscopy Sciences, Hatfield, PA), permeabilized when needed with
0.05% Triton X-100/PBS (5 minutes, 24° C; Sigma Aldrich), and blocked with 5% normal
goat serum/PBS (Sigma-Aldrich). A list of all antibodies used for analyses is given in
Table 1. Primary antibodies were diluted in 5% goat serum/PBS and incubated on cells
overnight at 4° C. DAPI nuclear stain (1:2000; ThermoFisher) was added (5 minutes, 24°
C), washed, mounted, and imaged using an Olympus IX81 fluorescence microscope
(Center Valley, PA).
Teratoma Formation. 3040-iPSC were cultured in mTeSR1 on Matrigel and
passaged with trypsin-EDTA five times then subcutaneously injected into NOD/SCID-null
immunocompromised mice (Jackson Laboratory, Bar Harbor, ME) [245, 249]. Teratomas
were dissected from the mice after the tumor reached 10 mm in diameter, followed by
fixing in 4% PFA overnight, paraffin embedded, sectioned, and stained with hematoxylin
and eosin for histological examination. Tissue identification was performed on the
Olympus IX81 microscope. All animal procedures were conducted in accordance with an
approved University of Louisville Institutional Animal Care and Use Committee (IACUC)
protocol.
Hepatocyte Differentiation. 3040-iPSC underwent directed differentiation to
hepatocyte-like cells as reported previously [245, 250]. qPCR analysis for stem cell and
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hepatocyte markers (Table 2) was performed at the end of each stage (including stage 0)
and immunocytochemistry at the end of stage 4.
Quantitative PCR analysis. At the end of each stage, 3040-HLC were lysed using
250 L of 0.1% -mercaptoethanol in RLT Buffer (Qiagen). The lysates were purified with
Qiashredder and RNeasy kits (Qiagen) according to the manufacturer’s instructions. RNA
was quantified with a NanoDrop 1000 Spectrophotometer (Genomics Core, University of
Louisville). cDNA was generated using SuperScript II Reverse Transcriptase kit
(Invitrogen) and qPCR performed using PCR Supermix (Invitrogen) with primers obtained
from IDT (Table 2). Amplicons were evaluated via 2% agarose gels (Bio-Rad). 10 L of
amplicons were added to 2 L TrackIt™ Cyan/Orange Loading Buffer (Invitrogen). Gels
were run at 120 V for 45 minutes and imaged via ChemiDoc MP Imaging System (BioRad).
Indocyanine-Green Assay. Indocyanine green (ICG; Cardiogreen; SigmaAldrich) was used to measure hepatocyte function. We adapted a protocol by Ho et al [251]
with modifications of dissolving the ICG dry powder at 1mg/mL in sterile water and
mixing with stage 5 media at a 1:1 ratio to obtain a 0.5 mg/mL stock solution. Cells were
imaged on the Olympus IX81 microscope at both bright field and phase settings.
Fluorescence-labeled LDL uptake analysis. Cells were plated in 8 wells of a 24well plate and taken through HLC differentiation (see above). At the end of stage 4, LDL
internalization was quantified as we have previously described [245].
Western Blot. Cells were starved overnight in 5% lipoprotein-deficient serum
media (Alfa Aesar, Tewksbury, MA) augmented with 5 M Lovastatin (EMD Millipore)
or excess sterols (10 g/mL cholesterol and 5 g/mL 25-Hydroxycholesterol; Sigma-
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Aldrich). The following morning, the cells were thoroughly washed Dulbecco’s PBS with
calcium and magnesium prior to adding 200 L RIPA lysis buffer (ThermoFisher) plus
protease inhibitor cocktail (ThermoFisher) to collect the cells. The DC Protein Assay (BioRad) was used for protein quantification and 20 g/sample of total protein was run on a 410% mini-protean TGX precast gel (Bio-Rad) at 80 volts for 2 hours. Proteins were
transferred onto nitrocellulose membrane (Bio-Rad) then blocked in 5% non-fat dry
milk/TBST. Membranes were incubated overnight with the LDLR antibody (1:5000; R&D
Systems, Minneapolis, MN) or Actin (1:500; Santa Cruz Biotechnology, Dallas, TX)
overnight at 4C. After 3-5 minute washes with 5% milk/TBST, the membranes were
incubated in either HRP-Rabbit Anti-Goat IgG H+L (Invitrogen) or anti-mouse IgG, HRPlinked antibody (Cell Signaling, Danvers, MA) the following day for 2 hours. Supersignal
West Femto Maximum Sensitivity Substrate (ThermoFisher) was used to visualize the
proteins on the Bio-Rad Imager. Densitometry was performed using Bio-Rad imaging
software.
CRISPR Editing Design:
sgRNA design and cloning. The MIT CRISPR Design Tool (crispr.mit.edu) was
utilized to design paired guides in close proximity to the 3 bp (TGG) deletion in exon 4 of
the

LDLR

gene

(Chr19:11,105,170-11,105,650)

(5’-

…TTCCACTGCCTAAGTGGCGAGTGCATCCACTCCAGCTGGCGCTGTGATGGT
GGCCCCGACTGCAAGGACAAATCTGACGAGGAAAACTGCGCTGTGGCCAC3’). We selected paired guides 1 and 9 to use with Cas9n. The guides were cloned into
pHL-H1-ccdB-mEFα-RIH (#60601, Addgene, Cambridge, MA) deposited by the Hotta lab
[192]. Briefly, primers were designed as previously described [172]; for guide specific
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forward primers, 19 bp (bases 2-20) of MIT sgRNA design were utilized and the first base
pair was changed to a G to enable H1 Pol III transcription. Infusion homology arms (in
blue) (Table 3) were added to the 5’ end of each primer pair to enable cloning into the
vector when cut with BamH1 and EcoRI. A PCR reaction was performed using Phusion
Hot Start Polymerase (Thermo Fisher, Walton, MA) and either guide primer paired with
sgUniversal Reverse primer (Table 3). The PCR product was cloned into pHL-H1-ccdBmEFa-RIH with In-fusion Cloning (Clonetech Laboratories, Inc.). Clones were sequence
confirmed with our H1-Fwd primer (5’-GCATGTCGCTATGTGTTCTG-3’).
Cas9n-GFP design. We obtained a humanized S. pyogenes D10A Cas9 nickase
plasmid, pHL-EFlα-SphcCas9(D10A)-iP-A (#60600, Addgene), deposited by Hotta lab
[192]. The puromycin gene, along with a portion of the internal ribosomal entry site
(IRES), was removed by digesting with KpnI and BamH1. In-fusion cloning was utilized
to reinstate the missing IRES sequence and concurrently insert a green fluorescent protein
(GFP) gene. The primers for PCR are listed in Table 4, sequences in blue are infusion
homology arms while underlined sequence is that of GFP. The Cas9n-GFP clone was
sequence confirmed.
ssODN design. A 157 bp anti-sense single stranded oligodeoxynucleotide (ssODN)
repair template with 50 bp left and right homology arms were designed to insert the missing
3-nucleotides (CCA) while simultaneously adding silent mutations within the PAM site
and guide target site (57 bp) to generate a novel XmnI restriction site (GAATGCATTC)
and prohibit further Cas9n editing by blocking guide recognition sequence (Figure 11).
The oligo was obtained from IDT (Coralville, Iowa) as a 4nM ultramer oligo and was not
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HPLC purified. The ssODN sequence has been modified from chromosome 19, gene
NM_00527.4 corresponding to nucleotides 750-896.
Transfection and Selection. Electroporation transfection of reprogrammed
GM03040 (3040-iPSC) was modified from previously described protocols [172, 246, 252].
Cells were transfected using a square-wave electroporator, Nepa21 cell electroporator,
(NepaGene, Ichikawa-City) carried out at 24C at different voltages and time to determine
optimum electroporation range and cell viability (Table 5). 3040-iPSC were pre-treated
overnight in 10 M Y-27632 and transfected at 150 V for 5 milliseconds. The transfection
occurred in 2-millimeter electroporation cuvettes (Bulldog Bio, Portsmouth, NH) with 106
cells in 90 L Opti-MEM and 20 g nucleic acids (5 g Cas9n, 5 g sgRNA1, 5 g
sgRNA9, and 5 g ssODN) in 10 L. Transfected cells were cultured in Y-27632-mTeSR1
media. After two days, we sorted for double fluorescent positive cells via fluorescence
activated cell sorting (FACS). A week prior to transfection and sorting, used media from
3040-iPSC was collected, centrifuged, filtered, and stored at -20C. On the day of sorting,
conditioned media was prepared by mixing used media and fresh mTeSR1 media in a 1:1
ratio with 1% penicillin/streptomycin (Invitrogen). Basic sorting buffer was prepared using
1X DCF-PBS (ThermoFisher), 1 mM EDTA (ThermoFisher), 25 mM HEPES pH 7.0
(Invitrogen), and 1% knock-out serum replacement (ThermoFisher) and filter sterilized.
To prepare for sorting, cells were dissociated to single-cells, counted, centrifuged, and resuspended at <106 cells per 0.5 mL basic sorting buffer in a 5-mL polypropylene tube on
ice. Cells were transported to the University of Kentucky FACS facility (Lexington, KY)
where cells were sorted for positive expression of both red fluorescent protein (RFP) and
GFP into 35 mm dishes in conditioned:mTeSR1 plus Y-27632 media. Cells were incubated
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for 48 hours at the University of Kentucky before being transported back to our lab at the
University of Louisville for continued cell culture. Percent dual positive cells was analyzed
via FlowJo (Ashland, OR).
Magnetic Sorting. Transfected cells were incubated overnight in 5% lipoprotein
deficient serum media supplemented with 5M Lovastatin. Magnetic-activated cell sorting
(MACS, Miltenyi Biotec, Bergisch Gladbach, Germany) separated LDLR+ 3040-iPSC
from LDLR- 3040-iPSC. Cells were disassociated into single cells, counted, and resuspended at <107 cells/60 L ice cold sorting buffer (DCF-PBS, 0.5% knockout serum
replacement, and 2mM EDTA filter sterilized, degassed for 15 minutes by keeping the
vacuum on). 20 L FcR blocking reagent (Miltenyi Biotec) and biotinylated anti-LDLRC7 antibody (1:100; Novus Biologicals, Littleton, CO) were added to the cells and rocked
for 2 hours at 4C. Cells were washed by centrifugation at 200 x g for 4 minutes with 2 mL
sorting buffer twice. 3040-iPSC were re-suspended in 60 L sorting buffer, 20 L FcR
blocking reagent, and anti-biotin Microbeads UltraPure (1:4; Miltenyi Biotec) and
incubated for 45 minutes at 4C with rocking. While cells were rocking, a magnetic
separation column was set up according to manufacturer’s instructions (Miltenyi Biotec).
Cells were washed once more and re-suspended in 500 L sorting buffer. Magnetic
separation was followed according to manufacturer and the column of LDLR+ 3040-iPSC
was removed from the magnet and eluted with 1 mL sorting buffer and plunger. Cells were
plated onto 35 mm dishes. An aliquot of the positively collected cells, negative cells, and
pre-sorted cells were processed further for sorting efficiency. Cells were pipetted into a 5mL polypropylene tube, centrifuged, and re-suspended in supernatant left in tube after
decanting (~50 L) plus 20 L FcR blocking reagent and anti-biotin-FITC antibody (1:5;
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Miltenyi Biotec). The cells were incubated at 4C for 45 minutes, washed twice with 0.05%
sodium azide/DCF-PBS, and re-suspended in 300 L 0.05% sodium azide in DCF-PBS.
FACS analysis grouped cells based on FITC fluorescence.
Clonal Isolation. Clonal selection was performed based on Rodin et al [253]
protocol with modifications. Dialyzed albumin was prepared as previously except using
endo-toxin free bovine serum albumin (A8806; Sigma-Aldrich, St. Louis, MO). 1.6 g/mL
laminin-521 (ThermoFisher) and 0.2 g/mL E-cadherin-Fc (#CDH1-274H; Creative
Biomart, Shirley, NY) were mixed at a 9:1 (wt/wt) ratio in di-cationic PBS and 50 L
coated the inner 24-wells of Sarstedt 96-well tissue culture plates (ThermoFisher) after
which they were washed twice with 80 L di-cationic PBS followed by addition of 50 L
mTeSR1:albumin per well. The MACS isolated 3040-iPSCs were prepared in single-cell
suspension and counted. Serial dilution of the cells to 1 cell/50 L was completed and 50
L cell suspension added per laminin-521/E-cadherin-coated well. Single-celled colonies
were selected and expanded into 24-well plates. Confluent clones were collected and
genotyped using restriction fragment length polymorphism (RFLP).
Restriction Fragment Length Polymorphism Assay. Genomic DNA was
extracted from cells following the manufacturer’s protocol (Qiagen Gentra Puregene Cell
Kit,

Germantown, MD). PCR

was

CGGCTATAGAATGGGCTGGG-3’)

performed with
and

LDLR

LDLR
exon

exon 4-F (5’4-R

(5’-

GAATACTTTCTTGGCATGTTGTTG-3’) for 34 cycles, with denaturation at 98C,
annealing at 62C, and extension at 72C. 5 L of amplicons were run on a 1% agarose gel
to detect presence of PCR product. 250 ng of PCR product, 0.3 L XmnI enzyme (New
England Biolabs (NEB), Ipswich, MA), 1.5 L 10X Cut Smart Buffer (NEB, Ipswich, MA)
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were combined with nuclease free water (Qiagen) for total volume of 15 L and incubated
at 37C for 2 hours. 3 L TrackIt™ Cyan/Orange Loading Buffer was added to the digested
sample followed by a 2% agarose gel run at 120 V for 45 minutes. Heterozygous and
homozygous correction was determined by observation of bands at 576 bp, 384 bp, and
192 bp on the gel relative to 1 kB ladder (Bio-Rad, Hercules, CA). PCR products were
Sanger sequenced to verify 3-nucleotide correction of the LDLR.
Off-Target Analysis. Potential off-target sites that each guide may have was listed
in the MIT CRISPR Design Tool. The three highest scoring genic and three non-genic sites
were selected to check for potential off-target effects of the sgRNA (Table 6). PCR primers
were designed and amplified with 25 cycles, denaturation at 98C, annealing at 62C, and
extension at 72C. 5 L amplicons were run at 120 V for 30 minutes on 1% agarose gel to
confirm presence of amplicon. Following this, 10 M forward primer of the selected
potential off-target sequence was added to PCR product for Sanger sequencing. Analysis
in SeqMan Pro (DNASTAR, Madison, WI) was performed to identify deletions, indels,
and SNPs. Control non-corrected 3040-iPSC were first tested to verify sequence followed
by comparison to corrected 3040-C-iPSC.
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Table 1
List of Antibodies and Fluorophores

Antigen
OCT4
SOX2
SSEA4
SSEA1
TRA-1-60
TRA-1-81
StainAliveTM TRA-1-81
(DyLightTM 488)
AFP
ALB
CYP7A1
CYTOKERATIN-18
LDLR
Actin
Biotinylated-LDLR-C7
Alexa Fluor Anti-Goat
488nm

Host
Rat
Goat
Mouse
Mouse
Mouse
Mouse
Mouse

Dilution
1:200
1:200
1:200
1:200
1:200
1:200
1:200

Distributor
R&D Systems, Minneapolis, MN
R&D Systems
ThemoFisher, Walton, MA
EMD Millipore, Billerica, MA
EMD Millipore
EMD Millipore
Stemgent, Cambridge, MA

Mouse
Rabbit
Rabbit
Rabbit
Goat
Mouse
Mouse

1:200
1:200
1:200
1:200
1:5000
1:1000
1:100
1:500

Invitrogen, Carlsbad, CA
MP Biomedicals, Santa Ana, CA
Santa Cruz Biotechnology, Dallas, TX
Santa Cruz
R&D Systems
Santa Cruz Biotechnology
Novus Biologicals, Littleton, CO
Invitrogen

Alexa Fluor Anti-Goat
594nm

1:500

Invitrogen

Goat anti-Mouse 488

1:1000

Invitrogen

Goat anti-Rabbit 488

1:1000

Invitrogen

HRP-Rabbit Anti-Goat IgG
H+L

1:4000

Invitrogen

Anti-Mouse IgG, HRPlinked

1:1000

Cell Signaling, Danvers, MA

Anti-Biotin Microbeads

1:4

Miltenyi Biotec (Bergisch Gladbach,
Germany

Anti-Biotin FITC

1:5

Mitenyi Biotec
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Table 2
List of Primers to Determine Expression of Hepatocyte Differentiation

Gene

Primer 1 (5’ → 3’)

Primer 2 (5’ → 3’)

Product
Size
(bp)

Primer-BLAST
Annealing
Temperature

POU5F1

TGATCCTCGGACCTGGCTAA

AACCACACTCGGACCACATC

744

SOX17

CCGCGGTATATTACTGCAACTA

CACCCAGGACAACATTTCTTTG

371

HNF4A

CCACGGGCAAACACTACGG

GGCAGGCTGCTGTCCTCAT

250

AFP

GCTGACCTGGCTACCATATTT

GGGATGCCTTCTTGCTATCTC

384

ALB

GGTGTTGATTGCCTTTGCTC

CCCTTCATCCCGAAGTTCAT

502

GAPDH

AATCCCATCACCATCTTCC

CATCACGCCACAGTTTCC

382

F: 60.03C
R: 59.97C
F: 58.1C
R: 58.02C
F: 61.32C
R: 62.34C
F: 57.8C
R: 58.2C
F: 57.93C
R: 57.28C
F: 54.14C
R: 56.43C

Table 3
sgRNA Primers
Guide 1

gagaccacttggatccGGCACTCGCCACTTAGGCAGgttttagagctagaaatagca

Guide 9

gagaccacttggatccGACTCCAGCTGGCGCTGTGAgttttagagctagaaatagca

sgUniversal
Reverse

gcccgggtttgaattcaaaaaaagcaccgactcggtgccactttttcaagttgataacggactagccttattttaacttgctatttctagctc

Table 4
Cas9n-GFP Clone Primers
IRES in-fusion PCR

GFP in-fusion PCR

Forward

AAGGATGCCCAGAAGGTAC

TAATATGGCCACAACgcgtatgGTGAGCAAGGGCGAGG

Reverse

GTTGTGGCCATATTATCATCGTG

CTTAAGCCTAGGATCctaGTACAGCTCGTCCATGC
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Table 5
Electroporation Conditions and Highlighted Optimal Condition

Voltage (V)

Length
(ms)

Interval
(ms)

No

Y-27632
Treatment

Electroporation
Survival

100

5

50

2

Y

Y

125

2.5

50

2

Y

Y

125

5

50

2

Y

Y

150

5

50

2

Y

Y

175

5

50

2

Y

N

200

5

50

2

Y

N

Table 6
Predicted Off-Target Cutting Sites

Name

Sequence

PAM
Site

Mismatches

Gene

sgRNA1
OT1-1
OT1-2
OT1-3
OT1-4
OT1-5
OT1-6

AGTGGATGCACTCGCCACTT
CCTGGCTGCACTCGCCACTT
AGTAGATGCCCTTGCCACTT
AGGAAATGTACTCGCCACTT
TCTGGATGCACTCGCAACTT
TGTGGATGAACTTGCCACCT
ATTGGATGAACTTGACACTT

AGG
CGG
CAG
TGG
TAG
CAG
CAG

3MMs [1:2:6]
3MMs [4:10:13]
4MMs [3:4:5:9]
3MMs [1:2:16]
4MMs [1:9:13:19]
4MMs [2:9:13:15]

NM_080740
NM_173651
NR_037711

sgRNA9
OT9-1
OT9-2
OT9-3
OT9-4
OT9-5
OT9-6

CACTCCAGCTGGCGCTGTGA
AACTCCAGCTGGCGCTTTGA
CCCACCAGTTGGCGCTGTGA
AATTTCAACTGGCGCTGTGA
CATTCCATCTGGGGCTGTGA
GACTGCAGGAGGCGCTGTGA
CCCGCCATCTAGCGCTGTGA

TGG
GGG
AGG
AAG
GGG
GAG
GGG

2MMs [1:17]
3MMs [2:4:9]
4MMs [1:3:5:8]
3MMs [3:8:13]
4MMs [1:5:9:10]
4MMs [2:4:8:11]

NM_001198551
NM_002479
NM_018936
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Location
chr19:+11105170
chr3:-61568161
chrX:+48796837
chr2:+23697312
chr22:-22874433
chr2:+186667138
chr17:+33434154
chr19:+11105170
chr11:-32410596
chr2:-239002161
chr1:-96939879
chrX:+62386714
chr1:+203053815
chr5:-140475007

RESULTS
FH Fibroblasts GM03040 have a Class IIB-FH Piscataway Mutation. We
acquired the FH skin fibroblasts (GM03040) from the Coriell Cell Repository (Camden,
NJ) described as homozygous receptor-defective; but no genetic information was provided.
We initially confirmed the inability of GM03040 to internalize cholesterol by culturing
them and a normal fibroblast control (IMR90) overnight in 5% lipoprotein deficient serum
media supplemented with either Lovastatin or excess sterols, followed the next morning
with incubation in low density lipoprotein labeled with 1,1’-dioctadecyl-3,3,3’,3’tetramethyl-indocarbocyanine perchlorate (DiI-LDL) [245]. Lovastatin inhibits 3hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase), blocking
cholesterol synthesis and leading to an upregulation of LDLR. The excess sterols act
independent of the LDLR leading to a decrease in LDLR expression. LDL internalization
by the LDLR-normal IMR90 was robust in response to Lovastatin, that was abrogated in
the presence of excess sterol treatment (Figure 6A). In contrast, GM03040 showed
virtually no DiI-LDL internalization, even under the same Lovastatin treatment conditions
that induced robust internalization in IMR90. We next wanted to know if any LDLR was
produced by GM03040. Under the same conditions for the LDL internalization assay, we
collected cell lysates for analysis by western blot (Figure 6B). Lovastatin treatment of
IMR90 showed strong expression of the mature LDLR protein with low expression of the
immature proteins. No LDLR protein was detected when IMR90 were exposed to excess
sterols. In the GM03040, Lovastatin induced low level LDLR expression with the greatest
increase in immature LDLR protein and very little mature LDLR (Figure 6B). Though
GM03040 expresses little LDLR, even with Lovastatin treatment, excess sterols
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downregulated LDLR indicating these FH fibroblasts are physiologically responsive to
cholesterol feedback control as described by Brown & Goldstein [235]. Sequencing of the
GM03040 (and IMR90 control) LDLR identified a pathological, homozygous 3-nucleotide
deletion in exon 4 (c.654_656delTGG (pG219del)) (Figure 6C). This is a Class IIB
mutation known as FH-Piscataway, which results in less than 5% LDLR activity and
misfolding of immature LDLR that is degraded by the proteasome pathway [92, 119].
Together these data confirm the FH cell line contains a 3-nucleotide deletion in exon 4 of
the LDLR gene resulting in little to no LDLR-mediated LDL internalization.
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Figure 6. Mutation Identification in HoFH Fibroblasts. (A) HoFHɸ and control fetal
IMR90ɸ were treated overnight in 5% lipoprotein deficient serum (LPDS) media
supplemented with either Lovastatin or excess sterols. A significant amount of fluorescent
DiI-LDL was visualized in IMR90ɸ treated with Lovastatin that was abrogated with excess
sterols. GM03040ɸ showed impaired DiI-LDL internalization with Lovastatin treatment
(Scale bars = 200 M). (B) Western blot for LDLR shows IMR90ɸ upregulate LDLR in
Lovastatin and suppress LDLR when exposed to sterols. In contrast, HoFH GM03040ɸ
express comparatively little LDLR under the same conditions. (C) Sanger sequencing
revealed a homozygous 3-nucleotide deletion in exon 4 of LDLR in GM03040ɸ. (IMR90ɸ:
IMR90 fibroblasts; GM03040ɸ: HoFH GM03040 fibroblasts).
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Derivation of 3040-iPSC and Differentiation into Hepatocyte-Like Cells.
Before reprogramming the parental GM03040, we confirmed the normal karyotype
(Figure 7A) and DNA fingerprinting (not shown). We reprogrammed the fibroblasts to
3040-iPSC using a modified synthetic mRNA cocktail containing OCT4, SOX2, KLF4, CMYC, and LIN-28 [245] and began seeing colonies that were morphologically compact
and refractile at approximately day 16. Manually picking of stem cell positive expressing
TRA-1-81+ colonies was initiated around day 20 for expansion into feeder-free culture
(Figure 8A). 3040-iPSC demonstrated immunoreactivity with pluripotence markers TRA1-81 and UEA1 (Figure 8B), TRA-1-60, SSEA4, Oct4 and Sox2, while being negative for
SSEA1 (Figure 8C). We confirmed that the reprogrammed cells were still karyotypically
normal (Figure 7B) and DNA fingerprinting (not shown) established the 3040-iPSC
originated from the parent GM03040 fibroblasts. Histological examination of harvested
teratomas confirmed 3040-iPSC pluripotence with differentiation into derivatives of all
three germ layers in vivo (Figure 8D).
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Figure 7. GM03040 are Karyotypically Normal. (A) Parent GM03040 fibroblasts and (B)
reprogrammed 3040-iPSC have a normal chromosomal arrangement as seen by
karyotyping.
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Figure 8. Reprogrammed 3040-iPSC are Pluripotent. (A) An iPSC colony is visible post
reprogramming, characterized by its small, clustered appearance at Day 16 (Scale bar =
100 μm) and live staining with pluripotent marker TRA-1-81 at Day 18 (Scale bars = 200
μm). (B) Assessment of expanding 3040-iPSC pluripotence is seen with positive TRA-181 and UEA1 immunostaining. (C) Micrographs further confirmed expression of
pluripotent markers TRA-1-60, SSEA4, Oct4 and Sox2, while being negative for mouse
SSEA1. (D) Teratoma generated in immunocompromised mice from 3040-iPSC (i)
differentiated into the 3 germ layers: endoderm-respiratory epithelium (ii), mesodermmuscle (iii), and ectoderm-nerve ending (iv).
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Most LDLRs are found on liver hepatocytes and are responsible for most LDL
regulation [235]; therefore, we wanted to confirm 3040-iPSC capability to differentiate
toward hepatocyte-like cells (HLC). Following a previously described five stage protocol
[245, 250], 3040-iPSC showed expression of stage specific markers after completion of
each differentiation stage as demonstrated by qPCR (Figure 9A; Table 2). As we have
shown previously [245], 3040-iPSC undergo differentiation, as demonstrated by
progression of expression of pluripotence marker octamer-binding transcription factor 4
(OCT4) at stage 0, definitive endoderm marker sex determining region Y box 17 (SOX17)
[250], in stage 1, hepatic lineage specification as indicated by expression of hepatocyte
nuclear factor 4a (HNF4A) in stages 2-5, the early hepatocyte marker alpha fetal protein
(AFP) [250] beginning in Stage 2, and standard albumin (ALB) [250] expression initiated
during stage 3. To examine protein expression, we differentiated 3040-iPSC to the end of
stage 4 and used immunocytochemistry (ICC) for detection of commonly associated
hepatocyte markers, albumin, AFP, CYP7A1, and cytokeratin 18 (Figure 9B) [245, 250].
Finally, we tested 3040-HLC functionality via an indocyanine green (ICG) exclusion assay,
demonstrating 3040-HLC could take up and clear the green dye within 24 hours (Figure
9C). These data confirm that the reprogrammed GM03040 FH fibroblasts are pluripotent
and can specifically differentiate to functioning HLC.
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Figure 9. Hepatocyte-Like Cells (HLC) can be Derived from 3040-iPSC. (A) Stagespecific markers were tested at both mRNA expression level (POU4F1, SOX17, HNF4A,
AFP, and ALB) by PCR (n=3) and (B) protein level (AFP, ALB, CYK18) by
immunocytochemistry (n=2) in 3040-HLC (Scale bars = 50 μm). (C) HLC function was
tested by uptake and exclusion of indocyanine green dye (ICG) over 24h (Scale bars = 50
μm; BF = bright field).
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CRISPR Correction of Homozygous 3-nucleotide Deletion in the LDLR in
3040-iPSC. Our lab has previously restored physiological function of the LDLR in FHiPSC using an episomal transgene; however, plasmid retention is compromised without
continuous antibiotic selection [245]. We opted to use CRISPR/Cas9 to permanently
correct the 3 bp pathogenic deletion in the 3040-iPSC. A schematic outline of our genome
editing approach is presented in Figure 10. Using the MIT CRISPR Design Tool
(crispr.mit.edu), we input the exon 4 LDLR sequence of the FH patient for identification
of sgRNA. Thirteen possible sgRNA were found that could be used with wildtype Cas9
that were arranged in suggested pairs for use with Cas9n. We utilized the Cas9n with a pair
of offset sgRNA since this grouping had previously been successful in facilitating specific
genome editing in human cells [246]. The double offset nicking approach has also shown
a higher likelihood of forcing HDR to improve specific repair and reduce off-target
mutations. Our guide pairs (sgRNA1 and sgRNA9) were selected based on Ran et al criteria
[246, 252]. The guides generate 5’ overhangs with a +2 offset and create at least one nick
within 6 bp of the target mutation site to increase the probability of HDR [186, 246]. HDR
requires a repair template for the DNA to utilize and precisely modify the genome [186,
198, 246, 247]. We designed an anti-sense ssODN template with right and left 50 bp
homology arms flanking the deletion in exon 4 of LDLR. The repair template contained
the deleted 3-nucleotides for inserting the missing 3 bp (ACC) and silent mutations in the
protospacer adjacent motif (PAM) of sgRNA 1 within the first 10 bp upstream of the PAM
site in sgRNA 9 to minimize rebinding after genome repair and to introduce a novel XmnI
restriction site (Figure 11A,B) [186, 198, 246, 247].
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Figure 10. CRISPR Correction Strategy Methodology Schematic. (1) 3040-iPSC were
transfected with 5 g Cas9n, 5 g sgRNA1, 5 g sgRNA9, and 5 g ssODN using (2) a
NEPA21 square-wave electroporator. (3) Double positive (GFP+/RFP+) cells were selected
for expansion via fluorescence sorting. (4) LDLR+ cells were enriched by magnetic sorting
and expanded in culture. (5) Clones were isolated on laminin-521 + E-cadherin-Fc
substrate then (6) analyzed for correction of the LDLR via RFLP, sequencing, western blot,
and LDL internalization.
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Figure 11. CRISPR ssODN Design. (A) Diagram of the CRISPR/Cas9 design to target the
mutation site of the LDLR. Paired single-guide RNA (target 1 and target 9) were selected
to target the mutation site, and a single-stranded oligodeoxynucleotide (ssODN) template
was created to mediate HDR. The ssODN contains a 10-nucleotide sequence (underlined)
as a novel XmnI restriction enzyme site, additional silent mutations (red nucleotides) at the
PAM for sgRNA 1 or within 10 bp upstream of the PAM for sgRNA 9 to prevent re-binding
of guides and cleavage with Cas9n following repair, and the 3 bp insertion (purple). (B)
157 bp single-stranded oligodeoxynucleotides (ssODN) repair template sequence. 50 bp
left and right homology arms (blue) surround the sequence target (57 bp). Silent mutations
(red) were inserted to prevent further re-binding of Cas9n post-correction and create a
novel XmnI site (underlined). 3 bp (CCA) insertion (purple) for correction was built into
the sequence.
We obtained Cas9n and sgRNA plasmids (Addgene # 60600 and 60601,
respectively) deposited by the Hotta lab [192] and cloned in our selected sgRNA (Figure
10, Step 1). The sgRNA plasmid contains a red fluorescent reporter (RFP) that can be used
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to select for cells positively transfected with the sgRNA. We opted to use double
fluorescence cell sorting post-transfection rather than antibiotic selection to potentially
maximize selection of transfected cells. The Cas9n plasmid deposited by Hotta was
modified to incorporate GFP into the vector.

Before transfection, we optimized

electroporation voltage necessary for highest transfection efficiency, referencing NEPA21
electroporator conditions by the Hotta lab [192] (Table 5). We then transfected the 3040iPSC with 20 g total nucleic acids (5 g Cas9n, 5 g sgRNA1, 5 g sgRNA9, and 5 g
ssODN) (Figure 10, Step 2). After 48 hours, we sorted for dual positive (i.e. GFP & RFP)
cells to subculture only cells transfected with both Cas9n and guide plasmids (Figure 10,
Step 3). We collected 2.4% of the 13.1% population expressing both RFP and GFP (Figure
12A). Because we used 2 plasmids for each guide, we could not guarantee that sorted cells
contained both guide plasmids for correction. To enrich the population of double-positive
transfected cells that actually contained the 3 bp insertion, we treated the culture with
Lovastatin to upregulate LDLR expression and targeted the cell surface receptor for
magnetic-activated cell sorting (MACS) (Figure 10, Step 4). Using a biotinylated-C7LDLR antibody, we enriched for LDLR+ cells within the bulk of transfected cells. We
analyzed the percentage of LDLR+ cells collected (green dots) after MACS by FACS.
FACS analysis showed a mix of LDLR+ (green dots) and LDLR- (red dots) before sorting
(left box). After MACS, we confirmed a collection of 19.1% LDLR+ cells, or corrected
cells, with a clear shift of green dots to the right (Figure 12B). After expanding the bulk
LDLR+ cells we adopted the clonal isolation protocol developed by the Tryggvason lab
utilizing laminin-521 and E-cadherin-Fc substrates in mTeSR1-albumin media (Figure 10,
Step 5) [253]. Using a clonal dilution approach, we plated 120 cells and after 7 days of
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culture, identified 16 wells with single colonies (empty and multi-colony wells were
counted as null clones) for a cloning efficiency of 13%. The clonal colonies were expanded
for analysis and cryopreservation.

Figure 12. CRISPR Positive Sorting. (A) After transfection, 3040-iPSC were sorted for
double positive RFP and GFP cells via FACS. 13.1% of cells were dual positive and 2.4%
of the population was collected and expanded to increase specificity of positively
transfected cells. (B) Magnetic-activated cell sorting (MACS) was performed on the FACS
sorted 3040-iPSC to enrich for LDLR+ expressing cells. Pre-MACS sorted cells had a mix
of both positive (green dots) and negative (red dots) LDLR+ cells. After MACS sorting, a
clear shift to the right showed 19.1% LDLR+ cells were collected.
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Since we created a donor repair template that contains a unique XmnI restriction
site (Figure 11), we could use restriction fragment length polymorphism (RFLP) analysis
to check for potential correction of the 3040-iPSC clones. Additionally, we could see if it
was a homozygous or heterozygous clone by band size (Figure 10, Step 6). The expected
LDLR PCR product without any enzyme or correction is 576 bp as indicated by 3040-iPSC
non-transfected control (Figure 13A). A homozygous corrected clone would have two
bands at 384 bp and 192 bp while a heterozygous clone would also retain the 576 bp band.
RFLP of the first clone (3040-C) tested indicated homozygous correction by the presence
of only 2 bands of the correct size (Figure 13A). RFLP analysis of the other clones showed
an additional 9 homozygous corrections and 6 heterozygous corrections (Figure 13B). To
confirm the RFLP results, we performed Sanger sequencing on all PCR positive clones.
Four clones were found to be homozygous corrected by sequencing; however, RFLP
demonstrated retention of the 576 bp band (Clone 2, 3, 4, 11). We presumed these were
not clonal and removed them from consideration. For 12 clones, the RFLP and Sanger
sequencing results agreed. Interestingly, sequencing indicated that not only did the
heterozygous corrected clones (C12 and C14) only correct a single allele, but they also
obtained different indels in the non-corrected allele proximal to sgRNA1’s target sequence.
In addition, our selected clone (3040-C) was determined to be heterozygous in 2 silent
mutation points denoted by the green box (Figure 13C). From these successfully isolated
clonal colonies, our efficiency of homozygous correction from the final isolation of 10
(from 12) homozygous corrected clones is 83%. Since sgRNA can target multiple regions
within the genome [198], we analyzed for off-target mutations. We selected 3 non-genic
and 3 genic regions identified by the CRISPR Design Tool for both sgRNA1 and sgRNA9
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with the highest potential for off-targeting (Table 6). Sequencing of 3040-C compared to
non-corrected 3040-iPSC indicated no changes in the selected regions of the genome (not
shown). While we were fortuitous in not detecting off-targets within the highest selected
regions, this may not be the case with other targeted mutations. These results illustrate that
the 3-nucleotide deletion was homozygous corrected without additional mutations in the
homozygous FH-iPSC.
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Figure 13. Genetic Analysis 3040-iPSC LDLR Correction by CRISPR/Cas9. (A) RFLP
analysis was used to determine 3040-iPSC correction status by restriction digest with
XmnI. Non-transfected 3040-iPSC showed no XmnI cleavage (576 bp) in the presence or
absence of enzyme. 3040-iPSC clone 1 (3040-C) contained two bands at 384 bp and 192
bp in the presence of XmnI, which remained uncut (576 bp) without enzyme. (B) RFLP
analysis confirmed the presence of 9 homozygous (two bands 384 bp and 192 bp) and 2
heterozygous clones (additional band at 576 bp). (C) Sanger sequencing of 3040-C
confirmed the permanent insertion of 3-nucleotides in exon 4 of the LDLR in both alleles
(purple box). Silent mutations (red line) including the novel XmnI site (blue box) were also
integrated into the gene. Bold letters beneath red lines indicate original native nucleotide.
Two silent mutations (green box) were introduced in only one allele. Ho= homozygous,
Het= heterozygous, C= clone.
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Genetic Correction Leads to Normalized LDLR Function in 3040-C-HLC.
Genomic mutations of the LDLR in FH patients can vary from a single nucleotide change
to large deletions that will denote the patient into a certain class [234, 235, 254]. The 3 bp
deletion in 3040-iPSC are classified as Class IIB FH-Piscataway since the LDLR does not
reach maturity and instead is retained in the ER as an immature protein that eventually is
degraded by the proteosomal pathway [92, 119, 254]. After treatment with Lovastatin, we
observed a robust induction of LDLR expression that was primarily in the form of
immature protein in the non-corrected 3040-iPSC, but very little mature protein being
detected (Figure 14i, ii & iii). Excess sterols downregulated LDLR protein production in
these cells as expected. In contrast, Lovastatin treatment of the corrected 3040-C-iPSC
showed a dramatic shift from predominantly immature protein to predominantly mature
protein (Figure 14i, ii & iii). Again, as expected excess sterol treatment of the corrected
cells downregulated LDLR protein expression.

When comparing the ratio of

mature/immature LDLR with Lovastatin treatment, the corrected cells were greater than
30-fold higher than the non-corrected cells (Figure 14iv) suggesting the CRISPR
modification restored the normal LDLR structure which would allow LDLR to proceed to
the Golgi for processing and movement to the plasma membrane. Comparing DiI-LDL
internalization under the same conditions with the hESC line H1, non-corrected 3040-iPSC
internalize very little DiI-LDL even with Lovastatin treatment (perhaps indicating the
function of “mature” LDLR in these cells is questionable) (Figure 14A). Confirming the
results of the western blot, corrected 3040-C-iPSC internalized DiI-LDL when exposed to
Lovastatin and this receptor-mediated endocytosis was abrogated by excess sterols to a
similar level as normal H1. These data strongly support the conclusion that there was
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complete genetic correction of the LDLR pathological mutation and normalization of LDLC receptor-mediated endocytosis.
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Figure 14. Protein Analysis 3040-iPSC LDLR Correction by CRISPR/Cas9. 3040-C-iPSC
and 3040-iPSC were incubated overnight in Lovastatin (Lova) or excess sterols (XS).
Western blot (representative image, i) showed 3040-iPSC respond with an upregulation of
an immature LDLR after treatment with Lovastatin that is reduced with excess sterols.
3040-C-iPSC had almost no immature LDLR with Lovastatin and increased mature LDLR.
Quantification (n=2 independent experiments) showed a 2-fold increase of mature LDLR
in 3040-C treated with Lovastatin compared to 3040 (ii). Immature LDLR was highly
expressed in 3040 that was almost lost in 3040-C (iii). Mature/immature LDLR was over
30 times greater in 3040-C than 3040 in Lovastatin that was abrogated in excess sterols
(iv). Bars shown as mean  S.E.M.
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Figure 15. LDLR-Mediated Endocytosis is Restored in Corrected 3040-iPSC and HLC.
(A) LDL internalization showed 3040-C-iPSC respond with an increased DiI-LDL
internalization similar to control H1 cells that is almost non-existent in non-corrected
3040-iPSC. LDL uptake is decreased with excess sterols. (B) DiI-LDL uptake was restored
in 3040-C-HLC after treatment with Lovastatin that was not obvious in 3040-HLC. H1HLC was used as a control for normal LDLR function. Bar graph (n=2 independent
experiments) shows measured fluorescence intensity of DiI-LDL that correlates a 4-fold
increase in DiI-LDL uptake in 3040-C-HLC relative to 3040-HLC. Excess sterols were
normalized to 1 and Lovastatin normalized to excess sterols. Bars shown as mean  S.E.M.
(Scale bars = 50 μm).
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The hepatocyte is responsible for production and metabolism of cholesterol which
is defective in FH; therefore, we differentiated non-corrected and corrected FH-iPSC to
HLC to determine if receptor- mediated endocytosis is corrected and functional in HLC.
After differentiation, HLC were treated overnight with either Lovastatin or excess sterols.
Fluorescence microscopy of 3040-C-HLC is consistent with 3040-C-iPSC indicating an
upregulation in DiI-LDL endocytosis relative to 3040-HLC. H1-HLC control was similar
to 3040-C-HLC (Figure 15B). Quantification of DiI-LDL fluorescence intensity showed
3040-C-HLC contained a substantially increased fluorescence intensity compared to 3040HLC (Figure 15B) that was comparable to H1-HLC. For all three cell lines, excess sterols
reduced DiI-LDL internalization to a basal level. Taken together, these data demonstrate
our CRISPR/Cas9 design successfully corrected the 3bp deletion in the homozygous FH
cells, restoring LDLR protein and LDLR-mediated endocytosis.

DISCUSSION
The novel and important findings of this study are that we have used CRISPR/Cas9
genome editing to permanently correct a homozygous pathological mutation in patientspecific iPSC. We have targeted a Class IIB 3 bp deletion in exon 4 of the LDLR that
causes a reduction in receptor activity to less than 5% of normal. The successful insertion
of the missing 3 bp has permanently corrected the genetic mutation and restored the
physiological feedback control of receptor expression and cholesterol metabolism. We
developed a stepwise enrichment protocol to enhance the probability of isolating corrected
clones. The placement of the guides with respect to the mutation site likely made our cells
more amenable to correction. Double-positive sorting with GFP and RFP improved
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selection of dual transfected cells while MACS sorting increased the yield of LDLR
expressing cells. Our systematic stepwise enrichment protocol allowed for the final
isolation of 10 (from 12) homozygous corrected clones (83%). This procedure is likely
adaptable to identifying any corrected surface protein and is a proof-of-concept that
CRISPR technology can successfully repair LDLR mutations causing FH.
The estimated prevalence of FH is 1:250 and 1:250000 for heterozygous and
homozygous FH, respectively [1, 237, 238]. It is not uncommon that receptor-defective
HoFH patients will present with clinically symptomatic CVD in the first decade of life
[18]. A critical issue for these patients is early identification and therapeutic intervention
[237]. Because FH is considered underdiagnosed, screening has been proposed for
newborns. For rare HoFH patients, life-style changes and statin/ezetimibe therapy may be
insufficient to achieve target LDL-C levels [1]. This requires more aggressive treatment
including newly approved pharmacologics (i.e. Mipomersen, Lomitapide), lipid apheresis
and even a liver transplant [15, 129, 240], all of which have their own potential
complications. It is also important to recognize that newly approved PCSK9-inhibitors rely
on LDLR expression and have a questionable effect on receptor-negative HoFH patients
[23]. This supports the need to develop alternative approaches for treating HoFH.
Gene and cell therapies, amenable to monogenic deficiencies [239], to restore
cholesterol metabolism homeostasis in FH have been investigated for decades [255]. Gene
therapy to deliver an LDLR transgene to the liver has evolved from retrovirus [256] and
adenovirus [47] to adeno-associated virus containing liver-specific promoters [241]. The
first gene therapy clinical trial using ex-vivo LDLR-transduced autologous hepatocytes
showed some benefit to lowering LDL-C, but was halted due to variable metabolic results,

88

in particular, in receptor-defective homozygotes [50, 51]. A Phase 1/2 clinical trial using
AAV-based vector to deliver LDLR is currently approved (NCT02651675). Virus-based
gene

therapy has

demonstrated

a

capacity to

lower

cholesterol

levels

in

hypercholesterolemic animal models [257], but issues remain including transgene
persistence, vector delivery efficiency, and lack of LDLR expression regulation because of
vector size limitations [245]. With regards to cell-based therapy for FH, multiple reports
of liver transplantation demonstrate the effectiveness of providing sufficient LDLR-normal
hepatocytes to resolve FH hypercholesterolemia [129, 240]. However, liver availability is
limited, as are quality hepatocytes. Additionally, transplanted hepatocyte engraftment is
very poor unless major insult to the liver is first performed [258]. Together, this
demonstrates that issues of transgene and cell delivery for treating HoFH have not been
completely solved.
CRISPR/Cas9 genome editing has been demonstrated to be a straight forward
methodology for creating mutations and for endogenous mutation repair. It has specifically
been used in animal models to repair mutations in the dystrophin gene Dmd which causes
Duchene muscular dystrophy [192, 259]. Pankowicz and colleagues used CRISPR/Cas9
in a mouse model of hereditary tyrosinaemia type I to delete hydroxyphenylpyruvate
dioxygenase (Hpd), which converted the animal to an asymptomatic tyrosinaemia type III
[260]. Jarrett, et al [187] delivered CRISPR/Cas9 in an adeno-associated virus to disrupt
the LDLR and cause hypercholesterolemia. They co-administered CRISPR/Cas9 to also
disrupt the Apob gene, which rescued the hypercholesterolemic phenotype. In a Chinese
clinical trial directed by Lu You, CRISPR was used to inactivate the T-cell PD1 gene, then
delivered back to the patient as a treatment for metastatic non-small cell lung cancer [257].
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NIH has now approved a Phase I trial for using CRIPSR modified T-cells in cancer patients
[261]. Certainly, the immediate benefit of CRISPR genome editing is rapid genetic
modification for molecular modeling. Long-term it may also prove of even greater value
for therapeutic applications.
CRISPR technology has also been used to modify iPSC [172, 252]. It can knock-in
reporters to specific loci, create knockout models and repair pathological mutations, as we
have demonstrated here. The significance of combining CRISPR genome editing with
patient specific iPSC is the ability to generate a completely repaired autologous cell source
with the potential to differentiate to any cell lineage. It is widely recognized that lack of
therapeutic cell sources is one of the major barriers to cell-based therapies and this includes
hepatocytes to treat liver diseases [262]. Here, we demonstrate the ability to correct a
homozygous deletion in the LDLR and normalize receptor-mediated endocytosis in
patient-derived-HoFH-HLC.
The FH-iPSC used in our study is considered a Class IIB FH-Piscataway mutation.
This 3 bp in frame deletion results in a missing Gly197 in the highly-conserved binding
domain in exon 4 of the LDLR and is highly prevalent in the Ashkenazi Jewish community
originating from Lithuania [92]. A class II mutation leads to an improperly folded LDLR
since the spacing between cysteine residues becomes abnormal. The immature LDLR is
retained in the endoplasmic reticulum and eventually degraded by the proteasome pathway
[119]. Once corrected, it is expected that the immature LDLR expression will decrease
since the LDLR will properly fold and transition from the endoplasmic reticulum to the
Golgi for glycosylation to a fully mature LDLR before it is transferred to the plasma
membrane. Our western blot with fibroblast cells (Figure 6B) shows a very low level of

90

mature LDLR protein in IMR90 and no immature LDLR in GM03040. This could be due
to the fact that these are fibroblast cell lines and do not express LDLR as hepatocytes do.
Our western blot data indicates that non-corrected FH-iPSC have a very small
mature/immature ratio of LDLR that is normalized in the corrected FH-iPSC. The total
LDLR protein (immature + mature) was less in the corrected cells (Figure 14i). The
precise reasons for this are unclear, but is likely the result of restoration of feedback
regulation, increased receptor recycling, and more efficient LDL-C processing. In noncorrected cells, expression is high and the immature LDLR expression appears to be
uncontrolled protein production. Further investigation would be needed to determine if this
is unique to a class II mutation.
What we’ve shown is an efficient way to fully correct a genetic mutation. By using
Cas9n the number of off-target mutations is reduced and using specific sgRNA mediates
specific on-target cleavage. Intriguingly, only the heterozygous corrected clones
introduced indels into their gene. It is known that other off-target modifications may occur
in places not predicted in the candidate list (Table 6) due to a variety of reasons including
genomic and epigenomic properties that may affect cleavage frequency; therefore,
unbiased detection of off-target cleavage such as whole genome sequencing is
recommended and would be required before any corrected cell would be delivered to a
human patient [263]. Although the CRISPR correction of HoFH-HLC does not solve all
cell/gene-based therapy technical hurdles, it provides a platform for autologous cell
replacement with a permanent genetic correction to the underlying pathology. CRISPR
corrected HoFH-HLC could provide an unlimited source of autologous hepatocytes that
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could be delivered directly to the liver or engineered into a functional liver-like tissue with
sufficient cell mass to have a significant effect or even restore LDL-C homeostasis.
To conclude, these data validate the feasibility of using Cas9n, dual sgRNA, and a
repair template to correct a genetic mutation in a homozygous FH cell line, which can be
differentiated into functional HLC that mediate LDLR endocytosis. In the future, the use
of CRISPR-edited iPSC could be tested in patients as is currently being performed in the
treatment of cancer [261].
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CHAPTER III
MAMMALIAN SPECIES WNT3A DIFFERENTIAL
MODULATION OF DERIVED-DEFINITIVE ENDODERM

INTRODUCTION
Liver dysfunction is caused by a variety of diseases including FH, alpha-1
antitrypsin deficiency, non-alcoholic fatty liver disease, hepatitis B, cancer, and cirrhosis
[264]. Although the liver has an innate ability to regenerate itself, the only successful
approach to curing any liver disease is through organ transplantation, especially when the
damage overtakes regeneration [265]. There are currently over 17,000 patients in the US
waiting for a liver transplant [264]. A major problem is the limited amount of donor livers
and quality hepatocytes available for patients. Many issues tend to arise post-liver
transplantation

including

donor-host

incompatibility,

requiring

lifelong

immunosuppressing medications, causing an increased susceptibility and recurrence of
infections [266, 267]. Other problems that may occur include a reversal back to the disease
state after transplantation. In patients with FH, long term post-liver transplantation has
shown that within 6 months to 2 years, many patients develop cholesterol levels above 200
mg/dl, requiring high statin therapy [240, 268, 269].
Hepatocytes are the major cell component of the liver [270]. Culturing and expanding
primary hepatocytes has proven difficult since their survival depends on the liver
microenvironment [271, 272]. Because of this, cultured hepatocytes begin to
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dedifferentiate and lose their polarity over a short time. An additional key factor that has
limited the application of hepatocyte transplantation is the significant cell loss posttransplantation [266, 267, 273-279]. Without immunosuppressive drugs, transplanted
allogeneic hepatocytes survive for only 7 to 10 days [258, 267, 280]. Other experimental
approaches to address the lack of therapy in diseases like FH have included the delivery of
normal LDLR transgenes via viral vectors [51, 244, 245, 281-284]. A clinical trial with
HoFH patients utilized ex vivo liver-directed gene therapy and engrafted 3-9 x 109
retrovirus-transduced autologous hepatocytes to treat FH [51]. Three of five patients had a
decline in LDL-C levels and none developed antibodies to either the LDLR or retroviral
proteins. However, HoFH receptor negative or defective patients did not respond to this
treatment. Alternative treatment strategies using induced pluripotent stem cells (iPSC) has
become one of the leading research fields for treatment of liver disease and dysfunction
[270].
Transcription factors, specifically 4 including Oct4, Sox2, Klf4, and cMyc, are
introduced into a differentiated somatic cell to reprogram it into a pluripotent stem cell
[242]. The result is an unlimited supply of self-renewable stem-like cells. There are debates
as to whether or not iPSC are equivalent to embryonic stem cells (ESC), especially at the
RNA and microRNA level [285, 286]. However, there are many advantages to utilizing
iPSC derived from patient cells including their immunological compatibility, limitless
supply, and their ability to be differentiated into other cell types like hepatocytes [242, 287,
288].
The Deng lab developed a stepwise protocol for differentiation of iPSC into
hepatocyte-like cells (HLC) [250]. This protocol used a 5-stage protocol that involved
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endoderm induction, hepatic specification, hepatoblast expansion, hepatic maturation, and
matured hepatocytes. Their process required the sequential use of growth factors for the
gradual progression from endoderm to mature hepatocyte. The critical factors were Activin
A (AA), bone morphogenetic protein 2 (BMP2), fibroblast growth factor 4 (FGF4),
hepatocyte growth factor (HGF), and Oncostatin M (OSM). These 5 factors were included
among 8 (keratinocyte growth factor, Dexamethasone, N2) different components necessary
in the 5-stage, 21-day protocol for differentiation of iPSC to HLC [250]. By the end of 3
weeks of differentiation, the HLC expressed hepatic markers including immature
hepatocyte marker alpha-fetoprotein (AFP), mature hepatocyte marker albumin, and
hepatocyte plasma membrane marker cytokeratin 18. In addition, the cells exhibited
activity of hepatocytes including glycogen and urea synthesis and albumin secretion [250].
Duncan and colleagues modified this protocol [289, 290] so that only 4 stages were
needed but more importantly, the growth factors required were decreased to 5 (AA, BMP2,
FGF4, HGF, and OSM). In addition, the environmental conditions were modified to a
hypoxic state (4% oxygen, 5% carbon dioxide). At the end of this differentiation, 70% to
90% of cells expressed albumin with a decrease in AFP expression indicating these humanderived HLCs when injected into mouse livers integrated into the existing mouse
parenchyma [289]. Both of these differentiation protocols were successful in
differentiating human iPSC to HLC [289, 290].
As mentioned in the previous chapter, ESC/iPSC can differentiate into 3 germ
layers: endoderm, mesoderm, and ectoderm. The proper development of the primitive
ventral endoderm that forms the liver requires Wnt3a [291]. Wnt3a is a member of highly
conserved glycoprotein family members that are necessary in normal development [292].

95

Knockout of Wnt3a resulted in mouse ESC that failed to express mesoderm and endoderm
genes suggesting the inability to generate a primitive streak [293].
Bearing this in mind, the lab of Dr. David Hay designed an HLC-differentiation
protocol that mimicked the developing embryo resulting in a homogenous differentiation
HLC population [294]. Eventually they developed a 3-stage protocol that used AA and
Wnt3a in stage 1, no growth factors in stage 2, and HGF and OSM in stage 3 [295]. This
yielded 90% albumin-expressing HLC.
Our lab has previously differentiated iPSC to HLC [189, 245] using the 5-stage
Song protocol [250]. This resulted in efficient generation of HLC as shown in Figure 9.
However, the cell yield was low. Differentiation to definitive endoderm is considered the
critical stage to HLC production. It is here that will decide the fate of whether or not cells
differentiate to hepatocytes and if they do so in an efficient manner. Therefore, we
investigated which protocol was the most efficient at producing endoderm.

MATERIALS AND METHODS
Cell Culture. H1 (WiCell, Madison, WI) were cultured on hESC-Qualified
Matrigel coated plates (BD Biosciences) in mTeSR1 with media changed daily
(STEMCELL Technologies) [245]. Cells were passaged using Gentle Cell Dissociation
Buffer (GCDB; STEMCELL Technologies) with 10mM Rock inhibitor (Selleck
Chemical) and maintained at 37C and 5% CO2 [245].
Hepatocyte Differentiation. H1-ESC underwent directed differentiation to
definitive endoderm as outlined in Figure 16 below.
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Figure 16. Hepatocyte-Like Cell (HLC) Differentiation Protocol. H1 stem cells underwent
differentiation to the end of stage 1 or definitive endoderm. Song stage 1 has been modified
for use of commercially available StemDiff (STEMCELL Technologies, Vancouver,
Canada) for 4 days. Duncan requires the use of AA, BMP4, FGF2, HGF, and OSM. Hay
utilizes AA and Wnt3a in the definitive endoderm stage and only adds OSM and HGF in
the final stage.
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Fluorescence Activated Cell Sorting (FACS). After differentiation to definitive
endoderm, cells were dissociated to single-cells, counted, centrifuged, and re-suspended at
<106 cells in 100 L stain buffer and kept on ice. The same was done with control HepG2
and non-differentiated H1 cells. The cells were incubated in their appropriate isotype
controls or antibodies (Table 7) for 30 minutes at 4 C protected from light. After 30
minutes, cells were washed twice with stain buffer. Cells were re-suspended in 300 L
stain buffer. The cells were run through the BD LSRII Cytometer (BD Biosciences) and
analyzed via FlowJo (BD Biosciences).
mWnt3a and hWnt3a Dose Course. H1-ESC were differentiated to definitive
endoderm following Hay’s stage 1 protocol (Figure 11). Mouse Wnt3a (mWnt3a;
Peprotech) or human Wnt3a (hWnt3a; R&D) were added to definitive endoderm media at
various concentrations [0, 10, 25, 50 ng/mL]. After 5 days, cells were collected and
analyzed via qPCR for definitive endoderm markers.
mWnt3a and hWnt3a Time Course. H1-ESC underwent directed differentiation
to definitive endoderm following Hay’s stage 1 definitive endoderm (Figure 11). 50 ng/mL
of mWnt3a or hWnt3a were added to definitive endoderm media. Cells were collected at
time point 0, 1, 3, and 5 days and analyzed via qPCR for definitive endoderm markers.
Quantitative PCR analysis. At the end of stage 1, H1 cells were lysed using 100
L of 0.1% -mercaptoethanol in RLT Buffer (Qiagen). The lysates were purified with
Qiashredder and RNeasy kits (Qiagen) according to the manufacturer’s instructions. RNA
was quantified with a NanoDrop One Spectrophotometer (ThermoFisher). cDNA was
synthesized using 1g RNA with SuperScript IV reverse transcriptase (Invitrogen) in a 20
L volume. The qPCR was performed using Fast SYBR Green Master Mix
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(ThermoFisher) with primers obtained from Integrated DNA Technologies (IDT) (Table
8). Reactions were run on the StepOnePlus Real-Time PCR System (ThermoFisher). Raw
data was analyzed in Microsoft Excel and graphs produced in GraphPad’s Prism 8.
Table 7
List of Antibodies for FACS
Tube

Particle/Cell

APC

AF700

Bead (+)

(+) bead/ (+) IgG bead

--

--

(+) bead/ (+) IgG bead +

10 l Tra-1-81

Tra-1-81-APC in 1ml SB

APC (R&D)

Bead Tra-1-81

-5 l CXCR4 AF700

(+) bead/ (+) IgG bead +
Bead CXCR4

-CXCR4-AF700 in 1ml SB

Control

H1

Control

H1

(R&D)
Tra 1-81 APC

CXCR4 AF700

Mouse IgM APC

Mouse IgG2b

(R&D)

AF700 (R&D)

Tra 1-81 APC

CXCR4 AF700

IgM APC

IgG AF700

Hay DE, Duncan DE,
Samples
Song DE
Hay DE, Duncan DE,
Song DE

Table 8
List of Primers Used for qPCR Analysis of Definitive Endoderm
Gene

Primer 1 (5’ → 3’)

Primer 2 (5’ → 3’)

Product
Size
(bp)

Oct4
Sox17
Hnf4a
P0

TGATCCTCGGACCTGGCTAA
CCGCGGTATATTACTGCAACTA
GGCCAAGTACATCCCAGCTT
TCGACAATGGCAGCATCTAC

AACCACACTCGGACCACATC
CACCCAGGACAACATTTCTTTG
TCATTGCCTAGGAGCAGCAC
ATCCGTCTCCACAGACAAGG

180
152
170
200
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RESULTS
Activin A and Wnt3a increase CXCR4+ Definitive Endoderm Cells. We began
by investigating which of the 3 endoderm differentiation protocols would deliver the
highest rate of this cell type. Efficient production of endoderm requires expression of the
endoderm markers Sox17 and CXCR4 [296]. Markers for ESC/iPSC like Tra-1-81 can
distinguish cells that have yet to begin differentiation [297]. We plated H1-ESC onto 35
mm dishes and began each of the differentiation processes according to Figure 16. To note,
we did not have a chamber available to maintain cells at 4% oxygen prior to or throughout
the course of differentiation as suggested by Duncan [289]. Instead, we focused on treating
H1 with only Activin A for the 5-day differentiation. We observed significant cell death at
day 2 with the Song/StemDiff and at day 3 with Duncan and Hay. However, cells grew in
most of the plates at the end of stage 1. We collected the cells for analysis of Tra-1-81 and
CXCR4 expression by FACS.
Our H1 non-differentiated control expressed only Tra-1-81 (Figure 17A) and no
cell-surface CXCR4. In contrast, all 3 endoderm differentiation procedures resulted in
expression of CXCR4 (Figure 17B, C, D, bottom right panel). However, there also
appeared to a substantial number of Tra-1-81 expressing cells present in all 3 cell cultures
(Figure 17B, C, D, bottom center panel). Compiling the data for Tra-1-81 and CXCR4
into single graphs indicated that indeed for all the differentiation protocols there were many
Tra-1-81 expressing cells, indicating they are still stem cells (Figure 18). In comparing
each protocol, Song/StemDiff appeared to have lowest expression of Tra-1-81 and an
increase in CXCR4 (Figure 18, blue). The Hay protocol resulted in a shift to the right for
both Tra-1-81 and CXCR4 compared to Song/StemDiff (Figure 18, green). Cells in
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Duncan’s modified protocol had the largest shift to the right in both Tra-1-81 and CXCR4
expressing cells indicating that while a large population were differentiating to endoderm,
a large population were still stem cells too (Figure 18, yellow). Although more cells
expressed CXCR4, the Tra-1-81 expression was greater than that of H1 control nondifferentiated cells. Since Hay’s protocol resulted in the greatest number of CXCR4
expressing cells, we used this protocol for the rest of this study.
Wnt3a species and dose impact differentiation of cells to definitive endoderm.
The Hay protocol calls for the use of 50 ng/mL of recombinant mouse Wnt3a (mWnt3a)
purchased from Peprotech [295]. Other sources have used human Wnt3a at lower
concentrations [298] although it has been shown that recombinant mouse Wnt3a (mWnt3a)
exhibited higher Wnt signaling activity than hWnt3a [299]. We began by investigating
whether mWnt3a or hWnt3a would be most efficient for endoderm. H1 cells were plated
and differentiated using Hay’s protocol (Figure 16) with the modification of either hWnt3a
or mWnt3a at concentrations of 0, 10, 25, and 50 ng/mL. After 5 days, the cells were
collected and qPCR was done to assess mRNA transcript levels for Oct4, Sox17, and
Hnf4a, which are common markers for distinguishing stem cells from definitive endoderm
(Figure 19).
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Figure 17. Differentiation for Endoderm. H1 stem cells were differentiated using 3
different protocols and analyzed for expression of stem cell or definitive endoderm markers
by FACS. In the top panels, control IgM and IgG2b are not expressed in the cell (A) Control
H1 non-differentiated stem cells bottom panels: H1 express no CXCR4 and are all Tra-181 positive. (B) Hay protocol for definitive endoderm: bottom panels: some cells still
express Tra-1-81 and there is clear expression of CXCR4 positive cells; most cells are
alive. (C) Song/StemDiff protocol for definitive endoderm: bottom panels: expression of
CXCR4 positive cells is greater than Tra-1-81 but there is also increased cell death. (D)
Duncan protocol for definitive endoderm: bottom panels: CXCR4 positive cells present but
a larger number of Tra-1-81 cells still present in culture. (n=1)
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Expression of octamer-binding transcription factor 4 (OCT4) is an indicative
pluripotence marker while sex determining region Y box 17 (SOX17) is a definitive
endoderm marker [250]. Hepatic lineage specification is indicated by expression of
hepatocyte nuclear factor 4a (HNF4A) [250]. Oct4 expression was highest in nondifferentiated cells in both groups. Noticeably, hWnt3a treated cells had low expression of
Oct4 across all doses that was only present with Activin-A in the mWnt3a treated culture
(Figure 19A). Expression of Sox17 was upregulated in mWnt3a treated culture and
appeared to decrease with increased dose (Figure 19B). hWnt3a treated culture had
reduced Sox17 expression, while its Hnf4a transcript levels were elevated compared to
mWnt3a treated culture in all doses (Figure 19C). Of interest, Oct4 expression levels were
10 times higher than Sox17 and Hnf4a levels. Graphs depicting this indicate just how low
expression of definitive endoderm and hepatic markers can be in a mixed cell culture
(Figure 19D, F).
Because definitive endoderm differentiation occurs over 5 days, we examined a
time course for changes in expression of iPSC markers recession and endoderm marker
appearance. Similar to the dose curve data (Figure 19), Oct4 expression was higher in
mWnt3a treated culture than hWnt3a treated culture. Still, Oct4 decreased greatly by day
3 in both cultures (Figure 20A). Sox17 expression was 10-fold higher in mWnt3a treated
culture than hWnt3a treated cells, particularly by day 3 across all doses in mWnt3a treated
cells. Hnf4a transcripts were also upregulated in mWnt3a treated culture as the dose days
progressed. This was surprising in that hWnt3a treated culture had an increased Hnf4a at
day 5 across all doses in Figure 14C. This was completed with a sample of 1 and requires
repeating.
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Figure 18. All Protocols Result in a Mixed Population of Tra-1-81 and CXCR4. Control
(red) non-differentiated cells expressed only Tra-1-81. StemDiff/Song (blue) showed lower
Tra-1-81 and higher CXCR4 expression but an overall smaller population of total cells.
Duncan (yellow) had the highest number of cells expressing both Tra-1-81 and CXCR4.
Hay (green) had a lower number of Tra-1-81 positive cells than Duncan and similar levels
of CXCR4. (n=1)
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Figure 19. Human Wnt3a Causes Increased Hnf4a Expression Compared to mWnt3a.
Stage-specific markers were tested at the mRNA expression level (POU4F1, SOX17,
HNF4A). (A) Oct4 expression was highest in non-differentiated cells. (B) Sox17 definitive
endoderm was increased in 10 ng/mL mWnt3a cells. (C) Hnf4a had high expression in
hWnt3a culture across all doses. (D,E) Sox17, Hnf4a expression modified to fit Y-axis of
Oct4 to distinguish the low expression of these 2 markers.
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Figure 20. Hnf4a Expression Occurs by Day 5 in Endoderm Differentiation. (A) After time
course of 5 days, Oct 4 expression was highest in mWnt3a at all doses but began to decrease
by day 3 in culture. The same pattern was observed in hWnt3a culture. (B) Sox17 was
elevated at day 3 in both mWnt3a and hWnt3a at all doses and begins to decrease at day 5.
(C) Hnf4a had high expression in m Wnt3a at day 5 as did hWnt3a.

DISCUSSION
There are many factors to consider when beginning the differentiation process of
cells. The starting confluence, the plating of single cells over clumps/colonies of cells, and
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even the logarithmic phase of the ESC/iPSC growth prior to passaging for differentiation
must all be scrutinized to reliably generate healthy HLC [289, 300]. A protocol described
in one paper effectively producing functional HLC does not mean that this will occur
universally in all labs. These protocols are like recipes that must be examined and
optimized for in your own kitchen. With this in mind, we sought optimize conditions for
differentiation of our ESC to HLCs.
The main finding of this report is that 25 ng/mL and 50 ng/mL of hWnt3a and
mWnt3a with the Hay protocol both upregulate expression of endoderm and hepatic
markers (Sox17 and Hnf4a) reaching similar levels [295]. This indicates that both may be
sufficient in producing definitive endoderm. To confirm this result, the experiment needs
additional replication. In addition, differentiation to HLC would provide evidence, if
favoring one or the other was optimal.
We observed that Duncan’s protocol yielded higher numbers of H1-CXCR4
expressing cells; however, the number of ESC Tra-1-81 positive cells was just as high
(Figure 18D). We did not follow the protocol precisely since we did not have access to a
cell chamber to maintain hypoxic oxygen levels. This may be the key to reducing the
number of non-differentiated cells. It has been demonstrated that hypoxic oxygen levels at
1% significantly increase Activin A-induced definitive endoderm cells compared to 21%
normoxia in mouse ESC [301]. With a controlled chamber for oxygen, we could determine
if Wnt3a is necessary for differentiation of our iPSC to HLC.
Despite this work, it is known that HLCs derived from iPSC will still present an
immature hepatocyte phenotype, which would limit their use in clinical therapy. The
extracellular matrix (ECM) is regarded as the foundation that can make or break derived

107

hepatocytes potential of becoming fully functioning mature hepatocytes. Matrigel is the
main ECM used for both stem cell culture and differentiation [290, 299, 302]. Matrigel,
unfortunately, varies from batch to batch and is still undefined with respect to various
components [303]. It also contains animal derivatives that would make it difficult to use in
clinical work. An alternative to Matrigel could be the use of laminins. Laminins (LN) are
glycoproteins that are part of the ECM. They are found in the ECM of the embryo. Hay’s
lab utilized two laminins, LN521 and LN111, to derive HLC from iPSC [304]. These two
laminins are present in the liver stem cell niche and have been shown to drive endoderm
and liver stem cell differentiation [305, 306]. LN521 and LN111/LN521 mixture increased
the number of cells with morphological appearance of HLC compared to the use of
Matrigel. Additionally, staining for bile canaliculi organization demonstrated a functional
bile canaliculi on the LN521 and LN111/LN521 mix that was present on Matrigel [304].
The use of patient-specific iPSC for studies in disease modeling, drug toxicity, and
organoid transplantation would require a highly pure culture of definitive endoderm in the
initial stage of differentiation. Taking into consideration these factors involved can help us
better understand and create protocols that can be useful in our research.
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CHAPTER IV
STATIN-INDUCED ACCUMULATION OF CLASS II IMMATURE LDL-RECEPTOR
IN FAMILIAL HYPERCHOLESTEROLEMIA DOES NOT ACTIVATE
THE UNFOLDED PROTEIN RESPONSE

INTRODUCTION
Familial hypercholesterolemia (FH) is an autosomal dominant disease primarily
caused by mutations in the LDL receptor (LDLR) gene leading to premature cardiovascular
disease (CVD) [17, 234-236]. LDLR activity ranges with disease severity and is based on
the mutation within the LDLR [92]. There are over 1200 LDLR mutations identified that
are categorized into six classes [236, 239]. As of 2012, greater than 50% have been
described as class II or transport defective mutations [92, 98]. After translation, a newly
synthesized and unfolded LDLR is processed in the ER as a partially glycosylated
precursor of 120-kDa [98], aided by ER chaperones glucose-regulated protein 78 (Grp78),
receptor associated protein (RAP) [98, 106, 307] and Mesoderm Development (MESD)
[110]. The LDLR is then transported to the Golgi where N-and O-linked sugars are added,
increasing the molecular weight to 160-kDa [116, 117]. Class II mutations are commonly
referred to as a “folding or conformational disease” [98, 120, 121] because these mutations
result in a misfolded LDLR that is either unable or has a less than 5% rate of leaving the
ER for the Golgi [92].
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The molecular mechanisms responsible for LDLR folding and maturation is still
unclear. The quality control system of the ER ensures that newly synthesized proteins only
leave the compartment when their folding criteria have been met [208, 209, 211].
Chaperones expressed in the ER play a significant role in the protein folding process [105,
214]. General chaperone Grp78 transiently binds the LDLR and aids in its proper folding
under normal conditions [124, 125, 215]. This correlates with studies of Grp78 acting
selectively in retaining proteins in the ER [215]. This quality control ensures that only
properly folded proteins exit the ER for the Golgi, while misfolded proteins are retained in
the ER for further processing. If unable to be corrected, misfolded proteins in the ER can
accumulate and cause ER stress, activating the unfolded protein response (UPR) [213, 217,
218]. The UPR’s major role is to maintain protein homeostasis in the presence of
accumulated un/misfolded proteins. The 3 major stress sensor pathways in UPR activation
are inositol-requiring transmembrane kinase/endonuclease (IRE1), PKR-like ER kinase
(PERK), and activating transcription factor 6 (ATF6) [213]. The UPR works to alleviate
ER stress by upregulating the folding capacity through controlling expression of
transcription factors and other downstream targets that specifically mediate protein folding,
ER-Golgi trafficking, organelle biogenesis, and ER-associated degradation (ERAD) [213].
Also classified as a misfolded protein disease [98], there is very limited research
into class II LDLR misfolding, primarily because of the accelerated devastating effect FH
has on the cardiovascular system. Evidence presented in the literature suggests that ER
stress occurs in FH class II mutations because of accumulating misfolded LDLR [124,
125]. We reprogrammed class II FH fibroblasts with a homozygous 3 bp deletion in LDLR
exon 4 (GM03040) with <5% receptor activity to iPSC [189]. We utilized the genome
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editing

tool,

clustered-regularly-interspaced-short-palindromic-repeats/CRISPR-

associated 9 (CRISPR/Cas9), to permanently correct the 3 bp deletion in the LDLR. The
successful correction restored physiological feedback control of receptor expression [189].
C-iPSC confirmed restoration of the mature LDLR protein and normalization of receptormediated LDL internalization compared to NC-iPSC. Prior to correction, we observed a
significant accumulation of immature LDLR protein upon treatment with statin in NCiPSC [189]. Understanding that ER stress activates UPR due to accumulation of misfolded
proteins and that overexpressed class II LDLR mutants express ER stress markers, we
questioned how statin therapy affects FH class II LDLR function. Using our FH class II
LDLR corrected and non-corrected model as a tool, we hypothesized that class II FH cells
differentiated to hepatocyte-like cells (HLC) activate UPR when treated with statins and
this effect is diminished with correction of the LDLR.

MATERIALS AND METHODS
Cell Culture and Hepatocyte Differentiation. Reprogrammed human induced
pluripotent stem cells (iPSC), 3040-iPSC and 3040-C-iPSC (derived from Coriell Cell
Repository GM03040 fibroblasts) [Add Omer et al here], were cultured on hESC-Qualified
Matrigel coated plates (BD Biosciences, San Jose, CA) in mTeSR1 with media changed
daily (STEMCELL Technologies, Vancouver, Canada) [245]. Cells were passaged using
Versene (ThermoFisher, Waltham, MA) with 10 M Rock inhibitor (Selleck Chemical,
Houston, TX) and maintained at 37C and 5% CO2 [245]. H1 cells (WA01/NIH 0043,
WiCell, Madison, WI) were cultured as the iPSC.
All three cell lines underwent directed differentiation to hepatocyte-like cells as
reported previously [308]. Briefly, iPSC were plated on hESC-Qualified Matrigel coated
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60mm plates at 5 x 105 cells. The next day, stage 1 definitive endoderm differentiation was
initiated by replacing stem cell media with stage 1 differentiation media (RPMI1640
(Invitrogen, Waltham, MA) with B27 (1X, Invitrogen)) supplemented with human Activin
A (100 ng/mL, Peprotech, Rocky Hill, NJ) and human Wnt3a (50 ng/mL; R&D Systems,
Minneapolis, MN). Media was changed daily for 5 days. This was followed with a 5-day
culture in stage 2 hepatoblast media (Knock Out Dulbecco’s Modified Eagle’s medium
(KO-DMEM, Invitrogen), 20% knockout serum replacement (KSR, Invitrogen), 0.5X
GlutaMAX (Invitrogen), 1% nonessential amino acids (Invitrogen), 0.1 mM mercaptoethanol (ThermoFisher), and 1% DMSO (v/v) (ThermoFisher) with media
replacement every other day. Cells were finally cultured in stage 3 hepatocyte maturation
media for 11 days (HepatoZYME (Invitrogen) with 10 M hydrocortisone 21hemisuccinate (Sigma-Aldrich), 0.5X GlutaMAX supplemented with human hepatocyte
growth factor (HGF, 10 ng/mL, Peprotech) and human Oncostatin M (OSM, 20 ng/mL,
Peprotech)). The media was changed every other day.
Quantitative PCR analysis. The iPSC or HLC were starved overnight in 5%
lipoprotein-deficient serum (LPDS, ThermoFisher) media supplemented with 5 M
Rosuvastatin (EMD Millipore, Burlington, MA) or excess sterols (10 g/mL cholesterol
and 5 g/mL 25-hydroxycholesterol; Sigma-Aldrich). Positive control cells were also
treated with 5 g/mL Tunicamycin (Invitrogen) for 4 hours. Control cells were treated with
DMSO overnight. At the end of treatment, iPSC and HLC were lysed using 150 L of
0.1% -mercaptoethanol in RLT Buffer (Qiagen, Valencia, CA). The lysates were purified
with Qiashredder and RNeasy kits (Qiagen) according to the manufacturer’s instructions.
RNA was quantified with a NanoDrop One Spectrophotometer (ThermoFisher). cDNA
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was synthesized using 1 g RNA with SuperScript IV reverse transcriptase (Invitrogen) in
a 20 L volume. qPCR was performed using Fast SYBR Green Master Mix
(ThermoFisher) with primers obtained from Integrated DNA Technologies (IDT) (Table
9). Reactions were run on the StepOnePlus Real-Time PCR System (ThermoFisher). Raw
data was quantified in Microsoft Excel and statistics performed in GraphPad’s Prism 8 (La
Jolla, CA). Polymerase chain reaction (PCR) was carried out for spliced-XBPI and XBPI
expression with PCR Supermix (Invitrogen). Amplicons were evaluated via 2% agarose
gels (Bio-Rad). 10 L of amplicons were added to 2 L 6X Loading Buffer (Invitrogen).
Gels were run at 80 V for 60 minutes and imaged via ChemiDoc Imaging System with
Image Lab Touch Software (Bio-Rad, Hercules, CA).
Western Blot. The iPSC or HLC were treated as described above. Following
treatment, the cells were thoroughly washed with PBS+/+ prior to adding 200 L RIPA lysis
buffer (ThermoFisher) plus protease inhibitor cocktail (ThermoFisher) for cell collection.
Lysates were rocked overnight at 4C, followed by centrifugation for 15 minutes.
Supernatants were used for protein quantification by DC Protein Assay (Bio-Rad). 10
g/sample of total protein was run on a 4-10% mini-protean TGX precast gels (Bio-Rad)
at 200 volts for 40 minutes. Proteins were transferred onto PVDF (Bio-Rad) then blocked
in 3% milk/PBST. Membranes were probed overnight with the LDLR antibody (1:1000 in
5% BSA/PBST; R&D Systems) or -actin (1:1000; Santa Cruz Biotechnology, Dallas, TX)
overnight at 4C. The membranes were incubated in either HRP-Bovine anti-goat IgG H+L
(Jackson ImmunoResearch, West Grove, PA) or anti-mouse IgG (Cell Signaling, Danvers,
MA), HRP-linked antibodies (1:5000 in 3% milk/PBST) the following day for 1 hour at
room temperature. Clarity Max Western ECL Blotting Substrate (Bio-Rad) was used to
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visualize the proteins on the Bio-Rad Imager. Densitometry was performed using Bio-Rad
imaging software. A list of all antibodies used for analyses is presented in Table 10.
Cellular Cholesterol Replenishment. Cells were plated on 35 mm tissue culture
dishes and differentiated until day one of stage three, as described above. Cells were treated
with LPDS media supplemented with 5 M Rosuvastatin for 48 hours. After 48 hours, cells
were treated with LPDS media supplemented with 5 M Rosuvastatin and 10 mM methyl-cyclodextrin (Sigma-Aldrich) for 45 minutes [309]. After 45 minutes (timepoint 0-hour),
cells were collected as described below. The remaining dishes were cultured with LPDS
media supplemented with 5 M Rosuvastatin and 10 g/mL LDL-C (ThermoFisher). Cells
were collected at 6 and 24 hours.
Cells were collected by incubating in TrypLE Express (ThemoFisher) for five
minutes then gently scraping and transferring cells to a 15 mL tube. After centrifugation
(200 x g, 4 minutes), the cell pellet was re-suspended in 200 L chloroform/methanol (2:1
v/v) mixture, vortexed, and centrifuged (14,000 x g, 5 minutes) to allow separation into
three layers. A micropipette was used to carefully discard the top aqueous layer containing
RNA. Next, a micropipette was used to gently push past the interphase layer (a thin
membrane of protein) to reach the organic phase layer containing the lipids. This bottom
lipid layer was transferred into a new microcentrifuge tube. The lipid solution was dried
using the Savant SpeedVac Plus vacuum (ThermoFisher) for 30 minutes. The dried lipids
were re-suspended in 1X reaction buffer supplied in the Amplex Red Cholesterol Assay
kit (ThermoFisher). The middle protein layer was re-suspended in RIPA lysis buffer,
incubated overnight at 4° C, and processed the day next day for protein analysis.
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Collected lipid content was analyzed with the Amplex Red Cholesterol Assay Kit
per the instructions. Readings were measured on the Synergy4 spectrophotometer (BioTek,
Winooski, VT) with Gen5 software (BioTek) at an excitation of 560 nm and emission
detection at 590 nm. Lipid content was normalized to total protein level as measured by
the DC protein assay.
Fluorescence-labeled LDL uptake assay. NC-iPSC and C-iPSC were plated in 3
of 4 wells of a 4-well chamber slide and differentiated to HLC (see above). Three wells
were treated overnight in LPDS media supplemented with 5 M Rosuvastatin. The
following day, two wells in Rosuvastatin were treated with 10 g/mL low density
lipoprotein

labeled

with

1,1’-dioctadecyl-3,3,3’,3’-tetramethyl-indocarbocyanine

perchlorate (fluorescently labeled DiI-LDL) (ThermoFisher) for either 6 or 24 hours while
the remaining well did not receive any DiI-LDL. Cells were fixed with 2% PFA/PBS (10
minutes, 24° C; Electron Microscopy Sciences, Hatfield, PA) and mounted with
VECTASHIELD Antifade Mounting Medium with DAPI (Vector Laboratories,
Burlingame, CA). Slides were imaged using Olympus IX81 fluorescence microscope
(Center Valley, PA) at 20X magnification.
Immunocytochemistry and Image Analysis. Following Rosuvastatin treatment
overnight in LPDS media, HLC were fixed with 2% PFA/PBS (10 minutes, 24° C),
permeabilized with 0.05% Triton X-100/PBS (10 minutes, 24° C; Sigma Aldrich) and
washed with PBS. Cells were then blocked with 5% normal donkey serum/PBS (Jackson
ImmunoResearch) for 1 hour followed by blocking with an avidin/biotin blocking kit
(Vector Laboratories). Primary antibodies were diluted in 5% donkey serum/PBS and
incubated on cells overnight at 4° C. Secondary antibodies diluted in 5% donkey
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serum/PBS (1:1000) were added to the cells (2-hour, 24° C) followed by washing and
mounting with VECTASHIELD Antifade Mounting Medium with DAPI. Slides were
imaged using Olympus BX61WI confocal microscope with Fluoview (FV10-ASW 4.1,
Olympus). The four channels were merged into a single image using AMIRA software
(ThermoFisher) [310]. Using Fluoview (FV10-ASW 4.1), confocal image stacks were
analyzed utilizing the colocalization processing tool to both visualize overlapping of
images as well as quantification of overlap. A list of all antibodies used for analyses is
listed in Table 10.
Statistical Analysis. Data from three independent experiments were analyzed via
one or two-way ANOVA with a post-hoc using Tukey multiple comparison test in
GraphPad Prism 8 and expressed as mean  SEM. Figure legends contain further details.
Table 9
PCR Primers for LDLR and ER Stress
Gene

Primer 1 (5’ → 3’)

Primer 2 (5’ → 3’)

Product Size (bp)

LDLR
Grp78
(S) XBP1
P0

GCAGTGTGACCGGGAATATGA
CCGTTCAAGGTGGTTGAAAAGAA
CCTGGTTGCTGAAGAGGAGG
TCGACAATGGCAGCATCTAC

GTTGGTCCCGCACTCTTTGA
TGGCGTTGGGCATCATTAAAA
GGCAGGCTGCTGTCCTCAT
ATCCGTCTCCACAGACAAGG

115
200
150; 124
200
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Table 10
List of Antibodies and Fluorophores for WB and ICC
Antigen
LDLR

Host
Goat

Calnexin
Biotinylated-Wheat
Germ Agglutinin
Actin
gIgG
mIgG2b
Alexa Fluor Donkey
Anti-Goat 488nm
Alexa Fluor Donkey
Anti-Mouse 546nm
Streptavidin-649

Mouse
-

HRP-Bovine Anti-Goat
IgG H+L
Anti-Mouse IgG, HRPlinked

Mouse
Goat
Mouse

Dilution
1:100 (ICC), 1:1000
(WB)
1:100
1:200

Distributor
R&D Systems, Minneapolis, MN

1:1000
1:100
1:100
1:1000

Santa Cruz Biotechnology, Dallas, TX
Novus Biologicals, Littleton, CO
Invitrogen, Carlsbad, CA
Invitrogen

1:1000

Invitrogen

1:1000

Vector Laboratories

1:5000

Jackson ImmunoResearch, West Grove,
PA
Cell Signaling, Danvers, MA

1:5000

EMD Millipore, Billerica, MA
Vector Laboratories, Burlingame, CA

RESULTS
LDL-C Internalization is Restored in Corrected Hepatocyte-Like Cells
Our previously published work was focused on iPSC and the restoration of LDL-C
internalization in FH-iPSC using CRISPR/Cas9 [189]. This is potentially important for
studying the effects of statins on pregnant FH patients. The hepatocyte is responsible for
cholesterol regulation and is the cell making up the liver parenchyma. After CRISPR/Cas9
correction of cells, we saw an internalization of LDL-C was restored in HLC [189]. We
wanted to examine a time course for replenishment of LDL-C and whether or not the NCHLC could recover over a 24-hour period by non-receptor mediated mechanisms. We
treated HLC overnight in LPDS media with Rosuvastatin (0h), then added 10 g/ml DiILDL for 6 (6h) or 24 (24h) hours. As expected at the 0h, no DiI fluorescence was detected
in either NC or C-HLC. After 6h, NC-HLC still had not internalized a detectable level of
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DiI-LDL as evidenced by lack of fluorescence signal. After 24 hours, a minimal DiI
fluorescence signal was detected suggesting internalization by non-receptor mediated
mechanism or through the expected 5% LDLR activity of this mutation (Figure 21A, top
panels). In contrast, the C-HLC presented a far greater capacity for DiI-LDL
internalization over this time frame (Figure 21A, bottom panels). At 6h, the C-HLC
showed bright DiI fluorescence that qualitatively increased over 24h (Figure 21A). This
indicates that the corrected cells are capable of internalizing LDL via receptor mediated
mechanisms and that statin treatment produces a time dependent LDL internalization
increase.
We next asked what is the ability of NC and C-HLC to restore cellular cholesterol
after depletion with methyl--cyclodextrin. HLC were incubated in LPDS media
supplemented with Rosuvastatin overnight for 48 hours as described, then treated with 10
mM methyl--cyclodextrin for 45 minutes to extract any cholesterol stored within the cell
[309]. Samples collected after 45 minutes and designated as time point zero or basal
cholesterol levels. At t0, unlabeled LDL-C was added to the remaining cells for 6 and 24
hours after which samples were also collected. Cholesterol content was measured using
Amplex Red quantification [311] and normalized to total protein (Figure 21B). At t0 after
cyclodextrin treatment, the starting cellular cholesterol content for both NC and C-HLC
were 15.7 and 11.6 M/(g/L) with no statistical difference, indicating the starting
cholesterol content was equivalent for both cell populations. Six hours after cyclodextrin
treatment the NC and C-HLC cholesterol content was 10.6 and 14.5, respectively, which
was still not significantly different between the cell groups at this time point nor different
from the t0 starting time point. It was only after 24h that a statistically significant difference
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was quantified. At 24h, the NC-HLC contained 21 cholesterol/unit protein, which
statistically was equivalent to t0 and t6h. When the LDLR is corrected, C-HLC contained
statistically significant (p < 0.05) increase in cellular cholesterol of 61 with treatment
compared to t0 and t6h as well as NC-HLC. This demonstrates a quantitative increase in
the corrected HLC’s ability to internalize cholesterol and the receptor corrected cells have
the ability to overcome cyclodextrin inhibited endocytosis [312]. Together this data
supports the normalization of LDLR mediated LDL-C endocytosis in FH differentiated
HLC when the class II mutation is directly corrected.
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Figure 21. LDLR-Mediated Cholesterol Internalization is Restored in C-HLC. (A) NCand C-HLC were treated overnight in 5% lipoprotein deficient serum media (LPDS)
supplemented with Rosuvastatin. This was followed by incubation with DiI-LDL for 6h or
24h. NC-HLC did not show any DiI fluorescence from LDL uptake until 24h. C-HLC
internalized DiI-LDL by 6h, which increased after 24h. Scale bars = 100 μm (B) HLC were
treated with LPDS media and Rosuvastatin for 48h followed by incubation in methyl-cyclodextrin (MBC) for 45 minutes when time point 0h samples were collected. Cells were
further incubated for 6h or 24h with unlabeled LDL then analyzed for cellular cholesterol
concentration with respect to protein. NC-HLC showed no statistical difference in cellular
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cholesterol for all three time points demonstrating the dysregulation of cholesterol
metabolism in FH HLC. Corrected cells did not have statistically different cholesterol
content after 6h demonstrating the effect of MBC treatment and plasma membrane
cholesterol chelation on receptor-medicated endocytosis. After 24h exposure to LDL-C,
receptor corrected HLC were able to increase cellular cholesterol to a statistically
significant level (61 M/(g/L) compared to t0 11.6 M/(g/L). There was no
difference in cholesterol concentration at t0 between NC- and C-HLC. The graph values
represent the mean  SEM (n = 3) per treatment, per cell type. Statistics were performed
using a two-way ANOVA Tukey post-hoc test. *p<0.05 compared to NC-HLC 6h, 24h and
C-HLC 6h.

Distribution of LDLR in FH and LDLR Corrected HLC
The normal LDLR is synthesized in the ER as a partially glycosylated precursor of
120-kDa. Upon reaching the Golgi, N-and O-linked sugars are processed for a molecular
weight of 160-kDa. This process is delayed or completely abolished in class II mutations,
trapping the misfolded LDLR in the ER [92]. Previous work using fibroblasts containing
the same homozygous 3 bp deletion in the LDLR as our patient FH cells were studied
through electron microscopy to identify the distribution of the intracellular LDLR [118].
Unlike normal fibroblasts where most all LDLR was found in coated pits, the class II
mutant cells had less than 5% of LDLR detectable on the cell surface, in coated pits or
vesicles in the endocytic pathway. Instead, most of the class II LDLR was present in
membrane extensions of the rough ER [118]. We sought to examine if NC-HLC retained
the LDLR in the ER and if correction allowed proper movement of the LDLR to the
membrane.
Situated within the ER is calcium-binding Calnexin [313]. Calnexin interacts with
newly synthesized proteins, acting to retain misfolded proteins in the ER [313]. Wheat
germ agglutinin (WGA) is a lectin that binds to N-acetylglucosamine found in the plasma
membrane of different cell types including hepatocytes [314, 315]. After differentiation,
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HLC were treated overnight in LPDS and Rosuvastatin after which we examined protein
localization using immunocytochemistry for Calnexin, LDLR, and WGA. Stacking of
images into a 3D rendering presented the appearance of class II LDLR localizing with ERCalnexin in NC-HLC (Figure 22A). Using Fluoview Program software, images were
further analyzed utilizing the colocalization processing tool to both visualize overlapping
of images as well as quantification of overlap. In Figure 22B, a slice from a 3D stack is
presented. To aid in visualization, for NC vs. C-HLC, we focused on two channels at a
time and pseudo-colored Calnexin or WGA red so that colocalization with LDLR (Green)
will display as yellow. NC-HLC detection of the class II LDLR shows a compact
localization that when combined with Calnexin, illustrates colocalization in the ER (top
row, left panel). When NC-HLC LDLR is combined with plasma membrane WGA (bottom
row, left panel), no colocalization as represented by yellow is detected. In contrast, C-HLC
present a smaller amount of merging of LDLR with ER-Calnexin (Figure 22B, top row,
right panel) while demonstrating a significant colocalization of LDLR with WGA-plasma
membrane (bottom row, right panel). Quantification of overlap confirmed NC-HLC have
almost twice the amount of LDLR colocalizing to the ER-Calnexin (0.34) than WGAplasma membrane (0.16) and the difference was statistically significant by one-way
ANOVA with Tukey post-hoc test (p < 0.05) (Figure 22C). In C-HLC, there was
significant variability between samples and though a slight increase in WGA-plasma
membrane and LDLR colocalization compared to ER-Calnexin was calculated, this was
not significant (Figure 22C). This data confirms that NC-HLC retains the LDLR in the
ER, but in spite of other evidence clearly demonstrating a function LDLR at the plasma
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membrane surface, we were unable to quantify a statistically significant change in
localization.
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Figure 22. LDLR Colocalizes with Calnexin-ER in FH-HLC. (A) After differentiation,
HLC were treated overnight in LPDS media supplemented with Rosuvastatin followed by
ICC and confocal imaging, 100x oil immersion objective. AMIRA software was used to
stack slices and merge channels to present an overview of localization of the LDLR (green)
Calnexin-ER (red), WGA-plasma membrane (magenta), and nucleus (DAPI). (B)
Fluoview software was used to visualize overlap between the LDLR-Calnexin-ER or
LDLR-WGA-plasma membrane. The channel for WGA-plasma membrane was changed
to red for visualization on overlap. Overlap is shown in yellow. NC-HLC appear to have a
greater amount of yellow with the LDLR-Calnexin (left, top row) compared to LDLRWGA (left, bottom row). C-HLC appear to have an increase in colocalization of LDLRWGA (right, bottom row) compared to LDLR-Calnexin (right, top row). (C) Quantification
of colocalization using Fluoview software indicated that NC-HLC did have a significantly
greater colocalization of the LDLR with Calnexin than WGA. C-HLC showed a slight
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increase in LDLR-WGA colocalization compared to LDLR-Calnexin though it was not
significant. The graph values represent the overlap index  SEM (n = 5) per cell type.
Statistics were performed using a one-way ANOVA Tukey post-hoc test. *p<0.05 of NCHLC LDLR-Calnexin to NC-HLC WGA, C-HLC WGA, and C-HLC Calnexin.

Rosuvastatin Upregulates LDLR Transcript and Protein Levels in FH and Corrected Cells
In our previously published work, we used Lovastatin in our studies and found that
NC-iPSC expressed immature LDLR compared to C-iPSC that converted its protein to all
mature LDLR [189]. We confirmed this once more in our iPSC cells after treatment with
Lovastatin in LPDS media. Lovastatin did increase LDLR protein expression in all 3 cell
types (Figure 23A), and the NC-iPSC presented both the mature and immature form of
LDLR similar to control recombinant human LDLR (rhLDLR). Lovastatin inhibits HMGCoA reductase, preventing cholesterol synthesis leading to an upregulation of LDLR. In
addition, Lovastatin has been cited to inhibit or modulate the 20 S proteasome pathway
[316-318]. The LDLR receptor class II mutants have been reported to be degraded via the
26 S proteasome-pathway [119]. To ensure the accumulation of immature LDLR that we
observed was not due to effects on the proteasomal pathway, we opted to use a
contemporary drug, Rosuvastatin.
To confirm the form of LDLR protein in NC, C, and control H1 stem cells, we
treated the iPSC with Rosuvastatin or excess sterols in LPDS media overnight. Excess
sterols act independently of the LDLR and enter the cell via pinocytosis to decrease LDLR
expression. NC-iPSC demonstrated a major accumulation of the immature LDLR not seen
in the C-iPSC or H1-ESC (Figure 23A), suggesting the CRISPR modification restored the
normal LDLR structure allowing LDLR to proceed to the Golgi for processing and
movement to the plasma membrane. Quantification and of total LDLR indicated a

125

significantly greater total LDLR in NC-iPSC than in C-iPSC and H1-ESC (Figure 23B).
Two-way ANOVA with a Tukey post-hoc test determined significance of total LDLR in
all 3 iPSC/ESC lines treated with Rosuvastatin compared to excess sterols (***p<0.001,
**** p<0.0001) and NC-iPSC Rosuvastatin compared to C-iPSC and H1-ESC with
Rosuvastatin (#p<0.001).
We differentiated the iPSC/ESC to HLC, and after treatment with Rosuvastatin, we
observed an induction of LDLR expression primarily in immature form in NC-HLC and
very little mature LDLR (Figure 23C). C-HLC and H1-HLC expressed solely mature
LDLR (Figure 23C). Excess sterols downregulated LDLR protein synthesis in all the cells
as expected. Quantification and two-way ANOVA with a Tukey post-hoc test confirmed
an upregulation of total LDLR protein mainly in NC-HLC compared to NC-HLC in excess
sterols and H1-HLC in Rosuvastatin (**p<0.01, #p<0.01) (Figure 23D).
To investigate if total LDLR protein and increase in immature LDLR (Figure 23B,
D) was due to differential transcriptional regulation of the LDLR between NC and C cells
in the presence of statins, qPCR analysis was used on both iPSC and HLC post-treatment
with control carrier DMSO, Rosuvastatin, and excess sterols. For both iPSC and
differentiated HLC, Rosuvastatin increased LDLR transcript levels across all the cell types
compared to excess sterols or DMSO control (Figure 23E, F), which two-way ANOVA
with a Tukey post-hoc test showed to be significant (**p<0.01, ****p<0.0001). However,
there was no difference in transcript levels when comparing statin treatment across cell
lines or differentiation state, which is to be expected with statin treatment.
Taken together, this shows that both iPSC and HLC can be induced to express
LDLR with statin treatment and while the NC generally has more total LDLR that
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accumulates predominately in the ER, this is not due to any difference in transcription.
This suggests the accumulating misfolded LDLR may be due to an issue with protein ER
processing or degradation.
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Figure 23. Rosuvastatin Increases Total LDLR Protein Levels and an Accumulation of
Immature LDLR in NC-cells. (A) iPSC were treated overnight in LPDS media
supplemented with either Lovastatin (Lova), Rosuvastatin (RS), or excess sterols (XS).
Western blot analysis for LDLR shows NC-iPSC upregulate immature LDLR in Lovastatin
while C-iPSC and H1-ESC express mature LDLR. Rosuvastatin treatment shows the same
response and LDLR is suppressed when exposed to sterols. Recombinant human LDLR
protein (rhLDLR) was used as detection control. (B) Quantification of total LDLR
demonstrated that statin-treated-NC-iPSC had a significantly greater total LDLR than CiPSC and H1-ESC treated with Rosuvastatin. All 3 statin-treated cell types were
significantly greater compared to their excess sterol treated counterparts. (C) iPSC/ESC
were differentiated to HLC. Under the same conditions of RS or XS treatment, NC-HLC
express greater total LDLR, predominately as immature protein, that is converted to all
mature in C-HLC and H1-HLC. LDLR levels decreased with sterols treatment. (D)
Quantification of total LDLR presented a significant increase in total LDLR in statintreated-NC-HLC compared to its excess sterols. In addition, statin-treated-NC-HLC had a
significantly larger amount of LDLR compared to statin-treated H1-HLC. (E) qPCR
analysis of LDLR shows Rosuvastatin (RS) treatment significantly increases LDLR
transcript levels statistically equivalently in NC-and C- iPSC like that of H1-ESC
compared to DMSO (DM) control and excess sterol (XS) treatment. (F) Similarly, HLC
showed consistent results with significantly upregulated LDLR mRNA levels with RS
treatment and no difference between cell type. The graph values represent the mean  SEM
(n = 3) per treatment, per cell type using a two-way ANOVA Tukey post-hoc test.
**p<0.01, ***p<0.001, ****p<0.0001 #p<0.05 between RS-treated cell type

Treatment of Cells with Rosuvastatin Does Not Induce ER Stress
Two studies reported that class II LDLR mutants are retained in the ER causing ER
stress and activating the UPR. Since statins cause an accumulation of immature protein in
NC FH-iPSC and HLC, we investigated statin treatment induced ER stress in class II
iPSC/HLC and if it was normalized in the corrected cells. ER chaperone Grp78 is a major
factor involved in maintaining ER homeostasis. It is also the first component activated in
the UPR. Little is known about the ER stress responses in iPSC or derived HLC, therefore,
we used the ER stress inducer, tunicamycin as a positive control. Tunicamycin functions
by inhibiting glycoprotein synthesis, inducing protein unfolding and activating the UPR.
iPSC/HLC were treated with either Rosuvastatin, excess sterols, and control DMSO
overnight or tunicamycin for 4.5 hours. We specifically looked at Grp78 mRNA transcript
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levels since it has been documented that Grp78 mRNA levels increase quickly in responses
to ER stress. In addition, in an overexpression class II LDLR mutant model, Grp78 mRNA
and protein levels are upregulated [124, 125]. After treatment with Rosuvastatin, both iPSC
and HLC did not produce any quantifiable increase in Grp78 expression in any of the cell
types (Figure 24A, B). There was no difference in transcripts between statin treatment and
control DMSO or excess sterols. However, tunicamycin significantly increased Grp78
transcript levels across all cell types in both iPSC and HLC demonstrating that UPR
pathways were capable of being activated (Figure 24A, B). Two-way ANOVA with a posthoc Tukey test confirmed a significant upregulation of Grp78 mRNA with tunicamycin
treatment (***p<0.001, ****p<0.0001).
X-box binding protein 1 (XBP1) is a transcription factor that becomes activated in
response to accumulation of unfolded proteins [218]. The splicing of a 26-nucletoide intron
from XBPI generates the transcription factor, spliced XBP1 (SXBP1) [213, 221, 223].
SXBP1 regulates UPR genes for folding, ERAD, autophagy, and organelle biogenesis
[213, 224-226]. The SXBP1 isoform can be detected through PCR and after tunicamycin
treatment, our cells exhibited the SXBP1 isoform (Figure 24C, D) in the iPSC/ESC or
HLC. However, no XBP1 splicing was detected with any other treatment in the NC or C
iPSC and HLC. Though H1 hESC did not show XPB1 splicing other than Tunicamycin,
curiously H1 HLC had a basal level of SXBP1 which was statistically equivalent to
Tunicamycin treatment. Quantification of SXBP1 to total XBP1 confirmed that
Rosuvastatin treatment did not activate SXBP1 or the UPR in NC, C, or H1 cells (Figure
24C, D). Two-way ANOVA with a Tukey post-hoc test showed that only tunicamycin
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treatment significantly activated the splicing of XBP1 in all iPSC/ESC (****p<0.0001)
(Figure 24C). No significance was found in HLC treated with tunicamycin.
We further evaluated the activation of the UPR through western blot. During ER
stress, ATF6 is cleaved and releases a 50-kDa fragment termed ATF6f that continues on to
act as a transcription factor and upregulate expression of UPR genes involved in protein
folding and degradation [221, 232]. CHOP is a protein downstream of the PERK pathway.
Its activation signifies the cell’s response towards an apoptotic state due to an
overwhelming amount of ER stress. We ran a western blot for ATF6, CHOP, and Grp78.
Across all HLC, Rosuvastatin and excess sterol treatment did not change the levels of
ATF6 (Figure 24E). HLC treated with tunicamycin had a decrease in expression of the
ATF6 protein; however, we could not detect the ATF6f (Figure 24E). The expression
pattern of decreased ATF6 with only tunicamycin was indicative that this was specific to
some sort of stress response that was not present with statin or excess sterol treatment.
CHOP was not present until HLC were treated with tunicamycin in NC, C, and H1 (Figure
24E). Grp78 levels were upregulated in all HLC treated with tunicamycin (Figure 24E)
correlating with qPCR data (Figure 24B). Altogether, this data shows that although FH
NC and C cells as well as normal H1 controls can be induced to activate ER stress and
UPR with Tunicamycin treatment, exposure to statins that cause downstream LDLR
upregulation does not induce ER stress, as has been shown by others.
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Figure 24. FH-NC Cells Do Not activate the UPR Following Rosuvastatin Treatment.
Following treatment with either carrier DM, RS, XS, or tunicamycin (TM; 5 μg/mL for 4.5
hours), cells were tested for ER stress and UPR markers at both mRNA and protein levels
in iPSC/ESC and HLC. (A) qPCR analysis in iPSC indicated Grp78 mRNA levels do not
change with RS treatment compared to DM/XS controls across the 3 cell groups. TM
significantly increased Grp78 mRNA in NC-, C-, and H1 stem cells. (B) HLC presented
the same trend with TM significantly upregulating Grp78 transcripts while RS did not. (C)
PCR for spliced-XBP1 (SXBP1) visualized on a 2% agarose gel indicated TM treatment
induced splicing of XBP1 that was not present in RS treated iPS/ES cells. Quantification
of SXBP1/XBP1 shows significant SXBP1/XBP1 activation in TM-treated cells across all
3 cell types. (D) HLC presented similarly to iPSC/ESC for SXBP1/XBP1. Quantification
of SXBP1/XBP1 did not show any significance. (E) Western blot analysis showed a
decrease in ATF6 levels in TM-treated HLC only while RS- and XS-treated HLC did not
change. CHOP was expressed only in TM-expressed HLC. Grp78 protein levels were
upregulated in TM-treated HLC while staying closer to basal level in RS-and-XS-treated
HLC. The graph values represent the mean  SEM (n = 3) per treatment, per cell type
using a two-way ANOVA Tukey post-hoc test. ****p<0.0001 of TM-treatment to all other
treatments in each respected cell group.
DISCUSSION
The novel and important findings of this study are that LDL-C internalization was
restored in corrected hepatocyte-like cells and that statin did not induce ER stress in noncorrected hepatocyte-like cells. This data provides proof of concept that these FH-corrected
cells are functioning and could be useful in the future as models to compare mutant to
corrected cellular response, drug testing or even cell-based therapy work. Overexpression
studies have provided evidence that class II LDLR mutants activate the ER stress UPR
pathway. Our model served as a tool to determine if a physiologically relevant statininduced LDLR expression would cause ER stress and if correction would alleviate the
response. We did not observe ER stress.
It has been hypothesized that class II mutations change the spacing between the
highly conserved cysteine residues which interferes with disulfide bond formation and
proper LDLR folding [92, 114, 122]. Retention of the class II mutant in the ER as an
immature protein suggests it is a transport problem [122] or a protein folding disease [98].
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We demonstrated previously that modification of the genomic mutation permanently
corrects the defect and allows for proper processing to the mature LDLR and receptormedicated endocytosis [189]. We also showed that statin treatment differentially caused
accumulation of more total LDLR in the FH class II mutant (predominantly immature)
compared to CRISPR corrected (predominantly mature) [189]. This led us to question why
the mutant FH cells are retaining more total protein with statin treatment.
Since most of our previous work was performed in cells in the pluripotent state, we
initially investigated if receptor-medicated endocytosis was also normalized in
differentiated HLC. A time course of internalization of DiI labeled LDL-C showed that
even after 24h, very little DiI could be detected in the mutant HLC, while robust
fluorescence is detected in the corrected HLC at both 6h and 24h. When cellular cholesterol
is depleted by statin and methyl--cyclodextrin, even at 6h neither FH or corrected HLC
showed a quantifiable change in cholesterol restoration. Even after 24h, no statistical
change in cellular cholesterol was quantified in FH-HLC. However, in corrected HLC,
between 6h to 24h, LDLR activity appears to have been sufficient to restore cellular
cholesterol levels likely including within the plasma membrane [312, 319].
Since the class II LDLR mutant is misfolded, we next asked if we could detect a
statin mediated accumulation of mutant LDLR in the ER that was resolved in the LDLR
corrected cells. We observed NC-HLC LDLR colocalized with calnexin-ER (Figure 22).
Previous work with Class II FH563 fibroblasts were also carefully studied through electron
microscopy to identify the distribution of the intracellular LDLR [118]. Less than 5% of
LDLR was detectable on the cell surface and in coated pits or vesicles in the endocytic
pathway. Instead, most of the class II LDLR was present in membrane extensions of the
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rough ER [118]. It is hypothesized that the extensions at which the mutant LDLR is
localized is the site where the ER is blocking exit of the LDLR and appeared to be
morphologically similar to the transitional zone of the ER implicated in transport of
secretory proteins to the Golgi [118, 127]. This correlates with our observation in the
internalization assays (Figure 21) in which very minimal LDL was internalized by the NCHLC. This small number may represent non-receptor mediated pathways of cholesterol
internalization, such as pinocytosis, in addition to the receptor-mediated pathway resulting
from the few functional, mature LDL receptors.
One possibility for the accumulation of misfolded LDLR with statin treatment was
the statin used. We originally used Lovastatin. Lovastatin was the first FDA approved statin
drug and has since been found to also inhibit the proteasome, which is reported to be the
mechanism of FH class II LDLR degradation [74, 316, 317]. However, this effect is only
seen in the closed-ring -lactone-form and does not inhibit HMG-CoA reductase [317].
When we compared the effect on mutant LDLR accumulation of Lovastatin to
Rosuvastatin, we detected the same increase in total protein levels of LDLR in NC-cells as
well as similar total mature protein between corrected LDLR and wild type control, which
demonstrates that Lovastatin proteasome inhibition was not the culprit causing misfolded
protein accumulation (Figure 23). The presence of immature LDLR in FH cells has been
demonstrated in past studies [122]. A pulse-chase study comparing unaffected and class II
FH fibroblasts (the same patient cell type we derived our iPSC from) found that normal
fibroblasts’ LDLR had been transported to the Golgi for processing to the mature 160-kDa
proteins. 95% of the class II LDLR remained as 120-kDa [122]. The accumulation of
mutant LDLR compared to the corrected LDLR was not the result of differential
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transcriptional control, which is what we expected since the cells were treated with statins
to inhibit HMG-CoA reductase and upregulate LDLR. We also found that a similar
accumulation of mutant LDLR occurs in FH-iPSC and differentiated FH-HLC, indicating
mutant LDLR accumulation is a post-translational regulation mechanism. FH class II
LDLR proteins are reported to be degraded by two mechanisms, 1) proteasome [119, 320]
and 2) lysosome [7, 28, 321]. It is possible that one or both of these systems is overwhelmed
by the statin mediated expression induction allowing misfolded protein to accumulate, but
then one would expect this to cause ER stress and UPR induction [217, 231].
It has been demonstrated that ER chaperones retain misfolded class II LDLR in the
ER. Two-class II mutant LDLRs, C646Y and W556S, were retained in the ER and bound
to Grp78 when overexpressed in model Chang cells shown through mass spectrometry and
western blot [125]. This was confirmed in CHO cells overexpressing another 2 class II
LDLR mutations where there was prolonged binding of Grp78 to mutant LDLR [124]. In
addition, ER stress activation in CHO overexpressing mutant G544V LDLR was observed.
Spliced XBP1 mRNA was present in the Class II LDLR mutant and absent in
overexpressed WT LDLR. Class II mutant LDLR overexpression resulted in a fold
induction of phosphorylated-PERK [124]. In contrast, we did not observe an increase in
Grp78 expression (Figure 24A, B) in NC-cells treated with Rosuvastatin. We did not detect
ER stress activation after Rosuvastatin treatment either (Figure 24C, D, E). Our study
specifically used iPSC and derived HLC rather than an overexpression model. It is possible
that statins are causing a low-grade chronic ER stress that we were unable to detect. A
study of liver samples from untreated patients with chronic hepatitis identified “ERstressed hepatocytes” in clusters scattered in the liver parenchyma [322]. These same
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samples showed protein expression of ATF-6, IRE1, and PERK. However, qPCR of UPRgenes did not show induction of ER stress; instead, genes involved in inflammation and
apoptosis were significantly upregulated in these patient samples [322]. Another case
study dissected whether liver hepatoxicity was due to statins or another cause [323].
Prolonged latency was seen in patients taking Atorvastatin, Simvastatin, Fluvastatin, and
Rosuvastatin, and they presented both hepatocellular and cholestatic patterns of liver
injury. Many of these cases resolved after discontinuation of statins. It appeared that statininduced liver injury takes months to years to instigate [323]. It is possible that our cells are
expressing ER stress through a non-canonical inflammatory response that we were unable
to detect with our methods.
Another chaperone that’s been implicated in binding and facilitating the proper
folding and maturation of the LDLR is RAP [106]. Mesoderm D (MesD) has also been
associated in binding LDL-like receptor proteins [98, 110]. Using this NC and C-HLC
model could connect whether or not RAP or MesD are involved in retaining or transporting
class II LDLR mutants into or out of the ER. It could also be interesting to investigate if
the accumulation of the immature LDLR has an effect on MesD and LDL-like receptor
protein interactions and regulation.
It is known that the UPR’s purpose is not only to increase folding capacity of the
ER, but to also eliminate misfolded proteins by ERAD [324]. The proteasomal degradation
pathway also plays a significant role in the degradation of class II LDLR mutants [119].
The 26 S proteasome is the main protein involved in the ERAD pathway of the cell and
degrades misfolded proteins translocated from the ER. Class II LDLR proteins
overexpressed in CHO cells were degraded through the 26 S proteasome and MG132
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inhibited LDLR degradation [119]. We observed both accumulation of immature LDLR
(Figure 23) and no UPR activation (Figure 24). It is possible that degradation is occurring,
rather slowly, yet, quickly enough to avoid wholesale UPR. It is also possible the
proteasome is not involved in what we are observing. Studies using MG132 proteasome
inhibitor can help begin answering these questions.
Our study currently has several limitations. First, differentiation of cells to HLC
must be modified to have a monoculture of hepatocytes. Our cells appear to still be a
mixture of hepatoblast and hepatocyte, which may answer for the variation in experiments.
In addition, our ER stress data must be extended with protein analysis via western blot to
assess inflammatory UPR elements like phosphorylated-JNK. Finally, more functional
studies for restoration of cholesterol metabolism should be assessed including HMG-CoA
reductase activity. To conclude, this data validates that an FH-corrected cell line can
physiologically mediate LDLR endocytosis and presents a suitable model to study class II
LDLR. In addition, we have determined that the UPR is not activated in a physiological
model of class II LDLR HLC.
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CHAPTER V
SUMMARY AND CONCLUSIONS

In this project, we proposed to correct a class II LDLR mutation and follow with
further modifying the LDLR and finally create a pre-vascularized liver organoid for
implanting these cells. Instead, we were able to create a familial hypercholesterolemia
model of non-corrected class II LDLR and corrected LDLR to study cholesterol
metabolism and investigate statin-induced immature LDLR accumulation effect on the
cell’s ER stress system.
We were able to use the CRISPR/Cas9 tool to target a 3-nucleotide deletion in
exon 4 of the LDLR of a homozygous patient-derived iPSC. We analyzed LDLR protein
levels at the iPSC and HLC level and found a mature LDLR expressed and at lower
levels than NC-cells. LDLR-mediated cholesterol internalization was restored in C-HLC
as was localization of the LDLR at the plasma membrane. These data provide proof of
concept that these FH-corrected cells are functioning and could be useful in the future for
cell-based therapy work.
We also are optimizing differentiation of these cells to HLC. There is currently an
array of protocols for differentiation of iPSC/ESC to HLC. However, there is no
universal standard set because each lab has taken note that what differentiation works for
their cells may not work as well in another lab’s cells. Efficiency of differentiation can be
severely affected by the quality of growth factors and reagents
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used, the type of plastic plate and the amount of cells plated, and the confluence of the
cells prior to passaging [290]. Additionally, the growth factors concentration can be
variable, as well as species specific. Mouse hepatocyte growth factor is active in mouse
cells but not human cells, but human hepatocyte growth factor works well in both human
and mouse cells. We are currently in the process of creating a protocol to achieve a high
percentage of mature hepatocytes for our studies and definitive endoderm is the primary
stage of differentiation. We have observed that both mouse and human Wnt3a are active
in our culture for differentiation to definitive endoderm with high expression of Sox17
and HNF4a. Further studies are necessary to verify these results.
We also investigated the role of ER stress in the non-corrected and corrected FH
cell lines. We hypothesized that when treated with statins ER stress would be activated in
class II LDLR mutant, but not in mutation corrected FH cells. Overexpression studies
have provided evidence that class II LDLR mutants activate the ER stress UPR pathway.
Our model served as a tool to determine if a physiologically relevant statin-induced
LDLR expression would cause ER stress and if correction would alleviate the response.
We could not detect ER stress in the statin treated cells.
Our findings have resulted in many more questions to answer. To begin with, we
observed an accumulation of immature LDLR in NC-cells that was not correlative with a
greater increase in LDLR transcript levels. Regulation of the cholesterol-LDLR feedback
loop is modulated by a set of membrane bound transcription factors called sterol
regulatory element binding proteins (SREBPs) [325]. A study using homozygous class II
LDLR FH patient fibroblast cells found that the SREBP-2 induced de novo cholesterol
synthesis and upregulation of scavenger receptor class B type I (SR-BI) for cholesterol
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uptake [325]. SREBP also plays a role in intracellular lipid accumulation during ER
stress [326]. SREBP is usually retained in the ER by Insig. However, during ER stress,
Insig translation rapidly declines allowing SREBP to escape the ER and activate
transcription of genes for lipid synthesis and uptake. We did not check the expression of
SREBP or its associated genes. In addition, changes could be occurring at the epigenetic
level. It would be interesting to evaluate through microarray which genes are up or
downregulated in an FH and corrected HLC cell line. This could be followed with a
CHIP assay to determine if SREBPs interaction with LDLR promoter is modified.
Statins are the most prescribed medication worldwide. Many studies have
evaluated the risks associated with short-and-long term use of the drug. Generally, statins
are well-tolerated. However, up to 15% of patients develop adverse effects to statins,
including myalgia. Even scarcer are reports of stain induced liver injury. A case study
dissected whether liver hepatoxicity was due to statins or another cause [323]. Prolonged
latency was seen in patients taking Atorvastatin, Simvastatin, Fluvastatin, and
Rosuvastatin, and they presented both hepatocellular and cholestatic patterns of liver
injury. Many of these cases resolved after discontinuation of statins. One patient who
died also had pre-existing alcoholic cirrhosis. Another patient who had restarted on
statins rapidly redeveloped acute injury. It also appears that statin-induced liver injury
takes months to years to instigate [323]. HoFH patients can begin treatment on statins as
young as 6 years old. Can a patient with a liver disease like FH be more susceptible to
statin-induced liver injury and not know it until it has become severe?
Statins are classified category X, meaning the drug should not be taken during
pregnancy [327, 328] because of studies that have shown problems in the fetus of animals
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or pregnant women who mistakenly took the medication without being aware of their
pregnancy. Human iPSC/ESC are useful tools in studying early human development and
could be a useful source to determine what, if any, effects occur with statin exposure in
NC versus C-iPSC. A study treating iPSC long and short-term with statins before forming
them into embryoid bodies could reveal an array of information on which genes are
changed because of treatment.
To conclude, we have established a cell line model to study class II LDLR
mutations that could provide a platform to answer questions.
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